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2Abstract
Industry pressures encourage and sometimes ‘force’ biopharmaceutical companies to implement
process changes throughout a product’s lifecycle, so as to enhance yields, purity, robustness and
cost-effectiveness. However, making a change involves technical, regulatory, and clinical risks.
Possible changes to a product’s quality mean that all changes must be backed-up either with
non-clinical bioequivalence studies or with lengthy and costly clinical trials and approved by
regulatory authorities. These hurdles combined with the upfront costs can results in a tendency
to avoid changes, whereas they may represent economic opportunity if evaluated holistically.
This thesis explores the possibility of creating a systematic evaluation framework that captures
the technical and regulatory activities involved in process changes to rapidly gauge the potential
cost and risk implications.
Fundamentaldrivers and consequencesof making bioprocesses changes were benchmarked in a
survey to help create the framework model. Key technical activities were captured, namely
development, manufacturing, retrofitting and validation at all stages of development. Impacts of
changes were linked to regulatory activities needed to assess comparability. Resulting
uncertainties such as the likelihood of repeating clinical trials, market losses, delays to market
from retrofit, revalidation, or regulatory approval disruptions, and the costs involved in proving
product equivalence were captured. The framework was translated into Microsoft Excel with
macros for Monte Carlo simulations to account for the uncertainties.
Minor and major change scenarios based on the purification of polyclonal IVIG by means of a
blood-plasma fractionation process were used to demonstrate the usefulness of the proposed
framework. The impact of ‘forced’ and optional changes were compared at different stages of
development. Changes made during late-phase development resulted in market share losses and
delays that outweighed any yield improvement modifications. The model predicted that it would
be more profitable to make process modifications either during early phase development or
post-product approval assuming stockpiling of approved product was feasible.
The feasibility of purifying a new product, alpha-1 antitrypsin (AAT) from a waste fraction,
Fraction IV precipitate, was another process change scenario explored using scale-down studies.
Experimental trials of the preliminary filtration and anion exchange purification steps were
carried out, yielding low recoveries of AAT. Ciphergen®’s SELDI-TOF-MS ProteinChip
technology was used to investigate the value of using a high throughput optimisation method to
improve the isolation of AAT. Quantitative analysis of the protein samples using the
Ciphergen® was compared to well-established protein concentration determination methods,
eliminating variability in samples and differences in MS intensity by normalising the data.
The work in this thesis has demonstrated the usefulness of a combined business, technical and
risk approach for evaluating the risks and benefits of implementing process changes.
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have not been shown. ....................................................................................................155
Figure 6.3 A contour plot portraying the variation in AAT, Albumin and Transferrin
concentration across a range of pH and salt conditions. Data is based on peak area under
the curve (AUC) at 50.1kDa/e, 66kDa/e and 79kDa/e respectively from the SELDI-
TOF-MS intensity profiles. Results from a range of pH and salt conditions used on the
SELDI-TOF-MS Q10 ProteinChips are shown. The intensity value correlates to the
concentration of each protein bound to the ProteinChip. The peaks are initially recorded
by summing the signal intensities between ± 0.3% of the mass. ......................................1
Figure 6.4 Data bars portray a summary of the abundance of AAT, Albumin, and
Transferrin based on peak area under the curve (AUC) at 50.1kDa/e, 66kDa/e and
79kDa/e respectively from the SELDI-TOF-MS intensity profiles. Results from a range
of pH and salt conditions used on the SELDI-TOF-MS Q10 ProteinChips are shown.
The intensity value correlates to the concentration of each protein bound to the
ProteinChip. The peaks are initially recorded by summing the signal intensities between
± 0.3% of the mass. Optimal conditions are highlighted in red. ...................................156
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Figure 6.5 Normalised SELDI-TOF-MS spectra based on SELDI-TOF-MS processed
data that is baseline corrected. The protein profiles portray the binding intensity and
isolation of proteins present in FIV filtrate fractionated using the ‘Q10’ ProteinChip
under a variety of buffer conditions: pH 5.1-8.0, 0-200mM NaCl. Based on
Baggerly,(2007) method. ..................................................................................................1
Figure 6.6 Data bars portray a summary of the concentration of AAT, Albumin, and
Transferrin based on peak area under the curve (AUC) at 50.1kDa/e, 66kDa/e and
79kDa/e for the additional buffer condition: pH 5.1 and pH 5.6, 0-200mM NaCl, and
pH 6.2, 6.8, 7.4, 8.0 at [200mM NaCl]. The intensity value correlates to the
concentration of each protein bound to the ProteinChip. The peaks are initially recorded
by summing the signal intensities between ± 0.3% of the mass. Optimal conditions are
highlighted in red. .........................................................................................................160
Figure 6.7 The percentage purity of AAT (AAT/ Total Protein) when fractionated using
the SELDI-TOF-MS ‘Q10’ ProteinChip under a range of pHs and NaCl concentrations.
.......................................................................................................................................162
Figure 6.8 A data bar summary of the percentage purity of AAT, Albumin and
Transferrin when fractionated using the SELDI-TOF-MS ‘Q10’ ProteinChip under
differing pH values and NaCl concentrations. Optimal conditions are highlighted in red.
.......................................................................................................................................163
Figure 6.9 An example of the elution profiles from the Hitrap Q Sepharose FF columns.
Fraction IV filtrate is loaded at pH 8, 150mM NaCl on to 1mL pre-packed columns:
The first peak represents the wash of unbound protein with 20mM Phosphate, 150mM
NaCl at pH 8, The second peak shows a salt step elution to 2M NaCl, and the third
peak is a 0.5M NaOH wash. Symbols are: (—) Absorbance, (−••−) NaCl concentration,
(…....) pH ......................................................................................................................164
Figure 6.10 SELDI-TOF-MS spectra representing protein profiles of Fraction IV eluate
samples. FIV filtrate were loaded onto a HiTrap Q Sepharose FF column, under the
conditions shown in the figure . Loading, equilibration and binding were kept under the
same conditions to mimic the SELDI-TOF-MS Q10 technique used earlier. A step
elution (2M NaCl) was used to remove all the protein bound onto the column, and so
the profiles represent the binding capacity of the matrix. The profiles were produced
using the non-selective SELDI-TOF-MS ‘NP20’ ProteinChip. A matrix of 9 conditions
(pH 5.6, 6.2 and 8,NaCl concentrations of 0mM, 150mM, and 200mM) were analysed
at 1mL column scale. The AAT peak is shown at a 52kDa/e; Albumin at 66kDa/e and
Transferrin at 79kDa/e. .....................................................................................................1
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Figure 6.11 SELDI-TOF-MS spectra representing wash peaks from Fraction IV filtrate
samples after they were loaded onto a HiTrap Q Sepharose FF column, under the
conditions shown in the figure load and wash conditions were the same . The profile
shows protein that did not bind to the column. The profiles were produced using the
non-selective SELDI-TOF-MS ‘NP20’ ProteinChip. A matrix of 9 conditions (pH 5.6,
6.2 and 8,NaCl concentrations of 0mM, 150mM, and 200mM) were analysed at 1ml
column scale. The AAT peak is shown at a 52kDa/e; Albumin at 66kDa/e and
Transferrin at 79kDa/e. .....................................................................................................1
Figure 6.12 A data bar summary showing the concentration of AAT, Albumin and
Transferrin present in the ‘eluate’ (bound protein) and ‘wash’ peaks (unbound protein)
(see Figure 6.9) from a HiTrap Q Sepharose Fast flow separation step over a range of
conditions (pH 5.6-8, [NaCl] 0-200mM). In A) the data is determined using ELISA
(AAT) and Siemens Turbitimer (Albumin and Transferrin) methods; in B) the data
shows the Peak Area (± 0.003) from the intensity profiles produced using the non-
selective SELDI-TOF-MS ‘NP20’ ProteinChip. The AAT peak is measured at a
50.85kDa/e; Albumin at 66kDa/e and Transferrin at 79kDa/e. Optimal conditions are
highlighted in red. .........................................................................................................168
Figure 6.13 A data bar summary of percentage protein yield in the ‘eluate’(bound
protein) and percentage yield loss in the ‘wash’(unbound protein) peaks (see Figure
6.9) from a HiTrap Q Sepharose Fast flow separation step over a range of conditions
(pH 5.6-8, [NaCl] 0-200mM). This is based on the concentration data( Figure 6.12)
determined using ELISA methods for AAT, and the Siemens Turbitimer method for
Albumin and Transferrin. Optimal conditions are highlighted in red...........................169
Figure 6.14 The purity of AAT, Albumin and Transferrin in the ‘eluate’ (bound
protein) and ‘wash’ (unbound protein) peak fractions from a HiTrap Q Sepharose Fast
flow separation based on A) Elisa methods for AAT and Turbitimer concentration
estimates for Albumin and Transferrin; B) AUC (Area under the curve of target peaks)
from NP20 chip SELDI-TOF-MS profiles. Total protein is considered to be the
summation of AAT, Albumin and Transferrin concentrations. The Peak Area (± 0.003)
is calculated from the intensity profiles produced using the non-selective SELDI-TOF-
MS ‘NP20’ ProteinChip. The AAT peak is measured at a 50.85kDa/e; Albumin at
66kDa/e and Transferrin at 79kDa/e. ............................................................................171
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NOMENCLATURE & ABBREVIATIONS
ABBREVIATIONS
A280 Absorbance at 280 nm
AAT Alpha 1-antitrypsin
AUC Area under the curve
BLA Biological License Application
BCA Bicinchoninic acid
BPL Bio Products Laboratory
CBER Centre for Biologics Evaluation and Research
CDER Centre for Drug Evaluations and Research
cGMP Current Good Manufacturing Practice
COG Cost of Goods
CRP C reactive protein
DI Deionised water
DTT Dithiothreitol
EAM Energy absorbing molecule
ELISA Enzyme-linked immunosorbent assay
EMEA European Medicines Evaluation Agency
FA+1 Fraction A+1 of the Cohn fractionation process
FDA United States Food and Drug Administration
FIV Fraction IV of the Cohn fractionation process
FV Fraction V of the Cohn fractionation process
F B+1 Fraction B+1 of the Cohn fractionation process
GC globulin Gc globulin/Vitamin D binding protein(DBP)
IgA Immunoglobulin A
IgG Immunoglobulin G
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MBL Mannose Binding Lectin
MHRA Medicines and Healthcare products Regulatory Agency
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NPV Net Present Value
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R&D Research and Development
S/D Treatment Solvent/Detergent Treatment
SELDI-TOF-MS Surface-enhanced laser desorption/ionization mass spectrometry
TMAE Trimethylaminoethyl
TRIS Tris(hydroxymethyl)aminomethane
TCEP Tris(2-carboxyethyl)phosphine
UCL University College London
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Chapter 1
Background and Thesis Scope
1.1 INTRODUCTION
The development and manufacture of biopharmaceutical drugs is a complex and heavily
regulated process. At any stage of a drug’s life cycle cost reduction, yield improvement,
technological advancements, and regulatory requirements can lead companies to make
regular changes to manufacturing processes. These changes can have a detrimental or
indeed positive effect on product quality and safety, and so every change must be
carefully monitored and approved by the appropriate regulatory authorities. This thesis
explores the management of process changes in the biologics sector, looking at the
different strategies used by companies to cope with change. The possibility of capturing
all manufacturing and regulatory consequences of manufacturing process changes in a
framework is proposed. Case studies based on blood-plasma fractionation are used to
demonstrate the impact of such changes.
In this chapter, background to this study and the scope of the thesis is provided. Section
1.2 gives an overview of the biopharmaceutical industry, and the challenges it faces
during development and manufacture. Section 1.3 provides background to the blood-
plasma fractionation industry and the manufacture of plasma-derived products, of
which the case study examples in this thesis are based. The economics of the plasma
protein therapeutic industry is described in section 1.4. Section 1.5 gives a brief
description of Bio Products Laboratory, UK. Methods for cost analysis and specific
examples found in literature are discussed in section 1.6, and the incorporation of risk
analysis is given section 1.7. Finally, the contributions, aims, and organisation of the
thesis are given in section 1.8.
1.2 THE BIOPHARMACEUTICAL INDUSTRY
The biopharmaceutical sector is the fastest growing segment of the pharmaceutical
industry, growing at an annual rate of around 15 percent(PharmaVision, 2009) and has a
market size estimated to be worth in excess of $40 billion in 2009 (Carlson,
2009;Georg, 2005) compared to $12 billion in 2003 (Walsh, 2003) and some $33
billion in 2004 (Walsh, 2006). ……………………………………………………….
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By 2006, there were 165 approved biopharmaceutical products, these include
recombinant proteins, monoclonal antibodies and nucleic acid–based (Walsh, 2006),
and account for approximately 10 percent of the total expenditure for marketed drugs
(PharmaVision, 2009).
1.3 CHALLENGES WITHIN THE BIOPHARMACEUTICAL INDUSTRY
The process of bringing these products to the market is costly and risky.
Biopharmaceutical companies incur colossal research and development (R&D) costs in
getting a therapeutic product to market, in developing the product and allowing for the
numerous failed drug candidates. A survey of 10 pharmaceutical firms concluded that
the average out-of-pocket costs per new drug to the point of marketing approval was on
average US$ 802M (DiMasi et al.. 2003).Given the uncertainty associated with drug
development, biopharmaceutical companies will typically juggle a pipeline of drugs to
remain profitable (Rajapakse, 2005).
The significant revenue potential in successful biotherapuetic drugs weighs up against
the enormous cost risks involved in development. Some of the challenges will be in
attempting to shorten the development time to market, reduce production costs,
maximise process robustness and potential, and improve product quality. These aims
can be conflicting and often improving one can only happen at the expense of the
others. Product development therefore will often focus on achieving whichever of these
is considered to be of most importance; every company has a different strategy.
1.4 UNCERTAINTY DURING DEVELOPMENT
Changes are made to processes at all stages of a product’s life cycle, during
development and commercial stages. The need for changes to be made will decrease as
a drug goes through development and processes are generally set at Phase III clinical
development stage. The impact of implementing the changes, which can be measured by
the costs accrued indirectly and directly and time delays, will increase as a drug is
further developed and closer to filing for regulatory approval and can increase the risk
of repeating clinical trials, clinical failure, and losses in market share. During Early
phase clinical development there is the highest risk of clinical failure (Werner, 2004)
and so companies may not be willing to spend money on making changes. At the end of
Phase III clinical development there is the highest risk of losing market share; it is likely
that there will be a lengthy delay to prove product equivalence. Post- product approval,
there is a lower risk of losing market share, as the product is already in the market and
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the changes can be made in parallel to processing the product. This is summarised in
Figure 1.
Table 1.1Impact of making process changes at different points in a drug's life cycle.
Stage of Drug
Development
IND Phase I Phase II Phase III
Post-product
Approval
Risk of clinical
failure*
High
(71%) (77%) (47%)
Medium
(45%)
Low
(5%)
* Percentages give risk of clinical failure in the development of Monoclonal Antibody
products. (Werner, 2004.)
1.5 REGULATORY AUTHORITIES
If the drug candidate successfully completes phase III clinical trials then the company
can submit a new drug application (NDA) to the regulatory authorities. This will consist
of all the data from pre-clinical and clinical trials along with details of the
manufacturing process and proof that the process will consistently produce a pure, safe
and reliable drug. The regulatory authorities will then review the application and if they
are satisfied with the quality and quantity of data supplied the drug will be approved for
sale. The harmonization of regulatory processes among the three main national
regulatory agencies (the EU, the US and Japan) is making it easier for
biopharmaceutical companies seeking to establish a global presence for their products
(Walsh, 2006).
1.6 OPPORTUNITIES AND FUTURE PROSPECTS
Annual biopharmaceutical R&D expenditure is roughly $19–$20 billion with pipelines
largely dominated by biotech-based. There are an estimated 2,500 biotech drugs in the
discovery phase, 900 in preclinical trials and over 1,600 currently are in clinical trials
(Walsh, 2006). Cancer indications are the most common targets for biopharmaceuticals
development, whilst the most significant products are monoclonal antibodies (mAbs)
and vaccines. Annual sales of approved biopharmaceuticals in were estimated at $33
billion. Sales values of therapeutic mAbs are expected to reach $ $33 Billion by
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2012(Research and Markets Report, 2009). In total, the total biopharmaceutical market
should approach or perhaps exceed $70 billion by the end of the decade.
1.7 COLD ETHANOL PRECIPITATION
In the 1940’s a method for precipitating proteins from human plasma by varying the pH
and adding ethanol was developed, this method became known as the Cohn
fractionation process (Cohn, 1946). The method is used to purify a number of proteins
from human plasma including albumin, immunoglobulins and the various prothrombin
complexes. The method of cold ethanol precipitation is robust, well characterised, cost
effective and has an excellent safety record hence it has been used more widely than any
other technique . The original method has undergone many changes since its initial
development but the main principles of the process remain the same and are still being
used by plasma fractionators today.
Alcohol water mixtures tend to have a lower dielectric constant than water alone, which
increases the force of molecular interactions. However it was demonstrated that the low
temperatures of the Cohn process cause the dielectric constant of the medium to remain
largely unchanged by alcohol addition and the real driving force to be the dehydration
of proteins by alcohol (Reynolds, 2004). The dehydrated proteins then become strongly
attracted to each other and begin to form agglomerates. Another parameter that has an
influence on the solubility of the proteins is pH. At pH values above or below the
isoelectric point the net charge of the protein moves away from zero making the protein
more soluble.
The use of cold ethanol precipitation to fractionate blood plasma is based upon the
varying solubilities of the different plasma proteins. By manipulating the five key
variables; ethanol concentration, pH, temperature, ionic strength and protein
concentration, selected proteins can be made to precipitate thus enabling their separation
from the others by either filtration or centrifugation. The purity and yield of each
precipitated protein is a function of all the variables above. The complex interactions
involved and the interdependence of the variables makes mathematical modelling of the
process problematic. For this reason the operating conditions of large scale fractionation
processes tend to be carefully selected based on a combination of experimentation,
knowledge and experience (Stryker, 1985).
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1.8 COST DRIVERS-IVIG, ALBUMIN, OTHER PRODUCTS
The demand for purified Human Normal IgG (HNIG) from blood plasma has risen
significantly and there is a current shortage as the demand exceeds supply (Lebinget al.,
2003). Some of the major indications are listed in Table 1.2.
The industrial scale production of human immunoglobulins has been taking place since
the late 1940’s. The product has an excellent track record in terms of safety and
efficacy, which goes some way to explaining why the technology used in production
has only begun to change significantly over the last two decades (More and Harvey,
1991). Several techniques such as chromatography have been successfully developed in
producing high purity IgG from plasma (Lebinget al., 2003; Liet al, 2002). A number of
other methods have combined chromatography with the traditional method of cold
ethanol precipitation. This approach combines the safety, and robustness of the
traditional process with the high product purities achievable using chromatography.
Table 1.2Some major uses of intravenous imunoglobulin (IVIG). HyperimmuneIgGs
are not included.
Neurology Haematology Immunology Dermatology
Nephrology
rheumatology,
opthalmology and
other
GuillainBarre
syndrome (RCT and
CR)
Immune
thrombocytopenia
(RCT)
Primary antibody
deficiencies (XLA,
CVID, HIGM, WASand
others)
Kawasaki
syndrome
(RCT)
Vasculitis (RCT)
Multifocal motor
neuropathy (RCT)
Post bone marrow
transplant (RCT)
Secondary antibody
deficiencies (myeloma,
CLL (RCT), drugsand
other causes)
Dermatomyo
sitis (RCT)
Sysytemic lupus
erythematosis
Chronic
inflammatory
demyelinating
polyneuropathy
(RCT)
Myeloma and
chronic lymphocytic
leukaemia (RCT)
Toxic
epidermal
necrolysis
Streptococcal toxic
shock syndrome
Dermatomyositis
and inflammatory
myopathies (RCT)
Parvovirus B19-
associated aplasia
Blistering
diseases*
Birdshot
retinochoroidopathy
Myasthenia gravis
(RCT) Immune neutropenia
Immune
urticaria Autoimmune uveitis
Lambert–Eaton
syndrome (RCT)
Immune haemolytic
anaemia
Atopic
dermatitis
Mucous membrane
pemphigoid
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1.9 THE VALUE OF USING SIMULATION TOOLS TO MODEL ASSESS PROCESS
CHANGES
Simulation models are useful to predict and understand the impact of changes to a
manufacturing system. They can be extremely useful as a means to ‘analyze,
communicate, and document’ process changes (Harrison et al., 2003). Modelling a
bioprocess can provide a common reference and evaluation framework to facilitate
process development. The impact of process changes can be readily evaluated and
documented in a systematic way. Once a reliable model is available, it can be used to
identify cost-sensitive areas of a process. These are usually capital intensive process
steps or operating costs and also low yieldsor production throughputs (Petrides, 1994).
Modelling results can then be used in conjunction with scaled down and pilot plant
studies in order to optimize those portions of the process, leading to reduced
developments times. Hollockset al. (1995) also noted the benefits to manufacturing
processes through simulation. These were found to be a reduction in operating costs,
reduction in throughput time, faster implementation of plant changes reduction in
capital costs, reduction in design-to-market time, reduction in risk and greater
understanding of process. As production technologies for new drugs become
progressively more complex, seamless process development is crucial to maintaining
and improving manufacturing operations and in order to shorten timelines and reduce
cost of goods (Byromet al., 2000).
Modelling drug development and manufacturing processes enables the interactions
between the different bioprocess activities and the resource demands to be captured and
quantified. Bioprocess modelling has previously been used to explore the cost-
effectiveness of manufacturing options and to aid decision-making (Faridet al.., 2000;
Lim et al., 2005; Mustafa et al.,2005; Rajapakseet al. 2005; Biweret al. , 2005). In
these past investigations decision-support tools have been used to measure the cost of
goods in biopharmaceutical manufacture and in some cases the quantify impact of
manufacturing decisions on development timelines and costs. In addition, simulating
the drug development process and a portfolio of drugs with their development activities
has been explored. This provides management with the capacity to investigate several
strategies and to use the insight gained to make real-life decisions that would add value
in both the short and long term to the portfolio (Rajapakse, 2005).
Currently there are no tools available for implicitly assessing a change in a
manufacturing bioprocess. However, Farid (2001) and Lim (2005) have both
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demonstrated tools for simulating processes catered specifically for the bioprocess
industry. Therefore, there is an increasing need for adequate modelling and simulation
tools for the design and analysis of implementing changes to processes. In the present
contribution, hierarchical modelling strategies have been used to simulate detailed
manufacturing processes. Detailed activity based costing methods are used accounting
for labour, cost of material and other ancillary task resources (Farid, 2000; Lim, 2005;
Mustafa, 2005; Rajapakse, 2005).
A tool which takes into account all technical and business aspects involved in making
changes is required to be able to assess the various strategy options for implementing
process changes. Previous work by Lim (2005) has seen the start of the use of such
work, where Quality Control and Quality Assurance based activity resources and costs
were estimated and implemented into a manufacturing model. However, a much more
accurate simulation of the activities involved is required. In this paper a hierarchical
framework is proposed that accommodates all manufacturing, business and regulatory
activities involved when implementing a change. The software approach detailed in this
paper would be useful in a company for ensuring adequate linkage between process and
business decisions. An example would be the choice of manufacturing route to adopt
e.g. in-house versus contract manufacturing, and the implications of this on the key
performance metrics.
1.10 BIO PRODUCTS LABORATORY (BPL)
Bio Products Laboratory, Herts, UK run a large-scale plasma fractionation scheme from
which a wide range of therapeutic products are extracted. Plasma is sourced exclusively
from the US Plasma Collection Centre and the finished products supplied competitively
to the NHS. Where surplus of product exists it is supplied to selected overseas market.
Case studies used to give examples of process change in this thesis are based on BPL’s
fractionation process.
1.11 PROCESS CHANGE MANAGEMENT IN THE BIOLOGICS INDUSTRY
There are many economic and regulatory safety drivers that lead to changes being made
in the biopharmaceutical industry. Traditionally in the past, there was a reluctance to
make process changesowing to regulatory hurdles and costs. But now increased
pressures mean it is necessary to make changes to remain profitable.
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1.11.1 CHALLENGES IN THE BIOPHARMACEUTICAL INDUSTRY
In the past, small differences in the production process of biologics have yielded
different products, and can affect the safety and immunogenicity of the product
(Wagner, 2005). However, the positive impact of making changes to process steps,
especially with new emerging technologies (Tetzlaff, 2005), can be hugely significant,
and so a series of tradeoffs must be evaluated when choosing which, if any process
changes to implement. Results of a survey (summarised in Chapter 3) on the impact of
changes made to processes made in the biopharmaceutical industry showed that nearly
half of respondents believed that five or more changes are made to a single process in its
lifetime; demonstrating its importance in this industry.
Increased pressures in the industry mean that it is necessary to make changes to remain
profitable. There are two general approaches to manufacturing. Some companies, such
as Eli Lilly adopt a more ‘aggressive’ form of development; by using more generic,
well-established processes, which are more likely to be approved more quickly, rather
than extensively refining the process at early stages of development. Other companies
will make changes along the way, if they realise that a particular process step is not
going to be economically feasible. An example of this is Protherics, UK, who were
producing a septic shock drug, and during development removed a protein affinity
chromatography step as they found the overall running costs over time would be in the
scale of between $500M-$1 billion. The ‘aggressive’ approach companies tend to have
an emphasis on speed of entry into market, thus, enabling the capture of a larger
percentage of the market share. This can inevitably lead to processes that are not
running at their optimum potential with low productivity levels and process
inefficiencies. Therefore, to remain real competitors, these companies will eventually
need to retrofit and modify their processes post product approval. The alternative is to
prolong development until the process is well defined and optimised allowing for
enough slack for process changes. These companies may make significant
manufacturing changes from early to the later stages of clinical development, if they
realise that a particular process step is not going to be economically feasible. However,
these delays can cause the company to lose a considerable percentage of their market
share to competitors, which can result in considerable loss in sales revenue. A day’s
delay in gaining regulatory approval and product availability could be worth
approximately US$ 1 million (Clementoet al. , 1999). However, such delays in the time
to market are more often due to the deficiencies in manufacturing rather than to the
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scientific or clinical sections in the biotechnology industry (Fisher &Pascucci, 1996),
and so implementing changes early on can be beneficial.
However, it is often updates in regulations that force companies to implement changes
to their processes, as well as the need to run more efficient processes. The impact of
making a change to a manufacturing process is not trivial; in the biologics sector it is
often quoted that “the product is defined by its manufacturing process”. Even small
differences to a process can have a huge impact on product quality and product stability;
however, this depends on the molecular complexity of the drug. These process change
challenges have been summarised in Figure 1.1.
 Greater emphasis on speed to market
- “Aggressive” manufacturing - refine process post-
approval
- Greater % market share
 Improving bioprocesses & reducing
manufacturing costs
- Maximise product yields & purity
- Minimise use of expensive resources, utilities and
operating costs
- Increases profit
 Regulations
- Tighter compliance
Pressures are drivers in making process
changes at all stages of drug development
 Change can affect clinical safety & efficacy of
process/product
 Studies to prove product equivalence
- Comparability studies
- Clinical Trials
Activities to accommodate change
- Validation
- Retrofit
- Shutdown
“The product is defined by its manufacturing
process”
Figure 1.1Challenges in the biopharmaceutical industry that lead to process changes
Some examples of manufacturing changes that have an impact on the process are
summarised in Table 1.3; these may have a direct impact on the process description, or
could be equipment related changes or based on analytical techniques utilised. Multiple
changes of different magnitudes are normally made to a single process in its lifetime.
All these challenges highlight the requirement for adequate software tools to aid the
design and analysis of implementing changes to processes and to provide a systematic
way of evaluating their economic impact.
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Table 1.3Examples of some of the more common types of biopharmaceutical process
changes (Agalloco and Carleton, 2007)
Type of Change Examples
Direct process changes  A change in batch size or process parameter such as an
increase in fermentation culture growth time, which
would result in and increase cell proliferation.
 New or revised procedures
 A change in formulation chemistry
 A more moderate process change would be a change in
cleaning procedure or cleaning agents.
Equipment related change  A major equipment change, such as the scale-up of a
fermentation process
 Converting a single-product facility into a multi-product
facility
 The addition of new but comparable equipment, which
has no effect on the process such as a new fermentation
train, would be classed as a more moderate change.
Analytical based changes  A change in control methods, such as the deletion of a
method specification or an analytical method. The
addition of new control methods which requires no
deletion of current methods would be classed as a more
moderate change.
 The extension of expiration dating, or a change in
stability storage method.
 A change in site location of testing facilities is another
example of moderate analytical change.
1.11.2 INDUSTRIAL EXAMPLES OF BIOPROCESS CHANGES
1.11.2.1 THE DEVELOPMENT OF AAT
The example of developing alpha1-antitrypsin (AAT, an alpha1-proteinase inhibitor)
can be used to portray the complex issues arising from making changes to a plasma
fractionation process.This protein is used to treat hereditary AAT-deficiency (hereditary
emphysema), asthma, chronic bronchitis, cystic fibrosis, and neonatal respiratory
distress syndrome (RDS) (Curling, 2002).
AAT is currently isolated from Cohn Fraction IV-1 using a process in which the starting
fraction contains only 31% of the protein (Mattes et al.. 2001). In this method devised
by Coanet al.(1985), the paste is dissolved, subjected to fractional precipitation with
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PEG, DEAE Sepharose chromatography, diafiltration,and ultrafiltration to yield sterile
filtered product, which contains 50% of the starting AAT(Coan et al.. 1985). The
specific activity of the product is ≥ 0.35 mg of functional protein/mg protein with
“small amounts of other plasma proteins”. This process has been modified by Bayer
using anion-exchange and cation-exchange steps, incorporating Solvent/Detergent (S/D)
treatment, reactant removal in a third cation-exchange step, and terminal dry heat
treatment. This method improves the yield to 64%–70%, and in some cases achieves a
purity of 95% (Curling, 2002).
1.11.2.2 HUMANIZED MONOCLONAL ANTIBODY (SYNAGIS®)
Monoclonal antibodies (MAbs) are complex biomolecules composed of protein and
carbohydrate moieties. During manufacturing changes, there are many opportunities for
posttranslational modifications such as changes in carbohydrate structure or
deamidation, which could introduce microheterogeneity(Schenerman et al.. 1999).
Synagis® is a humanized monoclonal antibody directed against the F protein on
Respiratory Syncytial Virus (RSV). Schenermanet al. compared the product Synagis®
manufactured following changes in scale and facility was evaluated using a broad range
of product characterization methods. The Synagis® manufactured following the process
changes was compared to the product used in pivotal clinical studies.
1.11.3 POTENTIAL FOR CHANGE IN BLOOD-PLASMA INDUSTRY
Plasma protein fractionation is the largest industry segment in global therapeutic protein
manufacture. Currently in source plasma, (collected by plasmapheresis: the removal,
treatment, and return of (components of) blood plasma through blood circulation) about
7g/L of IgG is available and processing yields are on average between 2.5 and 4.5 g/L.
Optimising such process would improve yields by another 1g/L. However, if major
changes are made to the process steps, using higher yielding unit operations then an
increase in yield of 70% or more could be seen.(Curling, 2002)
Plasma is a unique source of multiple products, it contains about 60g/L of protein of
which approximately 57 grams are used for different therapeutic products, all with a
wide concentration range. Any change in the unit’s operational sequence will affect all
the products downstream of the change, and so it is typical that large-scale plasma
fractionators leave the bulk of their processes unchanged.
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1.11.4 CHANGE CONTROL
A formal change control system is normally established to evaluate all changes that may
affect the production process. Written procedures are provided for the identification,
documentation, appropriate review, and approval of changes in raw materials,
specifications, analytical methods, facilities, support systems, equipment (including
computer hardware), processing steps, labelling and packaging materials, and computer
software. It is necessary that any proposals for GMP relevant changes are drafted,
reviewed, and approved by the appropriate organisational units, and reviewed and
approved by the quality control departments. The potential impact of proposed
changes on the product quality is assessed using scale-down studies and lot-to-lot
testing prior to changes being implemented.
1.11.5 PROCESS CHANGE CLASSIFICATION
A classification procedure may help in determining the level of testing, validation, and
documentation needed to justify changes to a validated process. For example, the FDA
classes changes as minor or major depending on the nature and extent of the changes,
and the effects these changes may impart on the process. Scientific judgement
determines what additional testing and validation studies are appropriate to justify a
change in a validated process. When implementing approved changes, measures are
taken to ensure that all documents affected by the changes are revised. After the change
has been implemented, there is normally an evaluation of the first batches produced or
tested under the change. The potential for critical changes to affect established retest or
expiry dates is also evaluated. If necessary, samples of the intermediate or approved
product is produced by the modified process is placed on an accelerated stability
program and/or can be added to the stability monitoring program.
1.11.6 PRODUCT EQUIVALENCE STUDIES.
Demonstration of comparability is a sequential process, beginning with quality studies
and supported, as necessary, by non-clinical, clinical and/or pharmacovigilance studies.
If a manufacturer can provide evidence of comparability through physico-chemical and
biological studies, then non-clinical or clinical studies with the post-change product are
not warranted. In other cases, additional non-clinical and/or clinical data will be
required. The need, extent and nature of non-clinical and clinical comparability studies
can be determined on a case-by-case basis in consideration of various factors that may
be associated with risk. The EMEA have summarised these factors concisely in their
‘Guideline on Comparability of Biotechnology-Derived Medicinal Products After a
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Change in the Manufacturing Process: Clinical and Non Clinical Issues’(European
Medicines Agency (EMEA), 2007) as follows:
• The process complexity, the nature of the change, the potential impact on the molecule
structure and on the final product profile. The nature and extent of differences
demonstrated by the physico-chemical and quality related biological characterisation,
including product-related substances, impurity profile, stability and excipients. Thus,
well-characterised differences may provide a background for a rational and focused
approach with respect to the need for non-clinical and clinical studies.
• Product complexity, including heterogeneity and higher order structure and the
availability, capabilities and limitations of analytical tests. If the analytical procedures
used are not sufficient to discern relevant differences that can impact the safety and
efficacy of the product, additional non-clinical and/or confirmatory clinical testing may
be necessary.
• Structure-activity relationship and strength of the association of quality attributes with
safety and efficacy;
• Relationship between the therapeutic protein and endogenous proteins and the severity
of (potential) consequences for immunogenicity; e.g. risk of autoimmunity
• Mode of action: unknown or multiple modes of action complicate the evaluation of the
impact of changes
• Therapeutic indications/target patient groups - The impact of possible differences can
vary between the target populations covered by the different indications.
• Posology, e.g., dosing regimen and route of administration, for instance, repeated
administration via the subcutaneous route is more likely to be associated with
immunogenicity than intravenous administration of a single dose
• The therapeutic window/dose-response curve
• Previous experience, e.g., immunogenicity, safety. Experience with the pre-change
product or with other products in the same class can be relevant. However,
biotechnology-derived proteins should be considered individually.
For products in development, all these points above should be taken into consideration.
However, the extent of the comparability studies will likely increase if manufacturing
changes are introduced at the later stages of clinical development. A change after
conduct of confirmatory efficacy and safety studies represents the most challenging
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situation. The selection of non-clinical and clinical studies is product-driven, i.e. a
strategy for comparability testing should be chosen that best predicts and detects
clinically relevant differences with sufficient accuracy.
1.12 CONCLUSIONS
For companies to remain economical and to uphold to the stringent regulatory system
they must continuously improve processes by maximising yield potential, whilst
minimising resources, utility usage and operating costs throughout product
development, post-approval and marketing (Chirino and Mire-Sluis, 2004).
All these requirements and pressures drive companies in the industry to consider
making changes to manufacturing processes throughout all stages of a drug’s life cycle
(Werner, 2004). At earlier stages of drug development, there is an emphasis on speed of
product entry to market. Many companies will opt for the more ‘aggressive’ approach
to development by emphasising their efforts in rushing to market with a more or less
generic process (Sofer and Hagel, 1997). This will help companies capture a larger
share of their target market, nevertheless, in many cases this will lead to alterations
being made to improve the process at later stages of development, including post-
product approval. Bringing a therapeutic to market six months early or six months late
can lead to a one-third increase or decrease, respectively, in its lifetime
profitability(Forgione and Van Trier, 2006).
1.13 CONTRIBUTIONS, AIMS AND ORGANISATION OF THESIS
The aim of this thesis is to explore the consequences of making manufacturing changes
to processes within the biologics sector. This includes the description of a framework to
encapsulate possible technical, financial, and regulatory outcomes of such changes. This
allows for informed decision-making, and strategic planning when managing alternative
change scenarios. To demonstrate the usefulness of this method, examples of possible
financial, regulatory and experimental outcomes have been provided.
In Chapter 2, a survey portraying the results of a survey designed to benchmark the key
drivers and implications of making changes to bioprocesses in biotechnology companies
is provided. More specifically statistics are presented on the most common types of
manufacturing changes made, the most important reasons companies cite for making
these changes, their frequency and timing in a product’s lifecycle and the typical delays
and costs incurred to demonstrate product equivalence and satisfy regulatory authorities.
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In Chapter 3 a framework to help gauge the technical, regulatory and financial activities
involved in making such bioprocess changes and their implications is suggested. The
framework set-up and methods used to calculate the cost of a process change activity is
provided. The inputs required are described along with the outcomes used to measure
the change. Data collected throughout the study together with general assumptions
required to model the implications of a change is also presented
A case study utilising the framework to investigate the consequence of making process
changes, whether these are forced or are made to enhance productivity is explored in
Chapter 4. The study looks at the impact of making process changes of varying
magnitude and type to an IVIG fractionation stream at different stages of product
development including post-product approval.
In Chapter 5, another process change scenario investigates the purifying a new product
from a current waste fraction. The potential in purifying AAT from Fraction IV (FIV)
precipitate at BPL is explored. The method trialled is based on a process designed by
Keeet al., 2004. Laboratory scale experiments are used to assess whether there is
sufficient AAT in FIV paste and whether the purification process suggested by Keeet al.
can be applied to BPL’s fractionation process. The experiments involved mimicking the
first two isolation steps in the process.
In Chapter 6 a high throughput optimisation method using Surface-enhanced laser
desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology is
used to improve the low recovery of AAT obtained with anion exchange
chromatography, as step highlighted in Chapter 5. The usefulness of analysing samples
using Ciphergen® non-selective (NP20) chips is also compared to well-established
concentration determination methods, such as ELISA methods.
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Chapter 2
Process Changes: Benchmarking Industry Drivers
2.1 INTRODUCTION
The biopharmaceutical industry faces mounting competitive pressure to reduce costs of
manufacturing whilst increasing speed to market (Kleyn and Kitney, 2007;Rajapakse et
al.. 2004). Product competition, governing regulatory bodies and customer
requirements dictate a need for companies to strive for enhanced product purity and
process robustness (Narhi and Nordstrom, 2005). The manufacture of biological
products is a complex process. For companies to remain economical and uphold to the
stringent regulatory system they must regularly improve processes by maximising yield
potential, whilst minimising resources, utility usage and operating costs throughout
product development, post-approval and marketing (Chirino and Mire-Sluis, 2004;Lim
et al.. 2006;Mustafa, 2006;Werner, 2004).
All these requirements and pressures drive companies in the industry to consider
making changes to manufacturing processes throughout all stages of a drug’s life-cycle
(Werner, 2004). At earlier stages of drug development, there is an emphasis on speed of
product entry to market. Many companies will opt for a more “aggressive” approach to
development. In a rush to get a product to market before their competitors, process
optimization can be sacrificed for speed (Sofer and Hagel, 1997). Given that bringing a
therapeutic to market six months early can lead to a one-third increase in its lifetime
profitability and in the past it has even been quoted that getting a new product to market
as little as one month early was typically worth more to an organization than the same
product’s entire research and development costthere is a real incentive in “aggressive”
development (Forgione and Van Trier, 2006). However, a hastily assembled process
may pose scale-up challenges or not be cost-effective at a commercial scale. Some
companies prefer to take this approach, and then later redesign the process post-
approval. Others design robustness and validation into the process at very early stages
of development using established guidelines(Sofer and Hagel, 1997).
The impact of making a change to a manufacturing process is not trivial; in the
biologics sector it is often quoted that “the product is defined by its manufacturing
process”(Wagner, 2005). Even small differences to a process can have a huge impact on
product quality and product stability (Wagner, 2005) and so companies require
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regulatory approval to continue with clinical trials or commercial production (English,
2007). Although such changes are often intended to benefit the patient, it is essential
that any change in the manufacturing process does not adversely affect the safety or
efficacy of the product (Chirino and Mire-Sluis, 2004).
In the past, small differences in the production process of biologics have yielded
different products, and can affect the safety and immunogenicity of the product
(Wagner, 2005). However, the positive impact of making changes to process steps,
especially with new emerging technologies (Tetzlaff, 2005), can be hugely significant,
and so a series of tradeoffs must be evaluated when choosing which, if any, process
changes to implement.
In section 2.2 a description of the survey methodology is given. In section 2.3 the
survey results look at the reasons for making process changes, the types of changes,
how frequently they are made, the timing and implications of such changes, why
changes are not made, and if it is easier to make changes now or not.
2.2 SURVEY METHODOLOGY
A web survey was set-up so as to gain an insight into why changes are made to
manufacturing processes, the types of changes made, the frequency and timing of
process changes, the cost and time delay implications of changes made and reasons why
companies do not carry out proposed changes. It consisted of 13 multiple-choice,
Percentage breakdown, rating and fill-in type questions. The survey took approximately
10- 15 minutes to complete. The survey was emailed to over 500 employees of
biopharmaceutical and biotechnology companies worldwide including subscribers of
the journal Bioprocess International in April 2006. 81 responses were received. The
profile of respondents is indicated in Figure 2.8.
2.3 RESULTS
2.3.1 WHY ARE PROCESS CHANGES MADE?
Firstly, the principal motivations that drive biopharmaceutical companies to make
manufacturing changes were determined. Respondents were asked to choose the five
most common reasons for implementing a manufacturing change out of a choice of ten
(Figure 2.1). Industry responses suggest that the most likely reason for making process
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changes is to reduce batch-to-batch variability and hence achieve a more robust and
stable process. The remaining top four motives are: to increase yield or purity; to
manage a change in raw material supply; to reduce costs and to replace outdated
equipment or equipment with insufficient capacity.
2.8
2.3
2.1
1.8
1.8
1.6
0.4
0.4
0.3
0 1 2 3 4 5
Reduce batch-to-batch variability
Increase product yield or purity
Manage a change in resources /raw material /supply available
Reduce process costs
Replace outdated facility or equipment of insufficient capacity
Comply with changes in regulations
Manage a change in site re-location
A company merger requires the consolidation of processes
Incorporate the addition of a new product from an existing process
Score
Figure 2.1The key reasons for implementing manufacturing process changes in the
biopharmaceutical industry ranked in order of their average scores. The maximum score
of 5 indicates the most likely reason for making a change and 1 indicates the least likely
reason.
Reducing batch-to-batch variability is key to satisfying the stringent regulatory
requirements where the process must operate within validated limits and meet
predefined acceptance criteria. It is common for the process to be refined as clinical
development proceeds so as to increase process robustness as the product gets closer to
market (Chan& Jensen, 2004). These are usually minor changes and hence tend to only
require comparability assays to prove equivalence.
Making changes so as to increase product yield or purity also scored highly since
process improvements process improvements can make a significant contribution to
lowering the cost of goods, while saving investments and freeing up capacity for new
business. Such process improvements can be realized by ongoing improvements with no
major regulatory impact or by step-wise and significant enhancements requiring
regulatory measures. Werner (2004) provides an example of the financial impact of
yield improvements; a10-fold increase in fermentation titre coupled with a 30% increase
in yield resulted in a 6-fold reduction in the annual cost of goods.
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For example, process optimisation and intensification in the traditional blood plasma
fractionation industry have the potential to increase yields of IgG by 1g/L, a 14%
improvement in yield (Curling, 2002). On the other hand, major changes such as
replacing precipitation units with high yielding chromatography steps offer the
possibility of yields reaching values of 70% or more (typical precipitation yields are on
average 46%) (Curling, 2002)at the expense of increased equivalent and efficacy
studies.
Yield or purity enhancement changes will generally occur during the development stage
and it is less likely to be implemented post-approval, as it is likely to have a significant
effect on the product stability. If the product stability or efficacy is affected, then a
company will need re-approval from the regulatory agencies, and in some cases may
need to repeat clinical trials.
The need to switch to alternative raw material or utility supplies also forces companies
to make changes. This can arise from the availability of a cheaper or more reliable
supplier, the vendor discontinuing their line of supply in favour of organisations or
countries that are more profitable, or the vendor going out of business. The other key
reason given was to replace an outdated facility or equipment of insufficient capacity.
Companies looking to expand their market size may want to use larger equipment or
switch to newer units of operation that offer greater efficiency. While this type of
process change may reduce overall costs in the long run, the disruptions during
implementation of the change and immediate costs from resulting regulatory activities,
may radically increase short-term costs. Hence, decreasing the cost of implementing the
process change will inevitably be a fundamental issue when choosing alternative
process options for making the change.
2.3.2 HOW FREQUENTLY ARE PROCESS CHANGES MADE?
The number of changes made to processes can influence the process scheduling
patterns, the manufacturing costs, and can cause major delays in the development of a
product. Respondents were asked to indicate the average number of changes that are
made to a single process throughout a product’s life span (Figure 2.2). For companies
with multi-product facilities, the number of products in their portfolio that were subject
to change was also determined (Figure 2.2). Across the whole sample, nearly half the
respondents (45%) estimated that more than five changes are made to a single process
throughout a drug’s lifecycle. The bulk of the remaining respondents (36%) believed
that on average 2 to 5 changes are made to a single process. This implies that 81 % of
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respondents believe that on average 2 or more changes are made to every process
throughout development. For companies with multi-product facilities this can initiate
substantial costs and may result in scheduling problems. Only 7% of respondents stated
that no changes were made.
7%
12%
36%
45%
0% 10% 20% 30% 40% 50% 60%
None
1 change
Between 2 and 5 changes
More than 5 changes
Percentage of Respondents (%)
Figure 2.2Percentage distribution of industry responses by the number of changes that
are typically made to a single process in a drug’s life cycle.
This is important in not only assessing the costs involved in making the change to a
process, but also the types of studies that will be involved in assessing product
Table 2.1 lists the percentage of the products in a portfolio of drugs that have changes
made to them as estimated by respondents. Nearly two-thirds of the respondents (65%)
estimated that more than 50% of the drug products in their company’s portfolio had
changes made to them. This clearly shows that process changes are inevitable in
bioprocess manufacturing.
2.3.3 TYPES OF CHANGES MADE TO BIOPROCESSES
In this section, the nature of the changes most frequently made, for example an addition
or removal of a unit operation are explored. The magnitude of the changes made,
specifically the Percentage of the changes that respondents considered to be ‘major’ or
‘minor’ was also established.
This is important in not only assessing the costs involved in making the change to a
process, but also the types of studies that will be involved in assessing product
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Table 2.1 Percentage distribution of industry responses by proportion of portfolio
products experiencing process changes.
Percentage portfolio products with process % Respondents
More than 50% 67
Between 10% and 50% 17
Less than 10% 15
0% 1
Total 100
Number of respondents 81
equivalence. Regulatory agencies such as the US FDA, categorise manufacturing
process changes into three categories: major, moderate, and minor.
A major change is one that has substantial potential to have an adverse effect on the
identity, strength, quality, purity, or potency of a product as they may relate to the safety
or effectiveness of the product. A major change requires the submission of a
supplement and approval by FDA prior to distribution of the product made using the
change. This could be a change in operating step for example, a change from filtration
to centrifugation in recovery. A minor change is one that is considered to have minimal
potential to have an adverse effect on the identity product characteristics e.g. changes to
equipment of the same design and operating principle or changes in scale.(FDA
Guidance Document, 1998).
Respondents were asked to estimate the Percentage of changes that involved replacing a
unit operation, substituting two or more steps with a single new step e.g. the use of
expanded-bed adsorption, the addition of one or more new steps (with no elimination
involved) or an elimination of one or more steps (involving no addition of new steps).
The industry responses were averaged for each type of change and the results are
summarised in Table 2.2.
On average, respondents estimated that nearly 30% of changes that occur involve the
replacement of a manufacturing step from a process. This often includes the scaling up
of equipment, which should have minimal impact on the final product as noted by the
respondents.
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Table 2.2Percentage distribution of the different types of change.
Type of change % Breakdown
Replacing 1 step with a new step 29
Elimination of steps (with no addition of new steps) 17
Addition of new steps (with no elimination) 16
Replacing 2 or more steps with a new single step e.g. use of EBA 16
Other 23
Total 100
Number of respondents 81
The addition of new steps (16%) and the elimination of steps (17%) occur less
frequently according to respondents. A large proportion of respondents (23%) cited
other reasons for introducing changes to a process. Most respondents noted that the
most frequent change made to processes were modifications to existing process
parameters to yield better purities and efficiency, as other types of changes are more
complicated to manage from a regulatory perspective. Contract manufacturers will
make changes regularly to transfer to a new customer process. Many of the respondents
noted that they were forced to replace process steps to improve process safety or due to
changes in regulations. An example of this is the removal of animal-derived raw
materials from processes. Changes in formulation and a change of expression system to
provide higher expression levels were also prominent.
Generally, the respondents believed that only one-third of the changes made to a single
process in its lifecycle are “major” changes. Many respondents stated that “major”
changes were avoided where possible. New steps are added to increase product purity in
a scenario where perhaps a clinical adverse reaction has occurred in patients and there is
no other choice, otherwise, the risk is not taken as highlighted in Table 2.3. One
respondent highlighted that in their company minor changes that are made post-
approval are typically made for cleaning steps (non-product contact) to improve yields
(e.g. affinity column cleaning) that requires minimal regulatory approval.
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Table 2.3Percentage distribution of process changes by their magnitude.
Magnitude of change % Breakdown
Minor 67
Major 33
Total 100
Number of respondents 81
2.3.4 TIMING OF MAJOR PROCESS CHANGES
The regulatory consequences of manufacturing changes will depend not only upon their
nature but also on the stage of clinical development. The stages of a drug’s life-span
where “major” changes are most frequently made was established. The results in Figure
2.3 show that changes that are more significant are made at the earlier stages of
development. More than half (59%) of all changes are made at the preclinical stage or
at early phase product development. At this stage, the process may not be fully defined
and so changes are inevitable; also, the changes made here are prior to large clinical
trials and so it will not be costly to repeat any regulatory activities required or a repeat
may not be necessary to at all. On average 30% of changes are made during the later
clinical phases and 21% post-market approval. Typically, changes made during pivotal
studies or just prior to submission of a marketing application require more data to
support product comparability than manufacturing changes made during earlier phases
of clinical development. It may be riskier to implement a “major” change during the
later stages of development than post-product approval, because any necessary
regulatory activities cause a delay to market. Once the product has gone commercial,
the manufacturers can generate their product in parallel to introducing changes.
2.3.5 IMPLICATIONS OF MAKING PROCESS CHANGES
Major changes, such as modifications in the expression system or in a process sequence
of a given product can influence the levels of both product-related substances (e.g. those
derived from anticipated post-translational modification, with properties comparable to
the desired product) and impurities related to the product (molecular variants of the
desired product that do not share the comparable efficacy and safety)(Weinberg, 2005).
Therefore, once a change has been implemented, regulatory authorities demand that
proof of comparability or dedicated clinical comparative efficacy and safety studies are
carried out. Changes in production methods of a biological product may necessitate an
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assessment of comparability to ensure that these manufacturing changes have not
affected the safety, identity, purity, or efficacy of the product. This assessment typically
Pre-clinical to early
phase product
development stage
51%
Clinical Phase
29%
Post-Market
Approval
20%
Figure 2.3Timing of “major” process changes that occur throughout a drug’s lifecycle.
The values represent an average of the percentage breakdowns provided by respondents.
consists of a hierarchy of sequential tests in analytical testing, preclinical animal studies
and clinical studies (Chirino and Mire-Sluis, 2004). Comparability studies require that
physicochemical properties, biological activity, and immunochemical properties are
highly similar for pre-change and post-change products, and that where
physicochemical differences are detected, these changes have no adverse impact upon
the safety or efficacy of the product (Weinberg, 2005).
The implications of making process changes can be established by measuring accrued
cost, time delay and the severity of the regulatory activities involved. In this section, the
respondents were questioned on the types of studies that they utilised to assess product
equivalence at the later stages of development and post-market approval and the length
of time taken to complete them. This is illustrated in Figure 2.4 where the regulatory
studies involved are compared for phase III of process development and post-market
approval. Industry responses suggest that most changes made during phase III process
development or post-approval only require bioequivalence or comparability studies
(37% and 47% respectively) rather than a repeat of phase I (12%, 13%) or full-scale
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trials (13%, 18%). This is probably a reflection of the industry’s reluctance to make
major changes at late stage of development as highlighted earlier in Figure 2.3.
Respondents estimated that on average 24% of changes during phase III development
demanded re-validation of process and equipment, in contrast to 10% post-approval.
This correlates with comments from many of the respondents, who stated that the
majority of changes made post-approval were to modify existing equipment, thus
reducing the extent of re-validation. At the phase III development stage, all assays and
methods should have already been validated and should not require major process
changes.
37%
24%
12%
13%
8%
6%
47%
10%
13%
18%
7%
5%
0% 10% 20% 30% 40% 50%
Bioequivalence/comparability
Studies
Re-validation of process and
equipment
Phase I clinical trials
Full- scale clinical trials
Re-registration of Product
Other
Phase III Post-market approval
Figure 2.4The proportion of regulatory activities involved in assessing product
equivalence for process changes made during phase III of process development (black
bars) and post-market approval (white bars).
Based on the responses, the most likely durations of each stage are summarised in
Figure 2.5. Bioequivalence studies typically take up to 3 months and 3-12 months. In
general, the analytical studies involved in these activities can be performed in-house or
they can be outsourced and completed parallel to the production of lots for
comparability testing, avoiding lengthy delays. At the other end of the spectrum, a
repeat of full scale clinical trials can cause lengthy delays of over 18 months, according
to 68% of respondents, while a repeat of phase I clinical trials or re-registration of
product are typically quoted as requiring 12-18 months. The typical costs that are
amassed when demonstrating product equivalence was also analysed.
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Figure 2.6 shows the Percentage breakdown of the typical costs that are accumulated
when process changes require only bioequivalence studies and with those that need a
repeat of clinical trials. Over 70% of respondents estimated that bioequivalence studies
incurred costs under $500,000, and over 64% of respondents believed that the cost of
also repeating clinical trials was greater than $2M. To determine a more accurate figure,
a subgroup of the respondents (57%) were asked to choose from a range of costs in
these two categories. The subgroup estimated that bioequivalence studies typically cost
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Figure 2.5Thepercentage distribution of industry responses of typical durations of a)
bioequivalence studies ( ), b) revalidation of process and equipment ( ), c) a repeat of
clinical trials ( ), d) a repeat of full-scale clinical trials ( ), e) product re-registration
( ).
below $250,000 (70%) and a repeat of clinical trials typically cost $2M-$15M (38%).
Comparability studies have made it much easier to prove product equivalence, but only
covers changes that do not affect the product stability. A summary of these implications
is listed. In Table 2.4.
The top three factors influencing the likelihood of repeating clinical trials are the nature
and hence extent (44%) followed by regulatory requirements (25%) and the phase of
development (17%). Several respondents claimed that they would not implement any
changes that would require repeated clinical studies post-product approval, which may
explain why many respondents ranked phase of development last. This can explain the
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relatively low percentage estimation of stage of product development (17%) as a factor
in determining the re-use of clinical trials.
The scheduling strategy used to retrofit a process is essential in determining any delays
that may occur. The respondents were asked to choose the average length of shutdown
periods, when post-approval changes are required, as well as the methods utilised to
keep a continuity of supply. Table 2.5 lists the respondents estimation of the length of
time a facility is usually shutdown to accommodate the changes made and to revalidate
the process, specifically for post-approval changes.
36%
38%
13%
13%
64%
Between $500,000and £2,000,000 Between $2, 000,000 and $15, 000,000
Between $15, 000,000 and $50, 000,000 Between $50, 000,000and $100, 000,000
b)
a)
Sub group > $2M
5%
22%
3%
70%73%
More than $2,000,000 Between $500,000 and £2,000,000
Between $250,000 and £500,000 Less than $250,000
Sub group < $500,000
Figure 2.6Percentage distribution of industry responses by typical costs that incur when
process changes require a) only bioequivalence studies or b) also a repeat of clinical trials. The
pie chart breakdown represents the total sample. The subset group breakdown, represents 57%
of total responses.
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Table 2.4Typical durations and costs of product equivalence studies. The values in
brackets indicate the Percentage of respondents selecting the category shown. A
breakdown of the typical duration results is shown in Appendix Chapter 2.
The majority of respondents indicated that seamLess integration of changes was
possible, with no shutdown periods (44%,) or if there were shutdown periods they
typically lasted for 3 months (41%).
Table 2.5Percentage distribution of industry responses by shutdown durations during a
post-approval process change
% Respondents
No shut-down periods are required 43
0-3 months 38
3-6 months 17
More than 6 months 2
Total 100
Number of respondents 65
In Table 2.6 a list of the methods used by companies to maintain their continuity of
product supply. It can be seen that 49%of respondents run processes in parallel and
39% maintain that they stockpile their product in advance. However, only 7% of
companies choose to outsource to interim manufacturing organisations, to keep their
supply continuous. 5% of respondents said they do not use any of the above approaches
when implementing a manufacturing change and subsequently experience delays.
Clearly, the overall basis for making a change is to enhance overall profits. We tried to
establish some cost financial benefits of making the process change; however, only a
few respondents (15) provided data for this questions. These are summarised in Table
2.7, and provide an indication that process changes maybe expected to typically yield a
16% decrease in Cost of Goods (COG).
Product Equivalence Study Typical Duration Typical Cost
Bioequivalence/comparability studies Less than 3 months (47%) Up to $250000(70%)
Re-validation of process and equipment 3-12 months (46%)
Repeat of phase I clinical trials 12-18 months (41%)
Repeat of full- scale clinical trials More than 18 months (68%)
$2M-$15M
(38%)
Number of respondents 81(subgroup = 15)
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Table 2.6Percentage distribution of industry responses toapproaches used to maintain a
continuity of product supply during process change.
% Respondents
Product is stockpiled in advance 52
Processes are scheduled to run in parallel 38
Outsource to interim manufacturing organisations 6
Other 4
Total 100
Number of respondents 69
Table 2.7Average estimates of long-term financial benefits resulting from process
changes.
Average Percentage Change
Net present value, NPV gain 19
Return on Investment, ROI 29
Profit margin* 22
Mark-up* 33
Change in operating costs 16
Total 100
Number of respondents 15
*Although mark-up and profit margin are often used interchangeably they are in fact
different, mark-up percentage is the percentage difference between the actual cost and
the selling price, while gross margin percentage is the percentage difference between
the selling price and the profit.
2.3.6 REASONS FOR NOT MAKING PROCESS CHANGE
It is clear that the cost of implementing manufacturing changes and lengthy regulation
paperwork and approval from governing bodies stop many biopharmaceutical
companies from going ahead with process changes. Consequently, manufacturers think
twice about upgrading equipment or revising processes, even if it means forgoing
opportunities to modernize outdated systems and improve formulations (Wechsler,
2007) . In this section the reasons for not making process changes is explored.
Respondents were asked to give the five most likely reasons for choosing not to make a
manufacturing process change out of the seven reasons given in Figure 2.7.
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The top five reasons for not making changes are: the costs involved, the delay in
production, the requirement of regulatory approval, delay in product launch, and the risk
of having to prove equivalence. The largest number of respondents chose the cost of
process change as the most likely reason for not implementing change. This includes
validation studies and the possibility of repeating clinical trials. This again confirms that
whilst process changes may lower long-term costs, the delays and short-term costs from
regulatory activities prevent many improvements from being made.
3.1
2.7
2.5
2.4
2.2
0.9
0.3
0.2
0 1 2 3 4 5
Cost of process change, including validation studies and possibility
of repeating clinical trials
Delay in production, interrupting continuity of product supply
Requirement of regulatory re-approval of manufacturing process and
product.
Delay in production delaying launch of new products to market
Risk of failing to demonstrate product equivalence
Risk of long-term profit loss
Increase in product yield or purity.
Other
Note: 1 least likely reason and 5 most likely reason
Figure 2.7The key reasons for rejecting manufacturing process change proposals in the
biopharmaceutical industry ranked in order of their average scores. Note score of 5
indicates most likely reason to make a change and 1 indicates least likely reason.
The prospect of repeating clinical studies is a big deterrent, because of the costs and
time-delays it poses. Delays in process already in production, which could interrupting
continuity of supply was a key reason for not making changes to processes. Another
probable reason for not making change is the delay to market of a process still in
development. Some companies rush to market with a generic process, without refining
it or making changes during early stages of development, as this will increase their
market share. The requirement of regulatory approval, which could include re-
registration, is another major reason for opting not to make changes to a process.
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2.3.7 IS IT EASIER TO MAKE PROCESS CHANGES NOW?
Respondents were asked to give their opinion on whether it is now easier to make a
change in a process now than 10 years ago. The results suggest that there is not an
obvious answer; 51% of respondents said yes, making changes to process is easier now,
but 49% thought it was harder than 10 years ago. Those who said it was more difficult
to make changes reasoned that regulations are increasingly stringent and lengthier to get
through the requirements of regulations such as the introduction of ‘Guidance for
Industry Part 11, Electronic Records; Electronic Signatures — Scope and Application’
CFR part 11 (FDA Guidance Document, 2003) in the last 10 years(Wechsler, 2007).
However, those who think it may be easier said that regulatory bodies generally have a
greater understanding of many biologicals such as monoclonal antibodies, which are
considered “well characterised proteins”, and so companies are able to place more
emphasis on showing equivalency through analytical methods versus clinical data. For
highly glycosylated products and viral products the experience and tools still require
more development to give scientists the confidence to make process changes. There are
also better analytical techniques available now to aid in gaining regulatory acceptance.
Although regulatory agencies say they are considering changes on a risk basis, they do
not appear to have decreased the data requirements for making a change or significantly
decreased review times. Patent expiries, the prospect of 'generic' biologics, long
regulatory review periods and limitations to the number of changes that regulatory
authorities will consider per year all remain hurdles which deter companies from
making changes.
2.4 CONCLUSIONS
From this survey, we can conclude that changes are frequently being made to processes
in the biopharmaceutical industry, at all stages of product development. The main
reasons for change are to reduce batch-to-batch variability. Major changes are not
frequently made once process have been approved for production; the major deterrents
are the costs and delays to production. If a repeat of clinical studies is required to
demonstrate product comparability after a change is made, then it is likely that the
proposal for change will be rejected. Knowledge of the product and process, an
understanding of the capabilities and limitations of the analytical methods, and a
definition of the relationship between the quality attributes and the safety and efficacy
of the product are critical for appropriate assessment of the impact of a manufacturing
change. Where quality attributes have not been linked to safety and efficacy or where
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physiochemical differences observed have been known to impact the clinical properties
of the biological product, comparability of pre-change and post-change product may
need to include a combination of quality, non-clinical, and/or clinical studies
(Weinberg, 2005) .
This survey gives an overview of the general position and direction of the industry.
Answers given are a matter of opinion; however, senior professionals in the
biopharmaceutical industry were targeted (see profile of respondents in Figure 2.8). .
Did not state job title
24.7%
Bioprocess unit
director/manager
16.0%
R&D unit director/manager
13.6%
Senior Scientist
11.1%
Technical Specialist
11.1%
Process Engineer
8.6%
Consultant to
Biopharmaceutical Company
6.2%
Regulatory/Quality Director
4.9%
Chief Scientific Officer
3.7%
Figure 2.8The overall profile of respondents
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Chapter 3
A Framework to Gauge the Technical, Regulatory and
Financial Implications of Bioprocess Changes
3.1 INTRODUCTION
As indicated in the preceding chapters, during the development phase
biopharmaceutical companies will often try to reduce the cost of manufacturing whilst
increasing speed to market, resulting in less than efficient processes. In general, forced
and unforced bioprocess changes can transpire from excessive costs, product
competition, regulatory rules, and customer requirements, amongst other reasons. In this
chapter, a conceptual framework to assess the economic and manufacturing impacts of
making process changes in the manufacture of biologics is presented. The impact of
uncertainties when changes are made is also explored. This is then followed by a
description of the implementation of the framework into a decision-making tool.
In section 3.2 a detailed description of the biologics industry and process change
domain is that is addressed by the framework is given. In section 3.3 a description of the
scope of the model basis is presented. The process change activity framework is detailed
in section 3.4, and the modelling approach utilised is provided in section 3.5.
3.2 DOMAIN DESCRIPTION
The key features involved in process change management of biologics manufacturing
are identified in this section. As described in Chapters 2 and 3, implementing a process
change, no matter how small involves an inherent risk. Biological products are more
complex than pharmaceutical drugs, and so the demonstration of comparability is more
difficult and any changes manufacturing and scale-up can impede regulatory approval.
The change will have a direct and indirect impact on cost, time to market (if in
development phase), and approval from regulatory authorities. A method to capture the
tasks, resources, business issues and uncertainties involved in process change
development and implementation can be used as part of a company’s process
management strategy. The framework should be able to capture the variety of scenarios
that can result in a process change and the different outcomes when implemented. Some
of these possible scenarios are described here.
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3.2.1 TYPES OF PROCESS CHANGE
3.2.1.1 FORCED CHANGES
Not all changes are made to solely to improve process efficiency or purity or to reduce
costs. As suggested in the introduction in the biopharmaceutical industry manufacturers
are frequently required to make changes to their processes as enforced by regulatory
bodies, such as the US based Food and Drug Administration (FDA) or the European
Regulations European Agency for the Evaluation of Medicinal Products (EMEA) or
occasionally to meet new customer demands. Companies that do not comply with the
suggested changes may eventually be forced to shut down or they could lose a large
proportion of their market capture to competitors. The forced modifications have been
classified into categories of ‘minor’ and ‘major’ changes. The FDA define different
types of manufacturing changes into similar classifications. A major change is defined
as having substantial potential to have an adverse effect on the identity, strength,
quality, purity, or potency of a product as they may relate to the safety or effectiveness
of the product will eventually require an applicant to submit and receive FDA approval
of a supplement before distribution of the product with the manufacturing change.
Minor changes will require notifying FDA of the changes only in an annual report
(U.S.Food and Drug Administration, 1997).
3.2.1.2 MAJOR YIELD-IMPROVEMENT CHANGES
Process performance can also be improved with a cost reduction or yield enhancement.
Minor changes usually increase the cost-versus yield performance of a process. Only a
major technological change has the potential to drastically change the cost-yield ratio,
potentially providing a company with a significant competitive advantage (Baker and
Wheelwright, 2004). This is highlighted in Figure 3.1. As this figure highlights most
changes increase both cost and yield, and the only way to jump back across curves is if
you have a change that results in a major increase in yield that outweighs the
implementation costs. The changes should results in either large reductions in the cost
of recovery or large increases in yield, each with little or no negative impact on the
alternative measure. Thus, given a defined a defined recovery and purification process
for any product, yield enhancements within existing unit operation should shift the cost
relative to yield.
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3.2.2 TIMING OF CHANGES
Changes are made to processes at all stages of a product’s life cycle, during
development and commercial stages. The need for changes to be made will decrease as
a drug goes through development and processes are generally set at Phase III clinical
development stage. The impact of implementing the changes, which can be measured by
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Figure 3.1A hypothetical ‘yield versus operating cost’ curve for any recovery process.
Effective implementation of major changes are jumps in performance independent of
cost see arrow A to B. Adapted from (Baker and Wheelwright, 2004)
the costs accrued indirectly and directly and time delays, will increase as a drug is
further developed and closer to filing for regulatory approval and can increase the risk
of repeating clinical trials, clinical failure, and losses in market share. During early
phase clinical development there is the highest risk of clinical failure (Werner, 2004)
and so companies may not be willing to spend money on making changes. At the end of
Phase III clinical development there is the highest risk of losing market share; it is likely
that there will be a lengthy delay to prove product equivalence. Post- product approval,
there is a lower risk of losing market share, as the product is already in the market and
the changes can be made in parallel to processing the product. This is summarised in
Figure 3.2.
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Figure 3.2The risk of implementing process changes at different stages of a drug’s
development cycle.
3.2.3 OUTCOME OF PROCESS CHANGES
There are different possible product outcomes when making manufacturing process
changes:
 No difference may be seen as a result of the change, in this case where no further
studies to prove equivalence are necessary.
 Differences may be seen but can be justified; again, no further studies will be
necessary.
 Differences with limited analytical discernment is shown. This time further studies
will be necessary.
 Differences are great enough to have an impact on clinical efficacy, that they cannot
be excluded. Further studies are necessary. The result of this study can be positive
and thus acceptable, or negative and thus rejected.
The next section describes the process change framework, which should be able to
capture the variety of backgrounds and results of a bioprocess change.
3.3 SCOPE OF MODEL
The purpose of this model is to assess the full impact of making different possible
process changes, at all stages of development and under a variety of circumstances.
More specifically, the scope of the framework is defined as follows:
 To assess the full impact of making process changes in biomanufacturing.
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The tool attempts to cover the full economic and manufacturing impacts involved in
any process change project, including the effect of time delay.
 To capture the technical and regulatory activities in a generic framework for dealing
with process changes at any stage of a drugs life cycle.
The assessment should cover the different scenarios that might occur throughout
the different developmental phases, including post- product approval.
 To conduct profitability and risk analysis.
The implementation of a process change could be strategic in that it will increase
company profits, or if it is a forced change, then it may have a short- or long-term
detrimental impact on cost. The risk involved in such process changes is quantified,
and the critical ranges in key parameters involved are defined, allowing for the
alternatives being explored to be compared economically.
 To be able to assess industrially relevant case studies to demonstrate the use of the
framework.
The framework should be generic to the biopharmaceutical industry, allowing for a
speedy assessment of any type of change. As aforementioned, in this thesis, example
case studies centred on a human-derived plasma fractionation process based at Bio
Products Laboratories (Herts, UK) are employed to demonstrate the usefulness of
this tool. The use of the company-derived data also gives the research a greater
sense of commercial reality than previous works have.
In summary, the framework captures the risk and the rewards of making
biomanufacturing process changes and provides a rational basis for confident decision-
making in biopharmaceutical drug development and process optimisation. The
following section gives a detailed description of the framework and approach used to
model bioprocess changes.
3.4 PROCESS CHANGE ACTIVITY FRAMEWORK
A structured model modelling approach is used in order to capture all the activities that
are affected by making a bioprocess change and new activities that transpire when
accommodating the change. The framework is based on a hierarchical structure, which
encompasses all the possible technical and business related activities that may be
involved. The theoretical framework incorporates manufacturing, resource-allocation,
and regulatory associated tasks. All of these tasks will affect the strategic process
change decision-making. The tool structure clearly covers the key tasks and resources
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involved when arranged in this hierarchical, task- oriented manner. This methodology
has been used previously in The Department of Biochemical Engineering, University
College London to model the manufacture of biopharmaceuticals by researchers (Farid,
2001;Lim et al.2004) and to model the phases involved in the process of drug
development (Rajapakse, 2005;Karri et al.2001). The framework in this paper extends
the hierarchy further to incorporate the extra activities involved when making changes
to a bioprocess such as comparability studies and process validation, see Figure 3.3. The
hierarchical breakdown proves useful in providing maximum flexibility, as it allows
processes to be simulated at various levels of details. Modelling at the higher levels
gives an overview of the entire process with its key operational and economic
parameters. Subsequent details of each higher-level activity can obtained by breaking
them down into sub-tasks. The more detailed levels of modelling at a lower level and
give more accurate statistics and results. For example, changes to product yield can be
modelled in the manufacturing blocks in addition to the influence of regulatory hurdles
by accounting for comparability or product equivalence studies. As a result,
manufacturing alternatives or modifications can be evaluated in terms of process
economics, time, yield and resource utilisation.
As portrayed in the framework, at the highest level a ‘process change activity’ is
modelled, this is then broken down into the key activities that may be involved in such a
change, these are manufacturing, development, validation, product equivalence study,
and market activities. At a greater level of detail, these tasks can be broken down again.
For example, manufacturing is broken down into the process stream and its associated
ancillary tasks. This can be broken down further into each process unit, and its
associated ancillary tasks. For example for the each process unit, there will be labour
requirements and there may be associated Cleaning in Place (CIP), and Quality Control
and assurance (QC/QA) tasks. Each activity will have different inputs of time and cost
and will vary according to the process change type and magnitude. Lower level
frameworks for validation and product equivalence activities show how the tasks can be
split further to gauge the impact of a process change more accurately (Figure 3.4 and
Figure 3.5.).
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Figure 3.4A framework to model the validation activities that might occur when
implementing a process change activity
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`
Figure 3.5A framework to model the ‘product equivalence’ activities that might occur
when implementing a process change activity
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3.4.1 KEY PROCESS CHANGE ACTIVITIES
In this section an outline of the fundamental activities involved when making a process
change is described.
3.4.1.1 MANUFACTURING
The manufacturing task is the operative section in the ‘process change activity’
framework; this is where the actual change is made and subsequently shapes all the
other activities. It comprises of two sub sections; a process stream, in which a proposed
process change is being made and its associated ancillary tasks. The process stream
comprises the product manufacture activities (e.g. chromatography, filtration), and the
ancillary tasks comprise of process-related activities. These activities can be equipment
or material preparation such as Cleaning-In-Place (CIP) of reusable unit operations or
preparations, or regulatory-compliant activities in cGMP manufacturing plants, such as
QC/QA, lot reviews and batch documentation. Including these support activities is
necessary to improve the accuracy of cost and time-delay calculations.
3.4.1.2 RETROFIT
The retrofitting of the new process step or modification must be taken into account. The
chief risk will be the delay in development or the risk and length of a shutdown period
when modifications are made to the plant, as well as the installation of new equipment.
Labour costs should be taken into account; this may be outsourced in this task.
Regulatory activity involved in a retrofit task, such as validation is considered in a
separated section.
3.4.1.3 DEVELOPMENT
A process change activity may transpire either as a result of new advancements
stemming from a company’s research and development (R&D) laboratories or from
external factors such as suboptimal recoveries or regulatory influences. Therefore, prior
to a change being made there will have been ‘development activity’ where the proposed
change is analysed and optimised at laboratory scale. Although, R&D work is ongoing
in any successful biopharmaceutical company, the development cost and time should
still be included in the process change economics. This has been divided into scale
down experiments and assay development work.
3.4.1.4 VALIDATION
Validation is described in the US Food and drug Administration (FDA) as the
“establishment of documented evidence” conveying “ a high degree of assurance” that
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a “specific process” , pertaining to a particular product of interest, consistently
produces a product that fulfils pre-determined criteria and quality attributes (Center for
Drug Evaluation and Research, 2009). It is a requirement for cGMP compliant
processes , so as to obtain and gain and maintain a product license in the United States,
European Union amongst other regions. The studies must span all stages of
development and will take into account variations in raw materials (e.g. different plasma
sources in blood-fractionation process), and operating variables (Sofer and Zabriskie,
2000). This is work is typically carried out in manufacturing and QC/QA sections of a
company. In this study, the validation task has been divided into two key sections
‘Qualification’ and ‘Conformance and Validation Studies’.
3.4.1.4.1QUALIFICATION
Re-qualification activities may arise from change controls arising from process changes.
Prior to the initiation of process validation, the utilities, equipment and software (or
computer) systems need to meet certain criteria or ‘be qualified’. The qualification task
is split into six main activities: Design Qualification (DQ), Factory Acceptance Tests
(FAT), Site Acceptance Tests (SAT),Installation Qualification (IQ), Operation
Qualification (OQ), and Performance Qualification (PQ).
 DQ is a preliminary step in equipment qualification. It involves the affirmation that
pre-determined equipment requirements have been established and detailed designs
completed. This is prior to any construction or production that takes place in a
current good manufacturing practise (cGMP) dedicated facility area. Documented
assurance that these stipulated requirements will typically include engineering
drawings, process and instrumentation diagrams, process flow documents, air flow
and instrumentation diagrams.
 IQ is documented verification that systems (equipment, facilities, and utilities) its
components comply are included, properly installed, and fulfil design qualification
and manufacturer specifications. Calibration of equipment and utilities will be
performed too.
 OQ certifies that all the components of a system operate together as specified in DQ.
Tests are performed on the critical parameters of the system and or the process.
These are usually the independent of manipulated variables associated with the
equipment. All test data and measurements are documented in order to set a baseline
for the equipment or process.
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 PQ is performed on the manufacturing process as a whole; it ensures that the total
system performs as intended within specified operating ranges. The system includes
all hardware and software components, associated equipment, labour and procedures
that make up the system. Individual components of the system are not tested
independently. Various parameters in a system such as speed, response, capacity,
power are typically measured. The ability for a process to perform over long periods
of time within tolerances deemed acceptable is verified (Agalloco and Carleton,
2007;Center for Drug Evaluation and Research, 2009;Sofer and Zabriskie, 2000).
3.4.1.4.2PROCESS VALIDATION STUDIES
Any significant change to a process will result in the need for subsequent re-validation.
Process validation will ensure a robust product that is highly reproducible over time.
The manufacturing process, in addition to the individual equipment, must be validated.
The goal is to create a robust manufacturing process that consistently produces a drug
product with acceptable variation that adheres to quality criteria of purity, identity, and
potency. A validation plan for the manufacturing process should be drafted and
executed by engineers in order to satisfy guidelines. It involves the assessment of scale-
down and large-scale manufacturing validation studies.
 Scale-down study activities will include laboratory-scale validation of cGMP,
operating criteria applicable to yield and purity rather than equipment efficiency as
seen in PQ, assays developed in the ‘development activity’, and system cleaning
protocols. The validation of operating ranges will demonstrate that a product
manufactured within set operating criteria meets release specifications. Critical
operating parameters include temperature, pH, and composition of raw materials
amongst others.
 Full-scale studies will involve the validation of scalability studies between full-
scale, pre-clinical, clinical and small-scale process runs
 Cleaning validation should ensure the cleaning effectiveness of new equipment and
post-batch cleaning for non-disposable units. Cleaning methods are developed and
qualified to prove the removal of residuals or by-products from manufacturing and
cleaning activities. At points identified in the cleaning validation protocol, swab and
rinse samples are collected and analysed using qualified methods. Results from
three ‘conformity’ batches are required.
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 Viral clearance and spiking studies involving a process where change is
implemented will require the demonstration that the removal or inactivation of
impurities is still sufficient within acceptable levels. Viral clearance studies are
performed in scaled-down model systems within biologically contained
environments. Other clearance studies can be performed at full-scale.
 Lifetime studies of membrane and resins, where the maximum number of resin
cycles allowed before a resin is discarded commonly established by laboratory-scale
studies. They are designed to show consistent product recovery and purity. Defined
maximum resin lifetimes specific to the process under review, rather than generic
claims without supporting data are required by regulatory agencies, as there is
variability, for example in the plasma source and in chromatography regeneration
conditions (temperature, solute concentrations, volumes and resin contact time).
Current regulatory guidance calls for evaluation of the virus removal capability of
resins at the beginning and end of their lifetimes. Over time and after repeated use,
the ability of chromatography columns and other devices used in the purification
scheme to clear virus may vary (Kelley et al.. 2008).
 Computer validation of changes to the computerized system are made according to a
change procedure and are formally authorized, documented and tested. Records of
all changes, including modifications and enhancements made to the hardware,
software and any other critical component of the system are made, demonstrating
that a validated state has been maintained.
 Change control is a ‘formal system by which qualified representatives of appropriate
disciplines review proposed or actual changes that might affect validated states’
(International Conference on Harmonisation (ICH) of Technical Requirements for
Registration of Pharmaceuticals for Human Use, 2009). Once the process and its
equipment have been qualified and the product and process consistency validated,
then it is necessary to ensure that the process has not been deliberately changed even
in a minor form, without prior authorisation by appropriate individuals. The scale of
change control will depend on the process’ stage of development, and more
documentation will be required if a process has already been fully validated, i.e. at
the late phase of development and once a product has gone to market.
 Documentation of all qualification and validation activities is required. All
documents are prepared, reviewed, approved and distributed according to written
procedures. This will be spread across all departments within a biopharmaceutical
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company (Agalloco and Carleton, 2007;Center for Drug Evaluation and Research,
2009;Sofer and Zabriskie, 2000).
3.4.1.4.3PRODUCT EQUIVALENCE
Typically, product equivalence is a stepwise procedure, beginning with limited or
comprehensive quality studies and then, as necessary, supported by non-clinical,
clinical and or pharmacovigilance data. If a manufacturer can provide evidence of
comparability through physico-chemical and biological studies, then non-clinical or
clinical studies with the post-change product are not warranted. The need, extent and
nature of non-clinical and clinical comparability studies will be determined on a case-
by-case basis in consideration of various factors that may be associated with risk, such
as: Non clinical and clinical equivalence studies. This includes all experimental assays
used to prove product equivalence as well as the cost of producing enough material for
comparability lot to lot testing. Here the activities have been divided as follows:
 Comparability studies can involve small scale analytical and biological or bioassay
methods, as well as full scale conformity batches:
i. Analytical tests include both chemical and physical assays. Methods include
assays routinely carried out on all production lots: those initially used to fully
characterize product structure and identity, establish product consistency from
one production lot to another, and new tests if applicable.
ii. Bioassays are functional tests which assess the activity or potency of the
product. These tests may also serve as measurements of the biological integrity,
e.g. the correct conformation of the product and thus complement other
analytical measurements. Both assay types are validated and have a specific
range of acceptable values for defining product activity; this is included under
the ‘validation’ task.
iii. Stability studies identify whether a product’s stability has been affected post
change, this can occur even with slight modifications to the production. Any
change not readily detectable by the characterization studies and with the
potential to alter protein structure or purity and impurity profiles is evaluated for
its impact on stability. Accelerated and stress stability studies are often used to
establish degradation profiles and a direct comparison of pre-change and post-
change products.
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iv. ‘Conformance lots’ also known as ‘consistency’ or ‘qualification’ batches at a
commercial scale. In the United States a minimum of three consecutive lots are
required, whilst for European filings it is common practise to perform up to five
manufacturing runs. Comparability is not just about meeting specifications, post-
change material may be better, and thus efficacy must be proven(Sofer and
Zabriskie, 2000).
 Non-clinical ‘bridging’ studies which include in vitro studies and in vivo studies,
obtain preliminary efficacy, toxicity, pharmacokinetic (PK), and pharmacodynamic
(PD) information. In vitro Studies entail quality-related bioassays of pre- and post-
change products that are tested concurrently using a comparative study design.
With invivo studies, one or more relevant species or properly validated animal
models are used to resolve uncertainties vis-à-vis pharmacokinetic parameters and
pharmacodynamic effects relevant to the clinical application, and safety (Sofer and
Zabriskie, 2000).
 Clinical studies are the only method of determining the true potency of a product,
and clinical ‘bridging’ studies may be required from as early as developmental
phases I-II. At all phases, trials are designed to assess the safety
(pharmacovigilance), tolerability, pharmacokinetics, and the pharmacodynamics of a
drug. These studies are normally randomized controlled trials, and as a minimum
should have adequate power to demonstrate non-inferiority in terms of protective
immune response and to detect common adverse events for the tested. From late
phase II to post BLA filing, dosing studies, clinical efficacy studies, specific safety
studies, and immunogenicity studies will be determined. Typically, changes made
during pivotal studies or just prior to submission of a marketing application require
more data, and thus resources, time and cost, to support product comparability than
manufacturing changes made during earlier phases of clinical development. The
extent of the trial depends on the type of change made. In this study, the clinical
bridging studies have been split into small-scale, and large-scale activities (Figure
3.5).
 Regulatory reporting of all the product equivalence study protocols and results is
mandatory. The FDA has varying report types depending on the magnitude of
change and where in a drug’s life cycle the change is made. Minor process changes
can be implemented without approval; these are documented in full detail in the
‘Annual Report’. Moderate changes, must be filed under either the ‘Changes Being
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Effected CBE-0’ file, which allows the immediate distribution of the product once
the supplement has been submitted to FDA or CBE-30 requires that you must wait
30 days wait preceding to distribution. Major changes will require FDA approval
before any distribution of product, and this is filed under the ‘Prior Approval
Supplement’ (PAS) (Center for Biologics Evaluation and Research (CBER),
2001;FDA Guidance Document, 1998).
3.4.1.4.4MARKET
The process change can have an advantageous impact on the products selling price, but
it can also cause significant delays in going to market. This can significantly reduce the
market share captured. An evaluation of the impact of cost and time on potential profit
before a change is made will need to be carried out.
3.5 MODELLING APPROACH
A structured approach is used in order to facilitate the calculation of the impact of
making a process change within a biologics manufacturing process. Figure 3.6 provides
a simplified schematic of the proposed framework modelling methodology. The
framework has four elements: the process change activity, which includes a detailed
biomanufacturing process model and all validation activities; a profit and loss model; a
risk model, and a set of criteria used to distinguish between the strategic process change
options. The figure shows some of the main input and output parameters used in the
calculation. The outputs of the model include the cost, delay and risk of making a
process change. The cost analysis was extended to include profitability indicators such
as the Net Present Value (NPV) and Cost of Goods (COG).The cost of the
manufacturing process is calculated pre- and post-change implementation. The model
framework allows for interactions between activities such as, manufacturing mass
balance, resource utilisation, costing with validation, product equivalence, retrofit and
development activities. The method also looks at implementing any of these changes at
various stages of a drug’s life cycle, from pre-development phase to post-product
approval. This is described in section 4. This approach combined with the
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Figure 3.6A Simplified schematic of the main inputs and outputs of the proposed
framework.
hierarchical ‘Process change activity’ framework’ enables the calculation of different
scenarios rapidly and allow the assessment of whether the process change alternative is
feasible in terms of cost and time-delay. Different outputs can also be accessed. The
costs and duration of each task is available for analysis and comparison.
3.5.1 GENERIC ATTRIBUTES
3.5.1.1 RESOURCES
Each activity in the process change framework will utilise a range of resources. Much of
these are involved in biopharmaceutical development and in the everyday running of
biological processes. These include both renewable, e.g. labour, and facility, and non-
renewable which includes some materials and costs.
3.5.1.2 COST
The costs considered include the capital expenditure and investments that are accrued at
all stages of drug development. General biologics development costs will conclude
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capital costs for facility building, manufacturing for clinical trials and commercial
manufacturing. In costing for manufacturing both for clinical trials and the market, the
cost of goods per gram (COG) was calculated per batch. Other costs include process
development, and validation studies. These were collected through, a survey on process
changes (Chapter 3), literature (Rajapakse, 2005;Farid, 2001;George et al.. 2007;Lim et
al.. 2004) and through conversations with industrial experts (Bio Products
Laboratories). A good indication of the direct impact is to look at the installed cost,
working capital, and operating cost pre- and post-change. This alongside validation,
product equivalence, retrofit and market costs will give a good indicator of the impact
of the change.
3.5.1.3 DURATION
The duration of each task was either calculated based on inputs or distributions. The
durations of each task was inserted into the profit and loss model, and changes in cost
and time to market were computed. Again, duration estimates were taken from the
survey on process changes, literature and industrial expertise.
3.5.2 MANUFACTURING
The manufacturing process is at the core of the process change execution, other process
change tasks, such as validation, and equivalence studies are consequences of this
change in manufacturing. Therefore, while it was important to model the
biomanufacturing process in detail, it was more important to capture the strategically
important costs and risks of the manufacturing change. The scale of manufacturing will
vary depending on the stage of development. For this study, assumptions have been
made concerning the scaling at each stage, with a focus on methods used at Bio
Products Laboratory, UK; however, the approach and scaling used will vary from
company to company, as some companies scale-up processes at very late stage of
development or even after BLA (Biological license application) approval. There are
some advantages to keeping everything scaled-down through Phase III, but this means
an enormous gamble of scale-up and comparability assessment success. Zeid, 2005 cites
that companies such as Bayer use this strategy in developing Kogenate, a recombinant
coagulation factor VIII, as did Genentech with Activase, a recombinant tissue
plasminogen activator approved to treat acute heart problems such as myocardial
infarction (AMI) and acute ischemic strokes.
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There have been several publications on successful biomanufacturing modelling at
UCL(Chattre, 2008;Farid, 2001;Farid et al.. 2007;George et al.. 2007;Lim et al..
2004) to name but a few. Therefore, it was decided that these method would be
employed to model the manufacturing task to a sufficient degree of detail. The model
concepts and equations used are described in subsequent chapters, these were primarily
focused on the models created by Farid, 2001 (SimBiopharma), and by Lim, 2004
(Biopharmkit).
3.5.2.1 INTRODUCTION
The manufacturing task comprises operational tasks (e.g. filtration, chromatography),
ancillary tasks such as general equipment preparation (Cleaning-In-Place (CIP), and
Steaming-In-Place (SIP)), and specific equipment preparation (e.g. chromatography
column re-generation, equilibration), and regulatory compliance (QC/QA activity and
batch documentation) and the resource data required for each task: equipment,
operators, renewable materials, non-renewable materials, and utilities (Lim, 2005).
Process stream compositions are determined using a mass balance, based on equations
centred on the law of conversion of mass suggested by Farid, (2001, 2007).
In this study, the manufacturing model is centred on process streams, which are part of a
plasma fractionation process used at Bio Products Laboratories, Herts, UK. A database
of equipment costs, process step durations, materials utilisation, and global input
parameters to the model such as annual demand and overall product yield are collected
and verified by industrial experts. Each unit operation has a process model comprising
of the design equations and mass balances. These are used to size equipment, determine
the composition of the output streams and the amount of materials required (e.g.
chromatography buffers). Equipment sizes are determined by matching processing
requirements such as volume to a database of equipment dimensions available at the
time of writing. In some instances, since this work is based on a real process, if exact
unit sizes or other resource data is already known, then it is inserted directly rather than
calculated. A summary of these inputs and outputs has been presented in, as has been
previously employed by Farid, 2001, and Lim. 2004.
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Figure 3.7The key components of the manufacturing model
3.5.2.2 PROCESS MASS BALANCE CALCULATIONS
As previously mentioned, the mass balance calculation used to compute process stream
compositions were based on those derived by Farid, 2001. This model was chosen, as it
does not require complex input data, and also provides simple outputs that allow for the
rapid assessment of manufacturing scenarios. Each unit operation is modelled by a set
of equations that calculate the compositions of the process streams, as well as certain
process variables. The general mass-balance equation for operations is based on the law
of conservation of mass:

n
i
out
n
i
in ii mm
3.5.1
Where m is the mass of components ito n. The basis for the process models the mass
balance models derived by Farid have been included in Appendix Chapter 3for
reference purposes.
3.5.3 DEVELOPMENT
Development is made up of manufacturing activities for non-clinical and clinical trial
phases. To model various scenarios, cost and duration assumptions have been used,
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these are described in more detail in the case study in Chapter 5. Normally, processes
are optimized just prior to phase III development (Agalloco and Carleton, 2007), and so
it is assumed that pilot-scale manufacturing was required for Phases I-II, and full-scale
manufacturing was required for phase III. Different companies have different strategies
regarding timing of scale-up, some even waiting to scale up after acquiring a BLA from
the FDA. Pilot-scale manufacturing for development is calculated using the process
flowsheet method described in section 3.5.2, other assay development costs are
approximated based on literature references, and the costs provided by assay
development outsourcing companies.
3.5.3.1 CLINICAL TRIALS
Clinical trial costs are based on the number of patients and durations. In this case costs
and durations used, are based on the EMEA note for guidance on ‘The clinical
investigation of Human normal immunoglobulin for intravenous administration (IVIG)’
(EMEA: Committee for Proprietary Medicinal Products, 2000), which gives indication
on number of patients and duration that are very different to costs and durations
required for the development of for example monoclonal antibody products. Plasma-
derived products clinical trials require fewer patients than monoclonals; their toxicity is
not an issue considering their human origin. In addition, the clinical trial process is
different in that volunteer studies are not required and so trials start in patients as phase
I/II. A number of plasma products are also considered to be orphan drugs, which again
limit the extent of clinical trials and the number of patients necessary. (Personal
communication, Thierry Burnouf, Human Protein Process Sciences, Lille, France)
3.5.4 MEASURING THE COST OF PROCESS CHANGES
3.5.4.1 BIOPROCESS PLANT FIXED CAPITAL INVESTMENT
A factorial method for capital cost estimation is often used in process engineering
(Farid, 2007). In an approach initially proposed by Lang (1948) for chemical
engineering plants, the fixed capital investment (FCI) can be calculated by multiplying
the equipment cost by a “Lang” factor. The estimates are based on historical cost data
and connect the total capital cost of the biomanufacturing plant to the cost of the
equipment utilised. The Lang factor is dependent upon the type of process plant being
used (Novais et al.. 2001). The specific value for such a factor applicable to
bioprocessing plants is the total summation of individual factors that constitute the fixed
capital investment. The equipment costs are based on conversations with industrial
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experts at BPL or from literature (Farid, 2001;George et al.. 2007;Lim et al..
2004;Mustafa et al.. 2005). Equipment sizes are determined by matching processing
requirements such as volume to a known equipment dimensions.
This method provides an order-of-magnitude estimate of the fixed capital cost. In
addition to the equipment cost, the Lang factor accounts for cost factors relating to such
as piping, instrumentation, electrical work, buildings, utilities and site preparation, as
well as design and engineering costs and contractor’s fees. The value of the factor
depends on the type of plant. A cost equation summarising this technique is given:
3.5.2
Where, FCI = fixed capital investment, E = total equipment purchase cost, and L =
“Lang factor” for the plant. The factors f1 to f10 relate to Econvto give the cost of process
and utilities equipment (f1, f1 4 1), pipework and installation ( f2), process control ( f3),
instrumentation ( f4), electrical power ( f5), building ( f6), detail engineering ( f7),
construction and site management ( f8), commissioning ( f9), and validation ( f10). A
contingency factor, c, is also normally included. This is summarised in Table 3.1. For a
bioprocess plant, a Lang factor value of 8.13 has been recommended by Novaiset al.,
2001.
3.5.4.2 COST OF GOODS MODEL
The manufacturing cost is calculated based on the direct operating costs from the
process flowsheet. The costs of the QC/QA labour are also calculated as a function of
utilisation. The cost of staff per hour is inputted, and for each unit operation in the
process flowsheet, the requirements of the QC/QA and batch documentation activities
are specified. The remaining costs are calculated as percentages of the direct operating
labour or fixed capital investment. As well as the fixed capital investment, the other
manufacturing plant output used to measure costs is the Cost of goods (COG).
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Table 3.1Capital investment factors for bioprocessing plants and corresponding “Lang”
factors as suggested by Novais, 2001
Description f i
f1 - Equipment and utilities 1.00
f2 - Pipework and installation 0.90
f3 - Process control 0.37
f4 - Instrumentation 0.60
f5 - Electrical power 0.24
f6 - Building 1.66
f7 - Detail engineering 0.77
f8 - Construction and site management 0.40
f9 - Commissioning 0.07
f10 - Validation 1.06
c - contingency factor 1.15
Lang Factor 8.13
The COG model employed is shown in Table 3.2. This is frequently used in
bioprocessing and includes costs associated with cGMP biopharmaceutical plants
(Farid, 2001). The direct or variable costs are computed based on the utilisation of the
material, utilities and staff resources. The indirect costs or fixed overheads are derived
from the capital investment. Staff costs are based on their utilisation rather than
considering them as a fixed annual salary-based cost, as has previously been used by
Farid, 2001, Lim, 2004, George, 2007. A cost category termed “general utilities”
accounts for ongoing utility charges, such as HVAC systems. The cost is derived as a
function of the facility size or floor area.
3.5.4.3 ADDITIONAL PROCESS CHANGE ACTIVITY INVESTMENT
The assessment of all process change activity costs and times, include not only the
development cost, but also the cost and time required to meet regulatory requirements
inherent to changing a manufacturing process in a regulated environment. Collectively,
these values characterize each alternative. The implementation of a process change can
result in the new investment of equipment. If this is the case then validation of the
equipment and revalidation of the process will be required. The retrofitting of the new
equipment will include new piping installations, design validation, building
construction, electrical supply and instrumentation.
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Table 3.2Cost of goods model breakdown, adapted from(Mustafa et al.. 2005)
Cost category Value
Direct raw materials f (utilisation)
Miscellaneous materials 0.5 * Direct raw materials
Direct utilities f (utilisation)
Operating labour f (utilisation)
Supervisors 0.2 * Operating labour
Direct cost of goods
Quality Control & Quality
Assurance f(utilisation)
General management 1.0 * Operating labour
Maintenance 0.1 * FCI * Y
Local taxes 0.02 * FCI * Y
Insurance 0.01 * FCI * Y
Depreciation FCI / Depreciation period * Y
Indirect cost of goods
General utilities Cost per unit area per year *Facility size * Y
Total cost of goods - Direct COG / Indirect COG
Total cost of goods
per gram (COGs) -
Total COG / Annual production
output
Where FCI is the fixed capital investment and Y the project duration in years.
Within a process change activity, the new revalidation costs and retrofit costs are
required to calculate the inclusive new equipment investment costs. The Lang factor
method has been employed to calculate this by calculating the new fixed capital
investment. The new equipment costs are sourced from literature or industrial experts at
BPL and Jacobs Engineering Group Inc, UK. The new retrofit cost are calculated using
the following equation:
3.5.3
where is the retrofit cost if >1, otherwise:
3.5.4
The new revalidation cost is calculated in the same fashion:
3.5.5
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where is the revalidation cost if >1, otherwise:
3.5.6
and so, the new fixed capital investment is calculated as follows:
3.5.7
where, En = total equipment purchase cost, and Ln = the additional Lang factors, i.e. the
summation of the retrofit factor (fRf) and revalidation factor (fRv).
As suggested previously, the type of change made can be categorized into two groups
of minor and major. The cost impact of a major change on revalidation and retrofitting
costs will differ to that of a minor change; this has been captured in the revalidation and
retrofit calculations (Table 3.3 and Table 3.4).
Table 3.3Capital Investment Lang factors to calculate retrofit and revalidation costs of a
‘minor’ bioprocess change
Description f i
New Capital investment 1
New Pipework and installation 0.9
New equip design and engineering 0.77
New electrical supply 0.24
New Instrumentation 0.6
Retrofit 3.51
Revalidation 1.06
Contingency factor 1.15
Total Process Change Lang Factor 5.26
Table 3.4Capital Investment Lang factors to calculate retrofit and revalidation costs of a
‘major’ bioprocess change
Description f i
New Capital investment 1
New Pipework and installation 0.9
New equip design and engineering 0.77
New Building (extension) 1.66
New electrical supply 0.24
New Instrumentation 0.6
Retrofit 5.17
Revalidation 1.06
Contingency factor 1.15
Total Process Change Lang Factor 7.16
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The new development costs will include scaled down manufacturing and assay
development. The new scaled down manufacturing activity is calculated as a function of
the new manufacturing cost, as has been done for general biopharmaceutical
development manufacturing in section 3.5.3. Any new assay development pre-process
change implementation has been estimated as a percentage of the cost for assay
development of a new drug, based on the project duration. These costs were verified by
industrialists, through personal communications at BPL. Development durations were
taken from benchmark data from the survey results in Chapter 2, from literature or
based on the ‘real’ industrial case examples at Bio Products Laboratory.
Comparability study costs are based on those from the manufacturing lots, and QC/QA
effort required to analyse and verify the necessary batches. The clinical bioequivalence
study cost estimates are dependent on the type of change made and stage the change is
made in, and these are classified as extensive or of small scale. These cost estimates
have been taken from benchmark data from the survey in Chapter 2, and literature
estimates.
As summary of the costing methods used to capture the process change activities is
portrayed in Table 3.5. The features of this costing method are further explored in the
case study presented in chapter 5.
Table 3.5A Summary of the Process Change Costing Methods
Item Basis
Manufacturing Costs f (Detailed process flowsheet)
Revalidation Costs f (New equipment cost, validation Lang factor)
Retrofit Costs f (New equipment cost, retrofit Lang factor*)
Comparability Studies f (Consistency batches, QC/QA)
Clinical Trials Costs f (Phase of development, type of change)
Development Costs f (Detailed process flowsheet**, assay
development cost)
*Retrofit Lang factor is the summation of capital investment, new pipe work and
installation, new equipment design and engineering, new electrical supply, and new
instrumentation; ** Indicates pilot scale manufacturing.
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3.5.5 PROFIT
Many financial performance metrics can be used to measure the profitability or the
potential detrimental costs of implementing a process change proposal. The most
widely used techniques are: Payback time, with or without interest, return on investment
(ROI), interest of rate of return (IRR), and net present value (NPV) (Humphreys and
Wellman, 1996). NPV is used as it gives a good indication of the layout of investments,
future costs and revenue outcomes across all phases of development through to
commercial phase (Rajapakse, 2005). In this case NPV has been used as an indicator of
how much value an investment or project adds or loses as the case may be for a process
change. The Net Present Value (NPV) of a project or investment is defined as the sum
of the present values of the annual cash flows minus the initial investment. The net or
annual cash flows are discounted or adjusted by incorporating the uncertainty and time
value of money. The calculation of NPV involves identifying the size and timing of the
expected future cash flows generated by the project or investment, determining the
discount rate or the estimated rate of return for the project, and calculate the NPV using
the equations shown in Table 3.6.
A project should only really be invested in, if the NPV is greater than or equal to zero.
If the NPV is less than zero, the project will not provide enough financial benefits to
justify the investment, since there are alternative investments that will earn at least the
rate of return of the investment. In theory, a company will select all the projects with a
positive NPV. However, because of capital or budget constraints a percentage change in
NPV can be used to compare process change options. This is determined as follows:
3.5.8
If NPVold>1, otherwise
3.5.9
Table 3.6The steps are used to calculate the portfolio NPV for each year of operation,
adapted from (Rajapakse, 2005;Rajapakse, 2004)
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Year (t)
Category 0 1 2 … n
A. Total capital investment
B. Revenue
C. Running costs (without depreciation)
D. Profit (B-C)
E. Depreciation
F. Taxable profit (D-E)
G. Tax (33% of F)
H. Net cash flow (-A+B-C-G)
I. Discount factor ( tr)1(
1

)*
J. Annual present value (H*I)
K. Net present value (

n
t
tJ
0
)
*r is the discount rate, and t is the year.
3.5.6 RISK
A great deal of uncertainty and risk is present implementing a process change. Factors
such as process yields, costs, delays, regulatory approval, pricing, and market share
capture all involve a factor of risk. By incorporating the effects of risk, the functionality
of the framework was enhanced as it enabled the certainty associated with output
measures to be expressed. Once the key uncertainties are identified, probability
distributions are assigned in order to reflect the risk of a proposed strategy. Expert
opinion was used to identify suitable distributions. Monte Carlo simulation technique is
used to determine resulting frequency distributions of the output measures using the
‘@Risk 5.0 for Excel’ risk analysis software ( Palisade Corporation, Newfield, NY,
USA). The software allows a wide variety of distributions, both continuous as well as
discrete to be applied. For each of the distributions, the mean and standard deviations
are set before the simulation starts. This allowed the possibility of setting the type of
distribution that best described each parameter during simulation studies. For example,
the product equivalence study could be described using a discrete distribution, e.g.
either with clinical trials or without situation, whereas the variation of the cost of
process validation or retrofitting could be specified using a triangular distribution.
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Probability descriptions of input variables and Monte Carlo sampling together provide a
practical method of finding the distribution of the desired output given the various
random and deterministic input variables (Farid, 2001;Rajapakse, 2004).
3.6 CONCLUSIONS
This chapter has provided a hierarchical framework that captures all activities involved
in introducing process change activities; capturing both the technical and regulatory
activities involved. An overall discussion of the framework set-up and methods used to
calculate the cost of a process change activity has been provided. Inputs into the model
and the outputs from the tool have been summarised to provide an understanding of the
capabilities of this method. Much work has been put into collecting data that can be
used as default data for the simulations. These have been presented along with other
assumptions made.
The application of the tool is demonstrated through a case study in the next chapter
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Chapter 4
Evaluating the Implications of Making Process Changes
Throughout a Drug’s Lifecycle
4.1 INTRODUCTION
As described in previous Chapters, forced and unforced bioprocess changes can emerge
as a cost-reduction exercise, or result from product competition, regulatory rule
changes, or to satisfy new customer needs. In this chapter, the conceptual framework
and methods suggested in the preceding chapter will be used to assess the economic and
manufacturing impacts of making different types of process changes at different stages
of drug development. The impact of uncertainties when the changes are made is also
explored. The case study in this chapter is based upon a plasma-fractionation process,
producing intravenous immunoglobulin (IVIG).
4.1.1 OPPORTUNITIES FOR CHANGE IN PLASMA-DERIVED IVIG FRACTIONATION
An industry where process change modelling is highly relevant is the human plasma
fractionation sector. Plasma protein fractionation is by far the largest industry segment
in global therapeutic protein manufacture. More than 500 metric tons (about 492
imperial tons) of human serum albumin (HSA) and more than 60 tons of intravenous
immunoglobulins (IVIG) are produced annually from more than 22 million litres of
source and recovered plasma(Curling, 2002). This $6.9 billion industry supplies
products to more than one million patients each year.
The Cohn–Oncley ‘backbone’ fractionation processes as described in the Chapter 2, was
primarily designed to purify albumin. Processes for other plasma proteins have been
developed either by addition of (cryo-)precipitation or adsorptive technologies before
using ethanol fractionation or by mainly chromatographic processing of fractions of the
Cohn system, and so consequently IVIG production is far from optimised. By
implementing minor changes and attempting to optimise their current processes,
fractionators have the scope to increase yields by another one g/L (Curling, 2002).
However, major improvements where process changes and the implementation of high
yielding units may also increase yields and purity of the final product significantly, an
increase in yield of 70% or more may be seen amongst all products derived from plasma
fractionation, as suggested by Curling, 2002. In general, major losses of IVIG of up to
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25% (approximately 1.6g/L) commonly occur during Fractionation III or B+1
precipitation stages (Curling, 2002;Teschner et al.. 2007).
High pathogen safety and high yields have also become the dominant goals of the
plasma fractionation industry, and thus improvements have frequently been made and in
some cases still can be enhanced (Buchacher and Iberer, 2006).
The purification principles of IVIG have not changed dramatically in the last two
decades (Buchacher and Iberer, 2006). Manufacturers operations have focused on the
prevention and removal of aggregates when it turned out that aggregates are responsible
for product related side effects. Demand for IVIG has escalated over the past 20 years
and currently exceeds availability (Lebing et al.. 1999). This growth in the market has
come about as a direct result of increased usage in healthcare procedures. The market
potential for IVIG is large, but it is virtually impossible for new plasma fractionators to
set up because of the huge costs involved, or for existing fractionators to increase their
overall production capacity due to a lack of a source of ‘processable’ human plasma.
IVIG yields, however, can be optimised by making changes to existing processes, and
there are several possibilities for improving process yields (Lebinget al., 2003; Curling,
2002).
In fractionation circles, regulators still hold the philosophy that ‘the process defines the
product’ and many companies are still reluctant to make any changes. With the
framework presented in this chapter, companies can make a more informed choice
based on costs, revenues, delays, and uncertainties involved.
The remainder of this chapter is structured as follows. Section 4.2 describes the
background to the case study and the process change scenarios investigated. Section 4.3
summarises the methodology and case study assumptions for the initial deterministic
analysis. Section 4.4 presents the results of the deterministic comparison of process
changes made pre and post-approval. Section 4.5 and 4.6 summarise the methodology
results and discussion of the risk analysis and cost where the impact of the technical and
regulatory uncertainties on the attractiveness of the process change scenarios was
evaluated.
4.2 CASESTUDY BACKGROUND
4.2.1 BPLIVIG PURIFICATION
The IVIG production process at BPL is based upon cold ethanol fractionation. Fresh
frozen plasma is purified to selectively precipitate major proteins in plasma, using
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variations in concentration of ethanol, salt, temperature. The exact conditions used are a
combination of those from Cohn -Method 6 (See Appendix 4- Figure 1) and those
developed by Kitsler and Nitchman (1962). Albumin and IgG are largely separated by
the second precipitation step (the Fraction A+1 stage) and then undergo a series of
further precipitations to remove impurities.Final purification is achieved using ion
exchange chromatography with DEAE-Sephadex media to capture impurities. After
chromatography the process stream is practically pure IgG (>99%), this is processed
further to remove adventitious agents such as viruses and is then adjusted to the desired
concentration, formulated and sterile filled ready for distribution (Reynolds, 2004). A
basic process flow sheet depicting the steps involved in the IVIG production stream is
shown in Figure 4.1.
Figure 4.1 A process flow sheet depicting and example of a plasma fractionation
scheme based on a combination of Cohn (Method 6) and Kitsler and Nitchmanmethods,
with a focus on the IVIG production stream.
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4.2.2 SCENARIOS
The use of this framework for assessing the impact of making manufacturing changes
on strategic technical and business indicators is exhibited via a case study. The case
study is based on a ‘real’ industry scenario where different changes have been
implemented to the IVIG processing stream of a plasma fractionation process over a
number of years. The aim of these examples are to illustrate how the decision-support
software can be used by biopharmaceutical companies to investigate the effects of
optimising their processes to increase the cost-effectiveness of their process, prior to
committing to a particular option.
4.2.2.1 FORCED CHANGES SCENARIOS
The IVIG purification process at BPL has undergone a number of changes over the
years. Two examples of process changes that were ‘forced’ upon the company are
described in this section. Forced changes could be set by the regulatory authorities or set
by customer demand. The ‘forced’ changes have been categorized as a ‘minor’ and a
‘major’ change. The ‘forced minor’ change scenario was the addition of a viral filtration
step to the IVIG process. This step was added to complete a three step viral log
reduction, in adherence with newer regulatory requirements, and to satisfy customer
preference, see Table 4.1.
If the change was not made, the company could lose a percentage of their market
capture, as it is a customer preference, but also it is foreseen that the addition of this
step will eventually become obligatory and so, if the change is not made, they could
lose all the market.
The ‘forced’ major change scenario is a set of formulation modifications. Firstly, the
final product is modified from a solid freeze-dried form to a liquid formulation. This
mainly consists of the removal of a lyophilisation step. Liquid formulations are
preferred to those that are freeze-dried, again because of patients, pharmacists and
doctor preference. Secondly, the formulation composition was changed, to using
Sorbitol and Polysorbate 80 as a replacement stabiliser to sucrose and albumin.
Advanced studies have shown that the old formulation containing albumin and sucrose
was not tolerated by all patients. Again, this is considered a ‘forced’ change, because
without the modifications, the company risk losing their customers and maybe even
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approval, and thus lose a share of their market capture to other IVIG fractionators. Also,
the use of albumin as the major stabiliser significantly added to the manufacturing costs
of the product, as it is a product itself, and any reduction in such costs is as
advantageous.
The risks of having to repeat clinical studies to prove efficacy increases with major
changes. In reality, the changes were made at various stages of development and some
changes were made simultaneously. However, to gauge the full impact of every change,
the changes are modelled separately and at all stages of a drug’s life cycle.
4.2.2.2 A MAJOR YIELD-IMPROVING CHANGE SCENARIO
One type of change that has not been implemented to IVIG process stream, is one that
would a greatly enhancing the product yield. Typical processing yields purify IVIG to
2.5–4.5 g/L. As stated earlier, minor process optimization can improve yields by
approximately1 g/L (Curling, 2002). Only major modifications to the process stream
can increase yield to up to 70% or more. These changes need to come from the
implementation of high yielding unit operations. At BPL, losses of 25%
(approximately1.6g/L) are identified at B+I fraction stage (seeFigure 4.2), whilst
moderate or low losses are also seen at other stages (BPL Internal Presentation, 2005).
There is good evidence to suggest that high recoveries can be achieved by replacing
fractionation steps with chromatographic processes (Curling et al.. 2005). The
replacement of this ethanol fractionation step may improve selectivity and specificity to
yield a product with a higher purity. Enhanced binding capacity may allow for
downsizing the following separation steps and improving productivity (Burnouf, 1995;
Lebing, 2003) suggest that chromatographic steps replacing the traditional ethanol
fractionation steps decrease overall production time, increase IVIG yield from plasma,
improve physiological IgG and purity. Therefore a proposal has been made to establish
chromatography-based purification stages, downstream process from Fraction II to bulk
formulated product. This change will lead to modifications that will require an
adjustment of the subsequent process steps. One such example of the replacement of
‘B+1’ fractionation and possible subsequent steps has been suggested at BPL(BPL
Internal Presentation, 2005), and is shown in Figure 4.2 d). This modification will
require extensive validation to demonstrate the quality and safety of the final purified
product, which will be costly and time consuming. Again, as this is a major change full-
scale clinical efficacy studies may be necessary, if insufficient product and process
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comparability is proven through bioequivalence studies alone. This is the riskiest
process change suggested, but if successful, could reap long-term profits.
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This yield-enhancing change suggestion as well as the forced change scenarios have all
been modelled at early phase and late phase development, as well as after the product
has been commercialised. The scenarios have been summarised in Table 4.1, and a
comparison of the different IVIG purification streams is shown in Figure 4.2.
(a) Base case 1
nothingaddedherejust
B+1 Precipitation
Fraction II
Precipitation
DEAE Sephadex
Adsorption
Solvent/Detergent
Treatment
CM Sepharose Fast
Flow I/E
Ultrafiltration
Formulation
Filling
Freeze-dry
IVIG
A+1 Precipitate
(c) Major change 1
Removal/Replacement
B+1 Precipitation
Fraction II
Precipitation
DEAE Sephadex
Adsorption
Solvent/Detergent
Treatment
CM Sepharose Fast
Flow I/E
Ultrafiltration
New Formulation
Filling
Freeze-dry step
removed
IVIG
(b) Minor change
Addition
B+1 Precipitation
Fraction II
Precipitation
DEAE Sephadex
Adsorption
Solvent/Detergent
Treatment
CM Sepharose Fast
Flow I/E
Ultrafiltration
Formulation
Virus Filtration (and
pre-filter)
Filling
Freeze-dry
IVIG
(d.)Major change 2
Replacement
Depth Filtration
Q-Sepharose Fast Flow
I/E
Ultrafiltration
DEAE Sephadex
Adsorption
Solvent/Detergent
Treatment
CM Sepharose
Fast Flow I/E
Ultrafiltration
Formulation
Filling
Freeze-dry
IVIG
Figure 4.2. Process change scenariosinvestigated: (a) the base case (b) a minor change
with the an additional virus inactivation step, (c) a major change where the formulation
process is modified and the freeze dryer step is removed, and (d) a major change where
Fraction B+1 precipitation is replaced with a chromatography-based purification
Chapter4 -Evaluating the Implications of Making Process Changes Throughout a Drug’s Lifecycle
87
step.Note. The formulation steps refers to the addition of either sucrose and albumin or
sorbitol and Polysorbate 80.
4.3 METHOD- DETERMINISTIC ANALYSIS
4.3.1 DATA COLLECTION
Part of the work involved in preparing a tool for prototyping drug development is to
collect data to populate the model and verify the outputs. In this study, BPL’s IVIG
manufacturing process was modelled, attempting to keep equipment sizes, and costs,
and resources utilised as realistic as possible, so as to be able to verify whether process
change activities simulated were acceptable or not. Therefore, the bulk of the data used
was obtained from personal communications at BPL, such as, facility size, material
costs, equipment sizes, plasma costs. However not all data was readily available, and
the remainder of costs were obtained from literature, such as clinical trial costs, risks
and durations (DiMasi et al.. 2003;EMEA: Committee for Proprietary Medicinal
Products, 2000;Rajapakse, 2004), typical unit yields (Curling, 2002;Farid, 2001). Other
costs for equipment were obtained from Jacobs Engineering Group Inc., UK. Process
change activity costs and durations were obtained from benchmark data resulting from
the survey in Chapter 3. Some costs, such as those for process validation and assay
development were given ‘ballpark’ costs obtained from outsourcing websites, such as
Immunochemistry technologies LLC, and verified with industrial experts at UCL and
BPL. Probability distributions used to simulate the risk involved in the process change
activities were approximated based on typical scenarios situations and again validated
via discussions with industrialist experts. While sensible inputs were sought, the prime
target was to demonstrate the application of the framework to capture all the activities
involved in a process change scenario.
4.3.2 MANUFACTURING AND FACILITY ASSUMPTIONS AND INPUTS
A summary of the default input values used in the model is given in Table 4.2 and Table
4.3. As described in the previous chapter, the method for calculating the fixed capital
investment was obtained by multiplying the total equipment purchase cost by a factor,
traditionally termed the Lang factor. The Lang factor was assumed to have a base
value of 8.13 according to Novaiset al.. (2000). The default value for the annual facility
cost of general utilities per unit floor area was assumed to be $300/m2(Limet al., 2004).
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The costs for known resources were inputted as raw data, these costs were sourced from
communications at BPL, and were based on their true sizes. However, some of the data
costs acquired from literature and Jacobs engineering Inc, were estimated using a ratio
of their sizes, raised to an index value.
This is shown in the following equation:
4.3.1
Where n is the index value, 0.6 (based on the six-tenth rule used by process engineers
(Sinnott, 1993). Some of the inputs, such as the plasma source, and initial process steps
are used to manufacture other plasma-derived products such as albumin, and the clotting
factor proteins, and so these costs and resources are divided amongst all the products.
IVIG, the current cost-driver in the fractionation process will typically use 40% of the
resources shared amongst the whole plant, and use 50% of resources shared solely
between IVIG and albumin.
Table 4.2A summary of some of the default model inputs
Default Inputs
IVIG or Plasma Input Value
Average plasma start pool weight (kg) av. 6200
Cost of plasma ($/g) 130
Max number of batches/Week 2
Typical number of batches/Year 80
Market patient size in the UK 3000
3,000IVIG Market Capture (%) 40%
Av. Vol Blood Plasma/ Batch (L) 6200
IVIG selling price ($) 45
6,200Facility Input Value
Lang Factor 8.1
Depreciation Period (%) 10
Facility Size for IVIG manufacture (m2) 7604
Equipment cost estimation factor 0.6
General Utilities Cost Per Unit Area ($) 300
NPV Input
Project Duration (Yr) 12
Depreciation (%) 10
Interest rate (%) 10
Discount factor (%) 10
Tax (%) 33
1GBP=1.6USD (2009)Exchange rate 1EUR=1.5USD (2009)
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Table4.3A summary of some of the resource cost data collected for the manufacturing
calculations
Manufacturing Resources
Labour Cost ($/hr)
Operator 30
section manager 60
QC/QA Staff 50
Utilities Cost ($)
WFI 0.032/L1
Steam 0.0144/Kg
Cooling Water 0.001/L
DEMIN 0.01/Kg
Chemicals and Biochemcials Cost ($)
Sodium Hydroxide 4/Kg
Sodium Chloride 1.5/Kg
Polysorbate 80 50/Kg
Sucrose 9/Kg
Albumin 3000/Kg2
TnBP (tri(n-butyl)Phosphate detergent ) 51/L
Glycine 16/L
Soy bean oil 55/L
Glacial Acetic Acid 5/L
20% Ethanol 670/tonne
Sorbitol 59/Kg
Filter Aid (Kg) Hyflo Super-Cel 944/Kg3
Consumables Size Cost ($)
Ultrafiltration modules 1m2 1,500
Virus removal pre-filter cartridge 1 m2 800
Virus removal 50nm Virus filter 36 m2 6,3004
Membrane Cassettes ($/unit) 0.5 m2 2,100
Lenticular depth filter sheet 3.2 m2 240
depth filter (0.5μm) 10" 128
Plate and frame sheets - 2
0.22 Micron Cartridge Filter () ($/unit) 0.05 m2 75
DEAE - Sephadex matrix($/Kg) 1kg 1,838
Ion Exchange Matrix ($/L) (reusibility * 250) 1L 420
1.(WFI costs varied from £5-16/m3)
2.£15000/Kg
3.£8850/15Kg
4. £3960/Filter
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Manufacturing Resources
Equipment Size Cost ($)
Cost of Balance (weighing) - 5,000
Cost of crusher - 5,000
Plasma thawing tank - 36,000
Holding Tank 1000L 37,500
Jacketed Fraction Vessel 500L 32,000
Disk Stack Centrifugation 65,00rpm 160,000
Heat Exchanger 100m2 10,579
DEAE Sephadex adsorption Tank 600L 16,000
Vibromixer - 8,000
Silverson Mixer - 16,000
CM Sepharose Fast Flow chromatography column 1.6mdiameter 208,000
Virus Inactivation Tank 0.1m3 2,750
Plate and frame filter press system - 16,000
Cuno Housing Filtration system2 housings/3trolleys - 1,320,0001
Depth Filtration Housing (Fraction B+1) - 9,600
Virus Filtration housing 14.5m by10m 112,000
Filtration system - 320,000
Millipore UF unit 14.5m by10m 700,000
Depth Filtration unit - 320,000
Dead-End Filtration unit - 75,000
CIP Vessel (mobile) - 120,000
Large Scale Chromatography System with Process Control - 1,000,000
Chromatography column, Height = 20cm, D= dm 0.7 120,000
0.8 165,000
1 200,000
2 550,000
Chromatography Rig - 250,000
jacket 500L vessel cost- 20K 500 32,000
Mobile vessel 500 80,000
Freeze dryer - 320,000
Filter press - 400,000
Mobile vessel 500 80,000
Bottle & Stopper filling system - 6,400,000
1- £35,000 per trolley
4.3.3 IVIG CLINICAL TRIALS
In general, clinical trial studies for plasma-derived products require fewer patients than
other therapeutics, as their toxicity is not an issue considering their human origin. The
studies do not involve a volunteer phase (normally phase I), but rather begin in patients
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as phase I/II. Also, a number of plasma products are considered to be ‘orphan drugs’,
which again limit the extent of clinical studies required and the number of patients
involved (EMEA: Committee for Proprietary Medicinal Products, 2000; personal
communication with Thierry Burnouf, Human Protein Process Sciences, Lille, France).
IVIG is primarily used to treat patients with antibody deficiencies, as described in
Chapter 1, of which there are many indications. It is assumed that two primary studies
took place: a primary antibody deficiencies (PAD) trial, this covers congenital
agammaglobulinaemia,hypogammaglobulinaemia, and common variable and severe
combined immunodeficiencies, and ITP trials (Idiopathic Thrombocytopenic Purpura)
which also covers, Kawasaki disease and Guillain-Barré Syndrome indications. The
costs, durations, and patient numbers used to calculate clinical study costs in this study
are given in Table 4.4.
Table 4.4 Resource assumptions for Clinical Trial of plasma derived IVIG
4.3.4 NET PRESENT VALUE
The drug life cycle is modelled from the pre-clinical study phase through to commercial
phase, and then for another 12 years. A typical drug life cycle runs 12–15 years after its
launch (Pandey, 2003). A depreciation value of 10% was used for the calculations, the
tax was set at 33% and a discount factor of 10% was used. At the end of each year the
model outputs the year’s expenses and revenues in order for the NPV calculation for
that particular year to be performed. A payback period of ten years was used for loans.
The interest was set at 10%.
4.4 RESULTS- DETERMINISTIC ECONOMIC EVALUATION
4.4.1 COST OF GOODS
Cost comparisons of the base case, a ‘forced’ minor change, an addition of a virus
inactivation step, a ‘forced’ major change where the formulation is modified, and a
major change- where B+1 precipitation is replaced with a chromatography-based
purification step is shown in Figure 4.3. In the plasma fractionation industry direct costs
are much higher than that of typical pharmaceutical manufacturing process, mainly due
Phase of Clinical trial
(IVIG)
Costs
($)
Duration
(months)
Number of
Patients
Pre-clinical Studies $0.16M 72 -
Phase II Studies $0.4M 2 15-50
Phase III Studies $3M 15 50-100
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to the exceptionally high raw material cost of plasma source at approximately
$150/L(Burnouf, 2005;Waller, 2005).The plasma source makes up 33% of costs in the
base case, with 29% making up the remainder of the direct costs. In industry, the plasma
costs have been shown to make up 22%-50% of total costs depending on the scale of
operation (Curling et al.. 2005;Curling et al.. 2009). The minor change shows an
increase in raw material cost, and this changes the cost percentage breakdown
somewhat. The major formulation change shows a significant decrease in raw material
costs, mainly from the removal of albumin in the product (IVIG ) formulation. Albumin
is itself a product and has a retail price of $3/g, this is removed along with sucrose at
$0.01/g, and both replaced with Polysorbate 80 at $0.05/g and Sorbitol at $59/Kg. This
‘forced’ change example gives a beneficial outcome when evaluating the cost of goods
alone. The major chromatography process change in Figure 4.3 d) portrays a significant
reduction in raw material usage, decreasing the percentage costs from 13% to 7%. There
is also a considerable increase in indirect costs mainly from the new capital invested in
new equipment.
Figure 4.4 shows the total annual cost of goods per gram categorised into direct and
indirect costs of the different process change scenarios. The variation in total cost of
goods per gram is principally from the direct costs. Only the major chromatography
change shows a significant increase in indirect cost of goods from $17/g to $20/g. Here
the minor change shows an increase in direct costs mainly arising from $30,000 in
additional direct raw material costs, this will in turn impacts on the miscellaneous raw
material costs calculated and the total direct costs. The slight decrease in variable and
fixed costs seen in the major formulation change is due to the removal of a freeze dryer
unit and a decrease in raw materials costs described earlier. The total cost of goods per
gram remains similar at $43/g, $47/g, and $42/g for the base case, the minor change and
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Source Plasma
26.2%
Direct Raw
Materials
14.2% MiscellaneousRaw Materials
7.1%
Direct Utilities
0.8%
Operating
Labour
2.9%
Supervisors
0.6%
General
Management
2.9%
Total Indirect
Cost
45.4%
Source Plasma
33.5%
Direct Raw
Materials
12.4%
Miscellaneous
Raw Materials
6.2%
Direct Utilities
0.9%
Operating
Labour
3.6%
Supervisors
0.7%
General
Management
3.6%
Total Indirect
Cost
39.2%
Source Plasma
32.7%
Direct Raw
Materials
13.2%
Miscellaneous
Raw Materials
6.6%
Direct Utilities
0.9%
Operating
Labour
3.6%
Supervisors
0.7%
General
Management
3.6%
Total Indirect
Cost
38.8%
A) B)
C) D)
Source Plasma
30.6% Direct RawMaterials
16.1%
Miscellaneous
Raw Materials
8.1%
Direct Utilities
0.9%
Operating
Labour
3.5%
Supervisors
0.7%
General
Management
3.5%
Total Indirect
Cost
36.6%
Figure 4.3Process change scenario cost comparisons of (A) the base case, (B) a
‘forced’ minor change -an addition of a virus inactivation step, (C) a ‘forced’ major
change where the formulation is modified (D) a major change- where B+1 precipitation
is replaced with a chromatography-based purification step.
the formulation change respectively. It is however, significantly decreased to $32/g for
the chromatography replacement option, making it a desirable option. This however
does not take into account ‘process change activity’ costs.
4.5 METHOD- RISK ANALYSIS
For every scenario, the process change framework was used to capture all the
subsequent activities that may be encountered. All three scenarios were implemented at
early phase clinical trials, late phase development, and post product approval. To be
able to compute the impact of a process change scenario, a number of cost, duration,
and uncertainty assumptions had to be made. The uncertain inputs are assigned
probability distributions and calculated using Monte Carlo simulations.
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Figure 4.4The total annual COG/g (direct and indirect costs) comparison of different
process change scenarios
4.5.1 PROBABILITY DISTRIBUTIONS
Probability distributions describe the range of possible values that a random
variable can attain and the probability that the value of the random variable is within
any measurable subset of that range. The distribution types used in the scenarios are
described next.
4.5.1.1 TRIANGULAR DISTRIBUTIONS
In probability theory and statistics, the triangular distribution is a continuous probability
distribution with lower limit (a), mode (b) and upper limit (c).
a bc
2/(b-a)
P(x)
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Where the probability is:
4.5.1
For each triangular probability distributions the lower limit, mode and upper limit
represent the worst case, base case and best-case scenarios, respectively. For discrete
distributions, the probability of occurrence is given. In this study triangular distributions
have been used to model uncertainty in costs, such as revalidation and retrofit costs.
4.5.1.2 DISCRETE DISTRIBUTIONS
A discrete distribution describes the probabilistic properties of a random variable that
takes on a set of values that are discrete, i.e. separate and distinct from one another.
Discrete values are separated only by a finite number of units. In this study it has been
used in situations where there is an ‘either/or’ scenario. For example, product
equivalence activities will entail either non-clinical comparability studies, or clinical
bridging studies.
4.5.2 MONTE CARLO SET-UP
To incorporate the risk of uncertainty in key input factors, the inputs were assigned
probabilities of occurrence and distributions, and Monte Carlo simulations were
performed. The Monte Carlo method relies on repeated random sampling to compute
the results.
4.5.3 SCENARIO ASSUMPTIONS
Table 4.5shows a list of the key input values, assumptions and probabilities used to model
the process change scenarios. Assumptions for the key activities involved in
implementing the change, their costs, durations and risk of occurrence have been
suggested for the three different stages of development, as well as for the scenario
possibility of no change being made, this is considered the base case option.
 Batch number - the number of batches was kept the same throughout all process
change scenarios. The batch size is determined by the plasma pool donated, on
average 6200L per batch, with a capacity to run 80 batches per year. However, to
account for possible batch losses or potential increased pool sizes, a triangular
probability distribution with the possibility of ± 5 batches was used.
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 Selling price - it is assumed that the selling price will not vary with the process
changes. Uncertainty in the pricing from competition and fluctuations in the market
have been reflected with a ±10% triangular distribution.
 Annual cost of goods – the cost of goods may vary for the base case and with the
minor and major formulation changes mainly from direct cost uncertainties such as
raw material costs and utility usage. For the major yield improvement change, the
costs are more uncertain, due to new equipment costs, as well as direct cost
uncertainties.
 Retrofitting and revalidation costs - these have been given a ±25% triangular
distribution.
 Product equivalence activities – this will either consist of solely non-clinical
comparability work or will also include clinical studies. This has been given a
discrete probability of occurrence. The likelihood of clinical trials occurring will
increase with the size of the change being made as well as the timing. The later the
stage of development, the more likely clinical trials will need to be repeated.
 The cost of product equivalence - this also increases with the change magnitude and
timing. This is also uncertain and has been given a ±25% triangular distribution.
 Delays to market– delays to the market may occur whilst a change is being
implemented. This disruption includes retrofitting, revalidation ad regulatory
approval d setbacks. Once a product is approved and is commercial, the product can
be stockpiled whilst a change is being made, and so will result minimal losses in
revenue.
 Market share – the company may see market share losses if customer requirements
are not met, i.e. if the ‘forced’ changes are not made. Therefore, losses are more
likely to occur in the ‘no change’ case. The scenarios are investigated with and
without market share loss considerations. The demand of IVIG normally surpasses
the demand, (although this may be changing with increased competition), and so the
market share may not be affected. Although, if regulatory recommendations are not
satisfied, it will be affected.
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4.6 RESUL
TS-
RISK
ANALY
SIS
In addition to
the cost of
goods, Net
Present
Value (NPV)
is used to
assess the
impact of
making the
different
process
changes.
This is where
the process
change
activities
have been
taken into
account.
When the
key
uncertainties
are
incorporated,
the range of
possible
expected
NPV values
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and their likelihood can be calculated. The expected NPV(ENPV), i.e. the mean of each
distribution, was computed for each scenario based on the inputs and assumptions
shown inTable 4.5, firstly, without considering market share loss uncertainties and then
including market share losses.
4.7 ENPV WITHOUT THE UNCERTAINTY OF MARKET SHARE LOSSES
Figure 4.5 shows the distribution of thenet present value for the ‘no change scenario’
compared to the ‘forced’ minor change scenario implemented at the various stages of
development: early phase development, late phase development, and post-product
approval. Making no change seems to be the most attractive option, with the most
positive percentagechange in ENPV over a 13 year time period, taking all uncertainties
into account . The early and late phase changes shift the distribution curves significantly
to the left indicating that the model predicts that making changes during development
significantly reduces the likelihood of it being profitable. Post-approval and early phase
changes give a bimodal distribution depending on whether a repeat of clinical trials is
required or not, but theENPV is more attractive for the change made post-product
approval.
Figure 4.6 and Figure 4.7portray the distribution of the net present value in for the
‘forced’ major change, and the major yield-enhancing change. There is not a significant
difference in NPV distribution between the two major change scenarios. In both cases,
the change made at early phase development is less profitable than the minor change,
but has a similar ENPV to the post-product approval change. Late phase changes again
show the least desirable outcomes, with an even greater decrease in ENPV. Again, a
binomial distribution is portrayed, this is dependent on whether clinical trials or
comparability studies are necessary, clinical trials giving the most undesirable NPV. For
the minor changes, we do not see binomial distributions, as the NPV is most sensitive to
the delays to market caused by the change; as the comparability study costs will be
lower, as in most cases there will be no requirement for a repeat of clinical trials.
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Figure 4.5Distribution of thenet present value in for a ‘forced’ minor change scenario at
the various stages of development: no change (), early phase development (), late
phase development (▲), and post-product approval ().The risk of potential market
share losses is not taken into account.
Figure 4.6Distribution of the net present value in for a ‘forced’ major change scenario
at the various stages of development: no change (), early phase development (), late
phase development (▲), and post-product approval ().The risk of potential market
share losses is not taken into account.
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Figure 4.7Distribution of thenet present value in for a major yield improving change
scenario at the various stages of development: no change (), early phase development
(), late phase development (▲), and post-product approval ().The risk of potential
market share losses is not taken into account.
The percent change in expected net present value from the base case of all the minor
and major changes at all stages of development is portrayed in Figure 4.8. This shows
that the best option is to not make any changes, as the percentage changes are all
negative. However, the ‘forced’ changes have to be made and so if there is an option in
timing then the optimal time to make that change, seems to be at early phase
development if it is a minor change but a major change with no great improvement in
COG or in particular an enhancement in annual throughput makes it the worst scenario
for a forced major change. The least profitable scenario is to make a minor change at
late phase III development, which tends to incur the biggest delays with the biggest risk
of having to repeat larger clinical efficacy and comparability bridging studies before
going to market. In this case the major forced formulation changes have caused an
improvement in percentage ENPV at late stage development, possibly due to the lack of
retrofit cost required and shortening of the processing stream (the removal of freeze
drying step). The major yield improving change gives more positive percentage changes
than both the minor and major changes that do not have an impact on yield if made at
early phase development or post-product approval if product stockpiling is factored in
However, if the change is made at late phase development, the NPV seems to be more
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sensitive to the delays to market caused by the change, and thus gives the least
profitable outcome.
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Figure 4.8The percent change in expected net present value from the base case (no
change () set-up when implementing three change scenarios: a ‘forced’ minor change
(), a ‘forced’ major change (), and a major yield-improving change (▲). The risk of
potential market share losses is not taken into account.
4.7.1 ENPV INCLUDING THE UNCERTAINTY OF MARKET SHARE LOSSES
The impact of market share uncertainty on the process change scenarios is considered
next. The potential for loss in product market share is directly proportional to the
reduction in NPV. The bigger the loss in market share the bigger the overall loss in
NPV. Figure 4.9 shows the NPV distribution for a minor change. The ENPV is greatest
when the change is made post-product approval and at early phase development.
Changes at late phase again show the least profitable outcomes. The foremost difference
here is in the scenario of ‘no change’, which now has a less attractive ENPV than early
phase development and post-product approval changes. The potential for market share
losses in this scenario are significant. If the product improvement changes are not made,
then the product may not be approved, either in Europe or internationally, depending on
EMEA and FDA regulations. In addition, the company may lose a share to competitor
products of a better quality. The same patterns are seen in the ‘forced’ major change and
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major yield change distributions Figure 4.10 and Figure 4.11, although the mean NPV
estimates have shifted further to the left,
Figure 4.9Distribution of the net present value with the addition of market share loss
uncertainties for a ‘forced’ minor change scenario at the various stages of development:
no change (), early phase development (), late phase development (▲), and post-
product approval ().
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Figure 4.10Distribution of thenet present value with the addition of market share loss
uncertainties for a ‘forced’ major change scenario at the various stages of development:
no change (), early phase development (), late phase development (▲), and post-
product approval ().
Figure 4.11Distribution of the net present value with the addition of market share loss
uncertainties for a major yield improving change scenario at the various stages of
development: no change (), early phase development (), late phase development
(▲), and post-product approval ().
with more negative mean values. This shows that ENPV is are more sensitive to market
share capture and so should be accounted for. Figure 4.12 shows the percent change in
expected net present value of the process change scenarios from the base case of the ‘no
change’ scenario with market share uncertainty incorporated. For all the changes, the
NPV is most negative when the change is made at late phase development. At early
phase development, the major yield-enhancement looks to more profitable than the
‘forced’ minor and major changes.
In this case, the annual throughput has a greater impact than product equivalence
studies. The major yield improvement step also results in higher NPVs than the major
formulation change at late phase development and at commercial phase. The best stage
to make a minor or non-yield enhancing change is post-product approval, when product
can be stockpiled. Although, the yield improvement change is better than the minor and
major changes at commercial phase, it has a more positive change in NPV at early phase
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development, where the risk of market share loss and clinical study repetition is the
lowest.
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Figure 4.12The percent change in expected net present value from the base case (no
change () set-up when implementing three change scenarios: a ‘forced’ minor change
(), a ‘forced’ major change (▲), and a major yield-improving change (), including
the risk of market share losses.
The process change option proposed to enhance process yield gives positive percentage
changes in NPV at early and post-product approval phases, making them more desirable
options in comparison to making no process change. However, the mean NPV values
are in reality largely negative as can be seen in Figure 4.11. The major yield-improving
step of substituting B+1 fractionation for QXL chromatographic step does not result in
a high enough yield to be a risk-free profitable option. Further analysis involved
increasing the IVIG yield per batch on ENPV for the major yield-enhancing process
change (Figure 4.13). This only showed early phase development changes to be
profitable. There have been many proposals in the industry for the substitution of
traditional fractionation-based purification of IVIG for chromatographic based steps
(Burnouf, 1995;Curling et al.. 2005), citing total process yield improvements of up to
20%. Such a change would necessitate new clinical trials and new product registration
Chapter4 -Evaluating the Implications of Making Process Changes Throughout a Drug’s Lifecycle
107
in all of the countries in which the products are licensed. This is a high price to pay for
possible yield increases of an already safe product. Only a company without a
manufacturing history, building a new facility on a “greenfield” site, will be able to
implement this process improvement,
despite the significant advantages of modern membrane and chromatographic
technologies in widespread use throughout the biotechnology industry.
Figure 4.13 The impact of percentage increase in IVIG yield per batch on ENPV at
early phase development (), late phase development (), and post-product approval
(▲).
4.8 CONCLUSIONS
In this chapter, a case study illustrating the implementation of various changes to a
plasma fractionation process is investigated. Process changes of varying magnitude and
type, were explored at different stages of product development including post-product
approval. The example illustrates how the framework described in Chapter 4 can be
used to investigate the effects of making process changes, whether these are forced upon
them or are made to enhance productivity.
The scenario results show that the stage of implementation is far more significant than
the process change type; it is not economically advisable in the three cases investigated
to make a change at late phase clinical development. The best approach would be to
implement that change once a product is approved and commercial or once the company
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are able to stockpile sellable product, to minimise the impact of process change delays.
Major yield enhancing changes made to traditional fractionation processes are not
economically feasible, cost and delays involved in undertaking clinical trials re-
registration the ‘new’ product in all of the countries in which the products are licensed
is too high a cost to pay for relatively small yield enhancements.
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Chapter 5
Purifying a New Product from a Side-fraction:
The Feasibility of Purifying Alpha 1-Antitrypsin from
Fraction IV Precipitate
5.1 INTRODUCTION
Biopharmaceutical companies are driven to maximising plant output potential whilst
minimising resources, utility usage and operating costs throughout all stages of drug
cycle, so as to remain economical and uphold to the stringent regulatory requirements
(Chirino and Mire-Sluis, 2004). They also typically need to have a portfolio of drugs in
development to remain successful (Rajapakse, 2005).
The plasma fractionation process is unique in that its starting material plasma is a
source of multiple products. Most fractionators have not maximised their product
portfolio potential. Newer product purification streams were based on older
fractionation processes created to purify initially only albumin and a few clotting
factors, and so subsequent product yields of newer products are far from optimal. One
reason for this is that any change in the unit operation’s sequence will affect all products
downstream of the modification. This distinguishes the design of fractionation processes
from more typical processes that recover single therapeutic entities from microbial or
transgenic sources (Curling, 2002). One way to increase portfolio without having a
direct impact on products already in the market is to purify material from a side (waste)
stream.
One such side stream in the plasma fractionation process is Fraction IV (FIV)
precipitate. At Bio Products Laboratory, Herts, UK (BPL), a large-scale fractionator of
human plasma-derived products, FIV precipitate is currently a side fraction that is
currently disposed of or a small-unprocessed volume is sold as a by-product. The
precipitate is currently unexploited, but it still contains a number of proteins, although
whether these proteins are damaged or are present in a useful form is largely unknown.
The research and development team at BPL wanted to investigate whether there was
any potential to purify sufficient protein from the precipitate. The fraction would be
treated as a new starting material for a purification process. This is advantageous in that
it would not affect the current plasma fractionation process or any other derived
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products that are already in the market. This may have created complicated regulatory
issues.
Alpha 1-antitrypsin (AAT or A1-AT or 1-antitrypsin), also known as alpha-1
proteinase inhibitor (1-P1) is one such potential protein present in FIV precipitate or
FIV paste, see Figure 4.1 and Figure 5.1. Plasma-derived 1-antitrypsin (AAT) has a
significant market potential and is currently marketed by several companies for the
treatment of hereditary emphysema and generates over $200 M in revenues annually
(alphaMed Pharmaceuticals Corporation, 2008). However, it is marked by significant
shortages, and it is often quoted that the demand is far greater than the current
supply(Karnaukhova et al. 2006;Mattes et al.2001).
The potential in purifying AAT from FIV precipitate at BPL is investigated in this
chapter. The method trialled is based on a process designed by Keeet al., 2004 (Figure
5.1). Laboratory scale experiments are used to assess whether there is sufficient AAT in
FIV paste and whether the purification process suggested by Keeet al. can be applied to
BPL’s fractionation process. The experiments involved mimicking the first two
isolation steps in the process.
5.2 ALPHA 1-ANTITRYPSIN
5.2.1 PROTEIN DESCRIPTION
AAT is a glycoprotein synthesised in the liver normally present at 2000mg/L in serum.
It is the most abundant of the serine proteinase inhibitor (SERPIN) family in human
plasma (Chen, 1998;Karnaukhova et al.. 2006). It consists of a single polypeptide chain
and has a molecular weight of 52 kDa. This protein’s primary function is the protection
of lung tissue (Chen, 1998;U.S.Congress: Office of Technology Assessment, 1985). It is
secreted into the blood circulation and diffuses into tissue space, inhibiting a wide range
of serine proteases, however, its main physiological role is in not as an anti-trypsin but
in inhibiting the enzyme neutrophil elastase (NE); a potent protease that degrades
structural proteins (Travis, 1988). It does this by forming extremely stable complexes
that are rapidly removed from circulation (Beatty, 1980;Chen, 1998). In addition to
inhibiting elastase, AAT is capable of inhibiting a number of proteases including serine,
trypsin, chymotrypsin, collagenase, thrombin, kalikerin and plasmin (U.S.Congress:
Office of Technology Assessment, 1985).
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Figure 5.1Keeet al. Method for the purification of AAT from Human Plasma FIV
precipitate.
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AAT is naturally folded in a metastable structure (Karnaukhova et al.. 2006),
thermodynamically this is not the most stable form, and therefore, the protein is prone
to conformational modifications and aggregation(Lomas, 1993).
5.2.2 INDICATION AND DOSAGE
AAT is currently only used as a replacement therapy to treat patients with genetic AAT
deficiency (AAD). AAD is a hereditary disorder which causes chronic obstructive
pulmonary disease (COPD), principally emphysema, in the early stages of adult life
from 30-40 years.
Emphysema is a chronic, hereditary, autosomal recessive disorder of the alveolar
structure associated with enlargement of the distal air spaces, accompanied by the
destruction of their walls. It is usually fatal in the majority of deficient individuals, and
greatly accelerated in cigarette smokers The average level of AAT needed for adequate
anti-elastase activity in the lung is 0.8g/L (Ho and Gibaldi, 2003). Patients with a
deficiency of serum AAT have little or no anti-elastase activity in their lower
respiratory tract (Gadek, 1981). Replacing AAT levels has been shown to effectively
increase levels in the serum and lung fluid, slowing the progression of emphysema
related changes in patients. However, treatment is limited to patients with early
evidence of the disease, and those with particular phenotypes (Ho and Gibaldi, 2003).
The second, more frequent, manifestation is disease of the liver that can affect newborn
babies, children and adults. Less frequent is an inflammatory disease of the skin called
necrotizing panniculitis. AAT may also be used as a medication for the treatment of
fibromyalgia (FM), a syndrome characterized by chronic generalized musculoskeletal
pain (Blanco B.I., 2007) and in the localised treatment (inhalation) of AAT to treat
cystic fibrosis; by again inhibiting excess elastase due to the chronic inflammation,
causing subsequent lung tissue damage(EMEA: Committee For Orphan Medicinal
Products, 2008).
Currently licensed treatments of pulmonary emphysema involve the intravenous
infusion of the plasma-derived AAT preparations, with a recommended dose of 60 mg
of active AAT per kg of body weight administered once weekly. To maintain a
threshold level of AAT of 11 μMol, AAT deficient-patients should receive
augmentation therapy for the duration of their lives, which slows down the progression
of emphysema.
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5.2.3 MARKET FOR AAT
The rate of prevalence of the syndrome is from 1.5 to 3% of the population of Europe
and North America (Blanco B.I., 2007) However recent publications indicate that it is
widely under- and misdiagnosed (de Serres, 2003;Karnaukhova et al.. 2006). WHO
estimate that less than 4% of individuals with AAT deficiency have been diagnosed and
only a portion of them are receiving treatment (World Health Organization, 1996). This
may be because even those with very low levels of the protein do not necessarily exhibit
problems. North-western Europeans are most likely to carry a mutant AAT gene. Recent
research reveals that clinicians are improving in time to making the diagnosis. However,
the delay is still significant especially in older patients and women. Furthermore,
manifestation of the disease is a mixture of genetic predisposition and environmental
factors. For example, a person who is heterozygous may simply have a predisposition to
COPD if they smoke.
AAT has received orphan drug designation for a variety of indications from the EMEA
and FDA. An aerosolized form of AAT has been given orphan drug status for
TalecrisBiotherapeutics, Inc. for the treatment of AAD; Kamada, Israel for the
treatment of Bronchiectasis and BCG (Europe) Ltd, United Kingdom, for the treatment
of cystic fibrosis amongst others. So-called "fast-track approval" guidelines set out by
the FDA are designed to encourage the development of therapeutics for these diseases,
and to bring them as quickly as possible to market. Although patient populations are
small the revenue from orphan drugs can be immense. The main product competitors
are listed in Table 5.1.
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Table 5.1Major Alpha-1 antitrypsin products in the market
*(de Serres, 2003)
5.3 METHOD AND MATERIALS
5.3.1 INTRODUCTION
An attempt to purify AAT from Cohn Fraction IV-1 precipitate (Bio Products
Laboratory plasma fractionation process) is provided. The method used is based on the
ZLB Behring, patent by Keeet al. (Publication Number: WO/2004/060528): ‘Method
for Purification of Alpha-1-Antitrypsin’. Based on the invention, protein impurities are
destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol,
which does not affect AAT. The destabilized proteins are then adsorbed on a solid
protein-adsorbing material, without the addition of a salt as a precipitant. Separation of
the solid adsorbent from the solution results in a purified AAT suspension that is
Trade name Company
Primary
Indication
Stage in Drug
Cycle
Source Dosage Purity
Prolastin TalecrisbiotherapeuticsAugmentation /Replacementtherapy Commercial Human-derived plasma60 mg activeAAT/kgbody 62%*Aralast Baxter Healthcare Corp.Augmentation /Replacementtherapy Commercial Human-derived plasma61 mg activeAAT/kgbody 70%*
Zemaira CSL Behring Augmentation /Replacementtherapy Commercial Human-derived plasma62 mg activeAAT/kgbody 99%*
Trypsone Grifols Institute Augmentation /Replacementtherapy Approved Human-derived plasma63 mg activeAAT/kgbody -
Alfalastin LFB Biomedicaments Augmentation /Replacementtherapy Approved Human-derived plasma33.33 mg /ml -Alpha-1antitrypsin Kamada (Israel) Bronchiectasis Orphan drug/Clinical TrialsHuman-derived plasma - -
Alpha-1antitrypsin BCG (Europe) Ltd Cystic fibrosis Orphan drug/Clinical TrialsHuman-derived plasma - -
rhAAT GTC biotherapeutics Augmentation /Replacementtherapy Orphan drug/Clinical TrialsMilk (Transgenic goat) - -
rAAT Baxter Healthcare Corp.Augmentation /Replacementtherapy Orphan drug/Clinical Trials Recombinant yeast - -
Alpha-1antitrypsin Other groups Augmentation /Replacementtherapy Early stageresearch/clinicaltrials
Transgenic animals,Rice, expression of AATin various hosts(Kaunaukhovaet al, 2006) - -
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suitable for chromatographic purification. Only the first filtration and anion exchange
chromatography steps were attempted.
5.3.2 CHEMICALS
All chemicals were of analytical grade quality, and were obtained from Fisher-Scientific
UK (Loughborough, Leicestershire, UK) unless stated otherwise.
Sodium monobasic Phosphate (NaH2PO4), and sodium dihydrogenPhosphate
(Na2HPO4) were purchased from BDH Limited, VMR International Ltd., (Poole Dorset,
England, UK). Buffers were prepared using deionised water, and were stored at room
temperature for a maximum of one month. AAT standard was a product of Sigma-
Aldrich Co. Ltd (Poole, UK).
5.3.3 SAMPLE COLLECTION
The FIV precipitate used throughout the experiment (Batch number LC5622) was
removed from centre of a disk-stack centrifuge (wetter paste) on a single day, and
frozen in a -40oC freezer. For each experiment, the frozen FIV paste (10-30g) was
allowed to thaw at room temperature. The paste was then re-suspended to 10% w/v
inPhosphate buffer (10mM Na2H2PO4, 10mM NaOH), pH 6.2. The suspension was
homogenized at low setting to minimise foaming for 20 minutes at 2-8C. The solution
was adjusted to a temperature of 2-8C and pH 7.5. The suspension was stirred for
approximately 20 minutes. At a high pH (above 8) the protein becomes less stable and
below pH 6.0, alpha-1-antitrypsin tends to denature and aggregate (Kee and Cook,
2004).
5.3.4 DISULPHIDE BRIDGE REDUCTION
Dithiothreitol (DTT) is used to reduce protein disulphide bonds, but not reduce other
protein bonds such as peptide linkages or other groups which would cause a
fragmentation of the protein (Glaser, 1982). In this case the method takes advantage of
the unusual disulfide bond in AAT, which consists of a single cysteine residue in the
polypeptide chain bound to a free pendant cysteine. In contrast to other circulating
plasma proteins, the disulfide bridge in AAT does not add to its structural stability.
Therefore, other plasma proteins in the solution are precipitated out in the presence of
the reductant, achieving a better subsequent separation of AAT(Glaser et al.. 1982),
mainly from AAT which has similar properties to AAT in size and isoelectric point.
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DTT was added to the solution to a final concentration of 0.03M. It was stirred for 15
mins at room temp and then stirred for 2 hours at 2-8C. If necessary the pH was
adjusted to 7.5 again.
5.3.5 PRECIPITATING OUT IMPURITIES FROM THE REDUCED SUSPENSION
Contacting the reduced suspension with an insoluble protein-adsorbing material
AerosilTM 380, an insoluble silica adsorbent was added to the suspension at 16.7g/L
suspension and stirred for 1 hour at 2-8C to precipitate the DTT-disrupted proteins.
5.3.6 FILTRATION
CeliteTM 1000 was added as a body feed to the suspension at a rate of 5 parts CeliteTM to
1 part Aerosil and the solution was stirred at 2-8C. The solution was filtered under
pressure at 2 mpa maximum. Firstly, through a 44mm diameter glass filter (Sartorius
AG, Goettingen ). 50 mL of sample was filtered at one time and pooled. The remaining
residue debris of the FIV paste not yet filtered was dissolved in an additional 100mL of
dissolution buffer; this was also filtered and added to the pooled filtrate. The filtrate was
then filtered through two sets of cellulose acetate filters, both 44mm in diameter: a
0.45μm and a 0.2 μm cut-off point filter stacked on top of each other. The samples were
filtered in 50mL batches and pooled. The filter was changed between samples as it
blocked each time. No washes were taken. This step is intended to filter out the
disrupted proteins.
5.3.7 PREPARATIVE ANION EXCHANGE CHROMATOGRAPHY
Chromatography was performed on an ÄKTA Prime (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden) equipped with a fraction collector. Two different strong anion
exchange chromatography resins were tested for the separation of AAT from the
remaining proteins present in the ‘Fraction IV’ filtrate:
1. Fractogel® TMAE (M) “Q-type” (EMD Chemicals Gibbstown, NJ, USA ),
which consists of a Methacrylate matrix, a hydrophilic synthetic vinyl polymer
with the functional group, trimethylammoniumethyl ‘CH2-CH2-N+(CH3)3’, and
bead particle sizes in the range of 40 – 90μm.
2. HiTrap Q Sepharose Fast flow (G.E. Healthcare), which consists of media
packed with macroporous, cross-linked agarose beads (particle size 45–165 μm)
with the functional group ‘CH2N+(CH3)3’ attached.
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Both were pre-packed 1mL columns. The filtrate is applied directly onto the
chromatography columns containing an anion exchange resin. Column fractions were
collected in plastic tubes using a FRAC-100 fraction collector (Amersham Biosciences),
Absorbance, pH, salt concentration and pressure were monitored on-line. This step is
used to isolate AAT from remaining Albumin, impurities.
5.3.8 BUFFER AND SAMPLE CONDITIONS
The conditions set in the Keeet al., 2004 patent describes the Fractogel TMAE (M)
column being equilibrated with an equilibration buffer of 50 mMTris and a pH of about
8.6-8.9, and then loaded to approximately 50-70% of a pre-determined protein capacity
with the AAT final filtrate. Contaminants are then be removed from the column by
washing the column with an wash buffer (approximately 50 mMTris, about 25-65
mMNaCI, and pH about 7.1-7.7), and AAT is subsequently eluted using an elution
buffer (approximately 50 mMTris, about 70-120 mMNaCI, and pH about 7.1-7.7).
However, the attempt at using these conditions yielded product peaks of extremely low
absorbance (~500 mAu), and 1% Agarose and SDS gel analysis revealed no AAT in the
peak. Therefore, alternative buffer conditions were investigated so as to obtain any
product recovery (Table 5.2).
The Q Sepharose fast flow and Fractogel® TMAE columns were equilibrated with
20mM Phosphate buffer (NaH2PO4:Na2HPO4) or with 20mM Phosphate buffer 30mM
NaCl at pH 6.2, these conditions are based on a method for AAT isolation using anion
exchange by Kumpalume(Kumpalume et al.. 2007;Kumpalume et al.. 2008). FIV
filtrate was loaded onto the column (4.5 or 9mL) at 1.5mL/min. Unbound protein was
removed by washing with the equilibration buffer. Bound protein was eluted with
20mM Phosphate pH 6.2 containing 1M NaCl at a gradient or step elution over 10
column volumes. The column was then washed with 2 column volumes of buffer
containing20mM Phosphate 2M NaCl, pH 6.2 to see if anymore protein would be eluted
from the column, the column was then sanitised with 0.5M NaOH to remove any
denatured proteins. The column was also sanitised with 20% ethanol to remove any
lipoproteins and lipids between runs. Eluted fractions were analysed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Western Blotting, total protein
and ELISA assays.
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Table 5.2Initial anion exchange run conditions including resin type, load volume,
equilibration, wash, and elution buffer compositions.
Run Resin Type
Load
Volume
(mL)
Equilibration
and Wash Buffer
Salt (1M NaCl)
Elution Type
A Fractogel® 4.5 20mM Phosphate, pH 7
Gradient 0-1 M
NaCl (10 CVs)
B Fractogel® 9 20mM Phosphate, pH 7
Gradient 0-1 M
NaCl (10 CVs)
C Fractogel® 9 20mM Phosphate, pH 7 Step to 1M NaCl
D Q Sepharose FF 9 20mM Phosphate, pH 7 Step to 1M NaCl
E Fractogel® 9
20mM Phosphate, 30mM
NaCl, pH 7
Step to 1M NaCl
F Q Sepharose FF 9
20mM Phosphate, 30mM
NaCl, pH 7
Step to 1M NaCl
G Q Sepharose FF 9 20mM Phosphate, pH 7
Gradient 0-1 M
NaCl (10 CVs)
5.3.9 PROTEIN CONTENT ANALYSIS
5.3.9.1 SDS PAGE ANALYSIS
SDS-PAGE was performed using a Bio-Rad Mini-PROTEAN II system (BioRadInc).
The samples were diluted to approximately 1 mg/mL in deionised water and reducing
buffer containing 62.5 mmol/L Tris-HCL, 2 %(w/v), 10% Glycerol(v/v), SDS,
0.03%(w/v) Bromophenol Blue, 5%(v/v) β-Mercaptoethanol. Samples were heated at
95C for 5 minutes, and centrifuged for 5mins at 13,000 revolutions per minute (RPM).
A 10-μL volume of each sample was applied to the gel (4–20% gradient SDS
polyacrylamide gel was used, Pierce ThermoScientific). Run conditions were 180 Volts
for 45 minutes. Standards run to allow identification of protein bands included protein
marker, and AAT (Sigma–Aldrich). After electrophoresis, gels were washed in dH2O
and then fixed and stained using 40% v/vmethanol 10% v/vacetic acid 0.15%
v/vCoomassie brilliant blue R-250 for 20 minutes. Followed by de-staining (overnight)
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using 30% v/vmethanol, 10% acetic acid. Gels were stored in 75% Acetic acid and
scanned.
5.3.9.2 WESTERN BLOT
Hybond ECL Nitrocellulose Membrane sheets and Hybond™ Blotting Paper were
obtained from GE Healthcare ( Little Chalfont, UK). Gels were run as in section 5.3.9.1,
and captured proteins were transferred to a nitrocellulose membrane Hybond-ECL
nitrocellulose membrane. The nitrocellulose membrane was blocked for 60 min at room
temperature in 10 mMPhosphate buffer (5 mM NaH2PO4, 5 mM Na2HPO4), 125
mMNaCl, pH 6.8 Phosphate-buffered saline (PBS) containing 1.25% w/vpowdered
milk (PBS plus milk). Specific antibodies (either enzyme conjugated or unconjugated)
against a single protein were added to PBS plus milk protein and incubated with the
membrane for 1 h at room temperature. Three 5 min PBS washes, were followed by
detection with horseradish peroxidase. Where the specific antibodies were not enzyme
conjugated, a second enzyme conjugated antibody (from Sigma–Aldrich), was
employed, followed by PBS washes and detection. Antibodies against AAT (Abcam
ab7633-1000, Cambridge, UK), were used.
5.3.9.3 TOTAL PROTEIN (BICINCHONINIC ACID) ASSAY
Total protein concentration was determined using the Bicinchoninic Acid (BCA) assay
kit from Pierce (Rockford, IL) in a 96-well format. This procedure is very applicable to
microtitre plate methods. BCA reacts with complexes between copper ions and peptide
bonds to produce a purple end product. The advantage of BCA is that the reagent is
fairly stable under alkaline conditions, and can be included in the copper solution to
allow a one-step procedure. A molybdenum/tungsten blue product is produced.
The assay was calibrated with bovine serum albumin, BSA (It is noted that a calibration
using AAT would have been preferable, but constraints in supply was an obstacle) using
a curve from 50 to 2000 μg/mL. Calibration standards and samples were diluted in 10
mMPhosphate buffer, pH 7 . Samples are spun at 14000 rpm for 4 mins. 25uL of each
standard and unknown sample are aspirated into a microplate well . Working reagent is
added (200μL) to each well and mixed thoroughly on a horizontal plate shaker for 30s.
The plate was then covered plate and incubated at 37C for 30 minutes. The samples are
then immediately read at 562 nm using a BMG Fluorostar (type) microplate reader.
Chapter 6-Improving ‘Q Sepharose’ Step Isolation of Alpha 1-antitrypsin using the SELDI-TOF-MS
Technology: A High Throughput Method
120
5.3.9.4 TOTAL PROTEIN (BCATM) MICROPLATE REDUCING AGENT COMPATIBLE
ASSAY
Samples are diluted and prepared as in 5.3.9.3. A sample control was created by
diluting the original sample buffer with reducing agent. 9 uL of standards, sample, and
control are transferred in triplicate to a 96 well plate (flat bottom). 4 uL of
Compatibility Reagent are added to each well. The plate is covered, mixed on a plate
shaker for 1 minute and incubated at 37oC for 15 minutes. Working reagent is added at
260 uL per well.The plate is then covered, mixed for 1 minute using a plate shaker, and
incubated at 37oC for 30 minutes. Absorbance at 562 nm is measured.
5.3.9.5 ALPHA 1-ANTITRYPSIN ELISA QUANTIFICATION
The Enzyme-linked-Immuno-Sorbent-Assay (ELISA) (Immunodiagnostik, Germany) is
used for the quantitative determination of AAT in serum or plasma. The assay utilises
the sandwich technique with 2 selected polyclonal antibodies that bind to AAT.
Standards, controls, and prediluted samples are added to wells of a microplate coated
with a high affinity polyclonal anti-human AAT antibody. During the first incubation
step, AAT is bound by the immobilised antibody. Then peroxidase-conjugated
polycloncal anti-human AAT is added into each microtitre well and a sandwich of
capture antibody-hAAT -peroxidase-conjugate is formed.TMB is used as a peroxidase
substrate. Finally, an acidic stop solution is added to terminate the reaction. The colour
changes from blue to yellow. The intensity of the yellow colour is directly proportional
to the concentration of AAT. A dose response curve plotting optical density at 450nm
against concentration is generated, using the values obtained from the standard. AAT
concentration present in samples is generated from this curve.
Prior to use, all reagents samples were warmed to room temperature and mixed well.
All microtitre wells are washed 5 times by dispensing 250mL of diluted wash buffer
into each well. After the final wash step, the residual buffer is removed by tapping the
plate on adsorbent paper. 100μL of standards, control and unknown samples were added
in duplicate to each well. The plate was tightly covered and incubated at room
temperature for 1 hour on a horizontal mixer. The contents of each well were discarded
and washed 5 times by dispensing 250μL of diluted wash buffer into each well. 100μL
of conjugate was then added to each well and again incubated for 1 hour at room
temperature on a horizontal mixer. The contents were discarded and washed 5 times.
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100μL of substrate was added into each well and incubated in the dark for
approximately 10 minutes. Once a good colour differentiation is observed, 50μL of stop
buffer is mixed into each well. Absorption was read at a wavelength of 450nm
(reference 620nm).
5.3.9.6 TURBITIMER ASSAY: ALBUMIN AND TRANSFERRIN CONCENTRATION
The concentration of albumin and Transferrin contaminants in the samples were
measured using turbidimetry, using the Turbitimer(R) apparatus from Siemens
(formerly DADE-Behring, Germany). Albumin, Transferrin and protein standard
turbiquantsare all products of Siemens.
5.4 RESULTS AND DISCUSSION
5.4.1 PROCESS TRIAL
The first process attempt was prepared based on conditions described by Keeet al.
(2004) process (Figure 5.1) up until anion exchange chromatography stage. The depth
filter provided ineffective recovery (Table 5.3). The process also produced anion
exchange product peaks of extremely low absorbance (~500mAu), and 1% Agarose and
SDS gel analysis revealed no AAT in the product peak (Figure 5.2). This was also
confirmed using BCA Total protein and AAT ELISA assays (Table 5.3)
Alternative buffer conditions were investigated so as to obtain any product recovery
(Table 5.2). The total protein loading capacity was found to reach breakthrough at
4.5mL protein load for Fractogel and, 5mL for QFF. Figure 5.3A) corresponds to
conditions A set in Table 5.2, and gives the elution profile for FIV filtrate on a 1mL pre-
packed Fractogel EMD TMAE column at maximum loading capacity of 4.5mL. Peak 1
represents the wash flow-through of unbound protein with 20mM Phosphate at pH 7,
Peak 2 shows product elution at a 10-column volume salt gradient elution (0-1 M
NaCl); Peak 3 is a 0.5M NaOH wash. The product eluate (peak 2) was of a low total
protein concentration and so the column was saturated at a load of 9mL seen in Figure
5.3 B) and G) for Fractogel TMAE and Hitrap Q Sepharose FF respectively again
corresponding to conditions set in Table 5.2 B) and G). Relative to the wash and NaOH
peaks, the product eluate peak still gave of a low UV absorbance reading. SDS page and
10% Agarose gel analysis revealed that AAT is mostly removed in the elution peak, but
so does many other proteins especially Albumin. Separation of albumin from AAT is
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Figure 5.2Initial process trial, based on Keeet al. conditions: Analysis of process
samples for the presence of AAT from successive steps in the purification of AAT from
Cohn FIV precipitate by I) electrophoresis on a 1% agarose gel. II) SDS-gel
electrophoresis. Samples (4-20% Pierce gel, Coomassie blue stain).
SDS Gel : Molecular weight marker (lane 1), Haptoglobin (lane 2), AAT standard (lane
3), AAT standard (lane 4), FIV paste dissolved in Tris, NaCl buffer (lane 12), FIV paste
plus 30mm dithiothreitol (lane 11), FIV paste + wash (lane 10), Ion exchange* Run 1:
peak 1 (lane 9), peak 3 (lane 8), Run 2: peak 1(lane 7), peak 2 (lane 6), peak 3 (lane 5).
II
I
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difficult because both proteins are similar in size (AAT 52 kDa and Albumin 67 kDa),
and in charge (AATpI 5.2 and albumin pI 4.8). There also seems to be AAT present in
some of the NaOH wash peaks. and so, in order to maximise product recovery in the
elution peak a step elution to 1M NaCl was also taken (Figure 5.6).
Table 5.3Total protein content and AAT content was measured for all process samples
using the Pierce microplate reducing agent compatible BCATM total protein assay and
an AAT Elisa kit (Immundiagnostik) respectively. All samples were desalted using
AmiconCentricon YM-3 regenerated cellulose filter devices, MWCO 3,000 to remove
DTT from samples prior to assays.
FIV paste in
Phosphate
buffer (10%)
Post Reduction
(DTT addition
(2 hours)
Aerosil
addition
(1 hour)
Celite addition Filtrate
Total Sample
Volume(mL) 302.0 303.4 307.0 327.1 169.2
Total Protein (g/L) 30.0 28.8 26.8 * 3.9
Total Protein Mass (g) 9.1 8.7 8.2 * 0.7
Total Protein Yield % 100% 96% 91% 7%
AAT (g/L) - - - - 0.018
Mass AAT (mg) - - - - 2.97
Mass AAT (g) - - - - 0.003
Purity (%) - - - - 0.44%
* Celite interferes with absorbance reading.
The profiles show elution with an initial flow-through wash of unbound protein with
20mM Phosphate at pH 7 and 20mM Phosphate, 30mM NaCl at pH 7. With no salt in
the wash a much bigger and sharper product peak is seen for both the Fractogel and Q-
Sepharose gels.
The Fractogel run also seems to give a much smaller peak when the column is washed
with caustic soda. The gel analysis reveals that AAT is present in all the unbound wash
samples, and in all NaOH washes except for the Run D: QFF with no salt in wash. This
is also confirmed in the western blots (Figure 5.13).AAT is present in all peaks, but it is
more highly concentrated in the product peak. In general, protein concentration after
anion exchange is very low, mainly because the filtration step prior to it was ineffective
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in that it yielded almost no protein and thus AAT recovery, see Table 5.3. Recovery and
purity of AAT post-anion exchange for each run is summarised in Appendix Chapter 5.
The purity of AAT post Anion exchange is extremely low at all conditions (≤ 5% ), with
the QFF column and no salt wash giving the maximum purity. In this case, the DTT
disruption, and AerosilTM precipitation steps do not remove of the surrounding protein
impurities as suggested by Glaser (Glaser, 1982;Kee and Cook, 2004)
Chapter 6-Improving ‘Q Sepharose’ Step Isolation of Alpha 1-antitrypsin using the SELDI-TOF-MS
Technology: A High Throughput Method
125
10 20 30 40 50 60 70
U
V
Ab
so
rb
an
ce
at
28
0n
m
(m
aU
)
0
200
400
600
800
1000
1200
N
aC
lC
on
ce
nt
ra
tio
n
(M
)
0.0
0.2
0.4
0.6
0.8
1.0
pH
0
2
4
6
8
10
12
10 20 30 40 50 60 70
U
V
A
bs
or
ba
nc
e
at
28
0n
m
(m
aU
)
0
200
400
600
800
1000
1200
N
aC
lC
on
ce
nt
ra
tio
n
(M
)
0.0
0.2
0.4
0.6
0.8
1.0
pH
0
2
4
6
8
10
12
Volume (ml)
10 20 30 40 50 60 70
U
V
Ab
so
rb
an
ce
at
28
0n
m
(m
aU
)
0
200
400
600
800
1000
1200
N
aC
lC
on
ce
nt
ra
tio
n
(M
)
0.0
0.2
0.4
0.6
0.8
1.0
pH
0
2
4
6
8
10
12
U
V
Ab
so
rb
an
ce
at
28
0n
m
(m
aU
)
N
aC
lC
on
ce
nt
ra
tio
n
(M
)
pH
U
V
A
bs
or
ba
nc
e
at
28
0n
m
(m
aU
)
N
aC
lC
on
ce
nt
ra
tio
n
(M
)
pH
U
V
Ab
so
rb
an
ce
at
28
0n
m
(m
aU
)
N
aC
lC
on
ce
nt
ra
tio
n
(M
)
pH
Figure 5.3Elution profiles of Fraction IV filtrate on 1mL pre-packed columns: (A) &
(B) Fractogel EMD TMAE column, and (G) Hitrap Q Sepharose FF. Peak 1 represents
the wash of unbound protein with 20mM Phosphate at pH 7, Peak 2 shows a 10 column
volume salt gradient elution (0-1 M NaCl), Peak 3 is a 0.5M NaOH wash. (A)
represents a load of 4.5mL and (B)/(G) a 9mL load. Symbols are: (—) Absorbance,
(−••−) NaCl concentration, (•••) pH.
(G)
(A)
(B)
Column equilibration& sample loading ‘Wash peak’
Product‘Elution peak’ NaOH wash
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Figure 5.4Elution profiles of Fraction IV filtrate on 1mL pre-packed columns: (C) &
(E) Fractogel EMD TMAE column, and (D) & (F) Hitrap Q Sepharose FF. Peak 1
represents the wash of unbound protein with 20mM Phosphate at pH 7 in profiles(C) &
(D); 20mM Phosphate, 30mM NaCl at pH 7 in profiles (E) & (F). Peak 2 shows a salt
step elution to 1 M NaCl, Peak 3 is a 0.5M NaOH wash. Symbols are: (—)
Absorbance, (−••−) NaCl concentration, (•••) pH.
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Figure 5.5Analysis of process samples for the presence of AAT by electrophoresis on a
1% Agarose gel. Standard marker used is N/T protein Control LC® (Dade-Behring).
Samples were electrophoresed at 80V for 30 minutes.
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Figure 5.6 Analysis of samples from successive steps in the purification of AAT from
Fraction IV precipitate, and preparative anion exchange runs using SDS-gel
electrophoresis. Samples were applied to a 4-20% Pierce gel and electrophoresed at
120V for 45 minutes. The gel was stained with Coomassie blue.
Gel I: molecular weight marker (lane 1), AAT standard marker (lane 2), FIV paste
dissolved in Phosphate buffer 10% (lane 12), FIV paste plus 30mm dithiothreitol (lane
11), FIV paste plus 2% Aerosil (lane 10), FIV paste plus 8% celite (lane 9), FIV filtrate
(lane 8), ion exchange* Run A: peak 1 (lane 7), peak 2 (lane 6), peak 3 (lane 5) , ion
exchange Run B: peak 1(lane 4), peak 2 (lane 3), peak 3 (see GEL II).
Gel II: molecular weight marker (lane 2), AAT standard marker (lane 1), Run B: peak 3
(lane 12), Run C: peak 1 (lane 11), peak 2 (lane 10), peak 3 (lane 9), Run D: peak 1
(lane 8), peak 2 (lane 7), peak 3 (lane 6), Run E: peak 1 (lane 5), peak 2 (lane 4), peak
3 (lane 3).
Gel III: molecular weight marker (lane 12), AAT standard marker (lane 11), Run F:
peak 1 (lane 10), peak 2 (lane 9), peak 3 (lane 8), Run G: peak 1 (lane 7), peak 1* (lane
6), peak 2 (lane 5), peak 3 (lane 4), Run B: peak 1 (lane 3), peak 2 (lane 2), peak 3
(lane 1). *(Peak 1 is unbound wash, peak 2 is salt elution, and peak 3 is NaOH wash)
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Figure 5.7Analysis of samples from successive steps in the purification of AAT from
Fraction IV precipitate, and preparative anion exchange runs using Western blotting
method. Samples were applied to a 4-20% Pierce gel and electrophoresed at 120V for
45 minutes.
Gel I: molecular weight marker (lane 1), AAT standard marker (lane 2), FIV paste
dissolved in Phosphate buffer 10% (lane 10), FIV filtrate (lane 9), ion exchange* Run
A: peak 1 (lane 8), peak 2 (lane 7), peak 3 (lane 6) , ion exchange Run B: peak 1(lane
5), peak 2 (lane 4), peak 3 (lane 3).
Gel II: molecular weight marker (lane 10), AAT standard marker (lane 9), Run C: peak
1 (lane 8), peak 2 (lane 7), peak 3 (lane 6), Run D: peak 1 (lane 5), peak 2 (lane 4),
peak 3 (lane 3), Run E: peak 1 (lane 2), peak 2 (lane 1), peak 3 (see GEL III).
Gel III: molecular weight marker (lane 5), AAT standard marker (lane 4), Run E: peak 3
(lane 10), Run F: peak 1 (lane 9), peak 2 (lane 8) peak 3 (lane 7), Run G: peak *1 (lane
6), peak 1 (lane 3), peak 2 (lane 2), peak 3 (lane 1). *(Peak 1 is unbound wash, peak 2
is salt elution, and peak 3 is NaOH wash)
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5.4.2 IMPROVING PROTEIN RECOVERY FROM FIV PRECIPITATE DEPTH
FILTRATION
The resulting elution profiles, and gel analyses from the process run trial indicate that
the conditions which give the highest protein content is with an initial wash the
unbound protein was with 20mM Phosphate buffer, no salt at pH 6.2. Bound protein
should then be eluted with 20mM Phosphate pH 6.2 containing 1M NaCl using a step
elution. There is no need to increase salt concentration as no more protein was eluted at
2M salt prior to the 0.5M NaOH column wash. The filtration stage showed an extremely
poor recovery total protein and AAT. To improve the recovery of FIV paste filtration
step, body feed addition and type was investigated. A very poor step yield of 8% total
protein is recovered, and a poor isolation of 0.003% AAT is attained after the depth
filtration step.
In this section, an improvement in filtration is attempted at this stage by assessing the
impact of body feed, and reducing agent on protein and AAT recovery.
5.4.3 BODY FEED FILTER AID TYPE
Various body feed types were mixed in with the sample prior to depth filtration. The
filtration method is described in section 5.3.6. The filter aid is added in order to
increase flux rates and improve cake permeability. These are inert, rigid powders with
25-30 m pores to trap solids while encouraging the formation of open flow channels
for the liquid(Reynolds, 2004). At this stage no reducing agent or precipitating agent
(AerosilTM) was added. The body feeds tested are: CelpureTM 100, CelpureTM 300,
CelpureTM 1000, CelpureTM HYFLO NF- an acid washed type , currently discontinued
at a pharmaceutical grade, (World Minerals Inc, Santa Barbara, CA, USA). The body
feed percentages and mixing times analysed are show inTable 5.4.
The suspension is added to a Sartorius SM16249 filter housing (Max pressure:10 bar,
max volume:220mL) (filter at 2 bar pressure) , with a 47mm Seitz K900 Depth filter
(already with a pre-coat) . The total protein recovery is measured crudely at absorbance
A280, and AAT concentration is measured using an Elisa kit.
The impact on body feed alone is portrayed in Figure 5.8. The maximum percentage
recovery of protein is 45%, using a 3%w/v, CelpureTM HYFLO NF mixture, an average
of 28% protein is recovered amongst all aids and concentrations. This may mean that
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the bulk impurities are retained. Percentage body feed and mixing times were tested
using CelpureTM 1000 and CelpureTM HYFLO NF , as they showed the highest
Table 5.4A summary of all the body feed types, mixing times, and concentrations
investigated using a K900 Seitz 47mm filter using a Sartorius SM16249 filter housing at
RT, slow mixing.
Body Feed Type
Body feed
(w/v) %
Mixing time
(min- max)
Celpure 100 3 15mins+
Celpure 300 3 15mins+
Celpure 1000 3 15mins+
Celite HYFLO NF 3 15mins+
Celpure 100 10 15mins+
Celpure 300 10 15mins+
Celpure 1000 10 15mins+
Celite HYFLO NF 10 15mins+
Celpure 100 3 overnight
Celpure 300 3 overnight
Celpure 1000 3 overnight
Celite HYFLO NF 3 overnight
Celpure 100 10 overnight
Celpure 300 10 overnight
Celpure 1000 10 overnight
Celite HYFLO NF 10 overnight
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recoveries. The impact of body feed type, content and along with the mixing time length
is shown in Figure 5.9. The longer mixing times and lower percentage body feed
content gave higher overall recoveries. This is however, measured very crudely using
absorbance at A280nm. AAT concentration is measured for all the conditions and the
yields calculated (Table 5.5). A very poor yield of 10-13% AAT is recovered under all
conditions through the single depth filtration step. Since there is not much change in
AAT yield under all the conditions tested, the removal of impurities at this stage is more
important at this stage. Therefore, the lower total protein recovery may be more
desirable. The cumulative mass of filtrate collected was recorded against time and
filtration curves for a range of pressures in the batch filter are shown in Figure 5.10.
These curves show how the mass of filtrate builds up over time. It can be seen that
using the Celite HYFLO NFTM at 3% body feed enables a fixed amount of filtrate to be
collected in a shorter time. The filtration curves all exhibit the same initial steep slope
gradually levelling out into a plateau. This shape is a result of the increasing resistance
of the filter cake as more solids are deposited and the depth of the cake grows making it
more difficult for the liquid to flow through. The filters quickly became blocked under
all conditions except with Celpure 1000TM, 3% body feed. This build up of cake usually
has the effect of improving the clarification with time since the cake captures a greater
proportion of the solids and may be more cost-effective.
Figure 5.8The impact of filter aid body feed type and percentage body feed on protein
concentration. 20g of FIV paste was filtered through a K900 Seitz filter using aSartorius
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SM16249 filter housing. The filtration process was stopped when the filtrate started to
foam.
Figure 5.9The impact of filter aid body feed type, percent body feed, and mixing time
on protein concentration. 20g of FIV paste was filtered through a K900 Seitz filter using
a Sartorius SM16249 filter housing. The filtration process was stopped when the filtrate
started to foam.
Table 5.5This table shows the concentration of AAT in FIV paste, and the recoveries
using various body feed types and conditions.
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FIV paste in phosphate buffer N/A N/A 0.392 N/A
Celpure 100 3 15 mins* - -
Celpure 300 3 15 mins - -
Celpure 1000 3 15 mins 0.040 10%
Celite HYFLO NF 3 15 mins 0.050 13%
Celpure 100 10 15 mins - -
Celpure 300 10 15 mins - -
Celpure 1000 10 15 mins 0.040 10%
Celite HYFLO NF 10 15 mins 0.042 11%
Celpure 100 3 overnight - -
Celpure 300 3 overnight - -
Celpure 1000 3 overnight 0.049 12%
Celite HYFLO NF 3 overnight 0.046 12%
Celpure 100 10 overnight - -
Celpure 300 10 overnight - -
Celpure 1000 10 overnight 0.052 13%
Celite HYFLO NF 10 overnight 0.051 13%
AAT Yield (%)Body Feed Type Body feed% Mixing time
AAT
concentration
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Figure 5.10Fraction IV paste filtrate recovery over time(s). 20g of FIV paste was
filtered through a K900 Seitz filter using a Sartorius SM16249 filter housing. The
filtration process was stopped when the filtrate started to foam.
(w/v)
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5.4.4 THE IMPACT OF REDUCING AGENT ON FIV PRECIPITATE FILTRATION
The impact of adding the reducing agents with body feed prior to depth filtration was
also investigated. A FIV paste suspension was made up in BIS-TRIS buffer (20mM, pH
7.1). The pH was monitored adjusted back to pH 7.1 throughout the experiment.
The impact of adding the reducing agents: DTT, TCEP and no reducing agent with and
without CelpureTM1000 body feed was investigated. Initially, a crude measure of
absorbance at 280nm was used to estimate total protein recovery. The reducing agents
disrupt the absorbance reading and so the yield calculation was based on the separate
filtrate feeds with its appropriate reducing agent. The highest recovery was observed
when no reducing agent or feed was added, and the lowest total protein recovery when
DTT was added to the FIV solution (Table 5.6). To eliminate the error in absorbance
reading caused by the reducing agents, a BCATMprotein assay-reducing agent
compatible kit(Pierce) was used to also measure total protein (Table 5.7). It shows a
similar result in that a FIV dissolution with no body feed or reducing agent yielded the
highest recoveries, but adding TCEP to the solution would seem to give the lowest
recoveries. Since AAT yield was shown not to be too variable with body feed or it may
be more appropriate to choose the condition that resulted in the lowest overall protein
recovery. This should signify the highest removal of impurities; however, more detailed
analysis of the samples can reveal what exactly has been removed. Also, at a larger
scale, the difference in 10-13% yield could translate to a much greater product mass
loss. The addition of the reducing agents to a commercial process could prove laborious
in that the removal of excess denaturants would be required by either dilution or a
buffer-exchange step, such as dialysis, diafiltration, gel-filtration chromatography or
immobilization onto a solid support. For commercial applications the need for
additional steps would be costly. The cumulative mass of filtrate collected was again
recorded against time and filtration curves for the range of body feed and reducing agent
conditions Figure 5.11. The FIV paste suspension with no additions of body feed or
reducing agent yield higher flux rates enabling a fixed amount of filtrate to be collected
in a shorter time.
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Table 5.6The impact of adding a reducing agent on filtrate recovery (Total protein
recovery %) prior to filtering Fraction IV paste dissolution. FIV paste was filtered
through a K900 Seitz filter using a Sartorius (SM16249) filter housing. The filters were
washed with dissolution buffer (20mM BIS-TRIS)
Sample
Total Protein Recovery in
Filtrate with
no Body feed
Total Protein Recovery in
Filtrate with
Celpure1000
FIV paste in No reducing agent
(1 hour)
43% 40%
FIV paste in DTT(1 hour) 32% 28%
FIV paste in TCEP(1 hour) 35% 34%
Table 5.7Analysis of total protein using the BCATM Reducing protein assay-reducing
agent compatible kit (Pierce) to assess the impact of adding a reducing agent prior to
filtering a Fraction IV paste dissolution on percent total protein recovery FIV paste was
filtered through a K900 Seitz filter using a Sartorius SM16249 filter housing. The filter
was washed with dissolution buffer (20mM BIS-TRIS) and added to the filtrate.
Concentration (g/L)
Sample
Feed
(+/-SEM),
n=3
Filtrate
(+/-SEM),
n=3
Filtration
step
Protein
Yield
(%)
FIV ppt in no reducing agent no body feed 26.2 1.51 14.5 1.05 55
FIV ppt in DTT, no body feed 43.3 7.66 13.8 1.66 32
FIV ppt in TCEP, no body feed 39.7 10.94 8.2 0.89 21
FIV ppt in no reducing agent plus C1000* 84.1 7.76 13.0 1.63 49
FIV ppt in DTT plus C1000* 70.5 6.25 15.5 2.71 36
FIV ppt in TCEP plus C1000* 60.8 17.37 7.1 0.57 18
* Celite interference in absorbance reading
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Figure 5.11Filtration curves for the recovery of Fraction IV filtrate over time(s). 20g of
FIV paste was filtered through a K900 Seitz filter using a Sartorius SM16249 filter
housing.
5.4.5 IMPROVED PROCESS RUN
Based on the results from the previous sections an improved process is set. The process
is a lot simpler than the process set by Keeet al., 2004, in that no reducing agents,
precipitating agent or body feedis added to FIV the dissolution prior to filtering. The
conditions used are Q Sepharose or Fractogel TMAE columns, pH adjusted to 6.2,
equilibrated and washed with 20mM Phosphate buffer at pH7, and product is recovered
using a step elution to 1M NaCl over 10 column volumes. Good elution profiles are
achieved when using the Hitrap QFF and Fractogel TMAE columns (Figure 5.12).
Very little protein is removed from the column after the caustic soda wash when using
the Q Sepharose column. SDS page gel and western blot analysis (Figure 5.13) show
that for Q-Sepharose run indeed there is little , if any protein in peak 3 (NaOH wash)
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(lane 12), but there is still Albumin in the product peak (lane 11). The conditions run
using the Fractogel column gives a purer product peak (lane 7) with less obvious
Albumin bands present. This is also shown in the total protein and AAT concentration
assays, with a purer product peak when using the Fractogel column. However, the
purity content of AAT is so small at 1-2% of total protein that it is difficult to compare
accurately. A maximum anion exchange step yield is achieved is with the Q-Sepharose
column at 51% . This is very low for ion exchange chromatography, and there is still a
great deal of room for improvement. The depth filtration step has been improved to give
a yield of 83% AAT recovery.
Table 5.8Total protein and AAT content of samples recovered from all stages of the
AAT purification process from the improved process run. Anion exchange data is for
Fractogel, and Q Sepharose FF
Sample type
Average
Total Protein
mass (mg)
Average
AAT Mass
(mg)
Protein
Step
Yield
(%)
Protein
Overall
Yield
(%)
AAT
Step
Yield
(%)
AAT
Overall
Yield
(%)
AAT
Purity
(%)
FIV paste
FIV paste dissolved in phosphate buffer 3229.8 46.1 - - - - 1%
Depth filtrate + wash 1912.7 38.5 65% 65% 83% 83% 2%
Membrane Filtrate + wash 1976.2 20.3 95% 62% 53% 44% 1%
Fractogel Run A Peak 1 817.8 6.5 - - - - -
Fractogel Run A Peak 2 365.1 8.4 29% 11% 41% 18% 2%
Fractogel Run A Peak 3 60.4 0.3 - - - - -
Q Sepharose FF, peak 1 1270.0 7.4 - - - - -
Q Sepharose FF, peak 2a 31.4 0.1
Q Sepharose FF, peak 2b 710.4 10.3
Q Sepharose FF, peak 3 38.8 0.1 - - - - -
Membrane Filtrate + wash pH adjusted
to pH 6.2 (load)
1228.5 20.3 64% 39% 100%
58% 23% 51% 23% 1%
44% 2%
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Figure 5.12Elution profiles of Fraction IV filtrate on 1mL pre-packed columns: (A)
Fractogel EMD TMAE column, and (B) Hitrap Q Sepharose FF. Columns are
equilibrated to pH 7 with 20mM Phosphate buffer, protein is loaded at pH 6.2, Peak 1
represents the wash of unbound protein with 20mM Phosphate at pH 7, Peak 2 (a-b)
shows a step elution to 1 M NaCl, Peak 3 is a 0.5M NaOH wash. Symbols are: (—)
Absorbance, (- -) NaCl concentration
a
b
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Figure 5.13 Analysis of samples from successive steps in the purification of AAT from
Fraction IV precipitate using SDS-gel electrophoresis and Western blot analysis.
Samples were applied to a 4-20% Pierce gel and electrophoresed at 120V for 45
minutes. For SDS PAGE analysis the gels were stained with Coomassie blue.
(A): Reduced SDS PAGE gel: molecular weight marker (lane 1), AAT standard marker
(lane 2), FIV paste dissolved in Phosphate buffer 10% (lane 3), Filtrate+ Wash (lane
4), 6.2 pH adjusted load (lane 5), ion exchange* Fractogel : peak 1 (lane 6), peak
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2(lane 7), peak 3 (lane 8), ion exchange* Q Sepharose peak 1 (lane 9) : peak 2a(lane
10), peak 2b (lane 11) peak 3(lane 12).
(B): Non-reduced SDS PAGE gel: AAT standard marker (lane 1), molecular weight
marker (lane 2), FIV paste dissolved in Phosphate buffer 10% (lane 3), Filtrate+ Wash
(lane 4), 6.2 pH adjusted load (lane 5), ion exchange* Fractogel : peak 1 (lane 6), peak
2(lane 7), peak 3 (lane 8), ion exchange* Q Sepharose peak 1 (lane 9) : peak 2a(lane
10), peak 2b (lane 11) peak 3(lane 12).
(C): Western Blot analysis. The blot is probed with a polyclonal goat alpha 1-antitrypsin
antibody conjugated with Horse radish Peroxidase (HRP): AAT standard (lane 1), FIV
paste dissolved in Phosphate buffer 10% (lane 2), Depth filtrate+ Wash (lane 3),
Membrane Filtrate (0.45μm and 0.2μm filters) + Wash (lane 4), 6.2 pH adjusted load
(lane 5), ion exchange* Fractogel : peak 1 (lane 6), peak 2(lane 7), peak 3 (lane 8), ion
exchange* Q Sepharose peak 1 (lane 9) : peak 2a (lane 10), peak 2b (lane 11) peak 3
(lane 12).
*(Peak 1 is unbound wash, peak 2 is salt elution, and peak 3 is NaOH wash)
5.5 CONCLUSIONS
In this Chapter an attempt was made to purify AAT from FIV precipitate of a plasma
fractionation scheme at BPL. Results show that whilst AAT can be purified from FIV
precipitate, the process based on the conditions set by Keeet al., did not prove
successful for the FIV precipitate from the fractionation process at BPL. The addition of
a reducing agent such as DTT to F IV to disrupt the protein structure and precipitate out
surrounding impurities did not prove valid here. The major impurity of Albumin was
still present at high concentrations post filtration, and so this step was also removed.
Anion exchange chromatography and depth filtration steps were effectively modified
and resulted in a fully functional process. The recovery of AAT filtrate from depth
filtration was improved greatly. The filtration performance was also improved by
removing all filter aids and reducing agents. The final recoveries of AAT are very low
at 18% or 23% when using Fractogel or Q-Sepharose media respectively. FIV
precipitate may not be the ideal start material for the purificationof AAT , as the start
concentration of AAT is far too low. However, the product is in demand, so a cost-
benefit trade-off for selling it as a cheap by product or purifying AAT from the paste a
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new product needs to be analysed further. Other proteins are present in FIV and may be
present at higher concentrations and so may be more suited to a purification from this
stage, this also needs to be assessed. Alternatively, AAT can also be purified from a
higher process fraction (Fraction A+1), but this was would have an impact on approved
products such as Albumin. This has been investigated by Kumpalume (2007, 2008).
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Chapter 6
Improving ‘Q Sepharose’ Step Isolation of Alpha 1-
antitrypsin using the SELDI-TOF-MS Technology: A
High Throughput Method
6.1 INTRODUCTION
In the previous chapter, a process to purify AAT from FIV precipitate of a human
plasma fraction process (a combination of the Cohn (Method 6) and those developed by
Kitsler and Nitchman (1962)) is given at laboratory scale. The first isolation step used
was strong anion exchange chromatography in the form of Merck’s Fractogel EMD
TMAE (M)and GE Healthcare’s ‘Q Sepharose Fast Flow’ media. Successful AAT
isolation was achieved using 1mL columns under the following
conditions:columnequilibration with 20mM Phosphate buffer (NaH2PO4:Na2HPO4) at
pH 6.2, FIV filtrate loading at 1.5mL/min, washing to remove unbound protein with the
equilibration buffer, and elution of bound protein using 20mM Phosphate 1M NaCl, pH
6.2 step elution over 10 column volumes. The column was then sanitised with 0.5M
NaOH to remove any protein stuck on the column. The average step-yield was low at
33% AAT recovery, with a purification factor increase of 1.74 based on AAT and total
protein concentrations. Analysis shows that there is AAT present at the wash, elution
and sanitisation stages. Protein lost during the initial no-salt wash stage may be a result
of column overloading or weak binding or a combination of both. Some protein may
also be bound too tightly to the column, and only detached during the caustic wash
stage. AAT and Total protein concentration, SDS-gel, and 10% Agarose gel analysis
also revealed that there were impurities in the salt elution step. The main impurities
were Albumin and Transferrin. An attempt to improve AAT recovery and reduce
impurities binding to the column is described in this chapter.
Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry
(SELDI-TOF-MS) ProteinChipArray (CiphergenBiosystems, Inc., Fremont, CA)
technology is used to mimic the isolation of AAT from FIV filtrate at microchip scale
using the ‘Q-chip’ array. This array carries the same functional group [CH2N+(CH3)3]
as the Q-Sepharose resin. The purpose of this work is to determine the usefulness of
using this high throughput technique to optimise the anion exchange step suggested.
Sample analysis using the SELDI-TOF-MS and Ciphergen® NP20 chips was also
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investigated to compare its usefulness against well-established concentration
determination methods, such as ELISA methods.
6.1.1 ION EXCHANGE CHROMATOGRAPHY
The principle of ion exchange chromatography is based upon the interaction between
charged groups on the surface of proteins (the mobile phase) and those of oppositely
charged groups on a chromatographic matrix (the stationary phase). The protein dipolar
ion displaces any counter ions e.g. sodium or chloride ions from the matrix’s functional
group, and then will be displaced by an increasing amount of counter ion. This can be
done by adding an increasing amount of salt to an elution buffer i.e. a salt gradient
elution. Alternatively, a pH gradient can be used, so that the net charge on the adsorbed
protein decreases. The pH of the solution at which the overall charge is neutral (the
isoelectric point or pIof the molecule) will not interact with a charged medium. At a pH
lower than the pI, the molecule will have a net positive charge; and if its pH is higher
the net charge is negative. When a mixture of proteins is added to a column, the starting
conditions of buffer, pH, and ionic strength will change the net charge of the protein of
interest, and so can be manipulated to interact with the matrix. As a result, either
everything passes through except the protein of interest or in some cases impurities are
bound to the column, either way successfully separatesthe protein of interest. It is
important to find the optimum combination of mobile phase conditions and matrix to
maximise recovery.
The matrix comprises spherical particles substituted with ionic groups that are either
negatively (cationic) which bind to positively-charged molecules or positively (anionic)
charged which bind to negatively-charged molecules. Proteins bound to an anion
exchanger will elute as pH is decreased, and will elute as pH is increased when bound to
a cation exchanger(GE Healthcare Handbook, 2002).
In general, matrices differ in the type of ligand used and the density of its binding sites.
The matrix is usually porous to give a high internal surface area. This medium is packed
into a column to form a ‘packed bed’. The bed is then equilibrated with buffer, which
fills the pores of the matrix and the space in between the particles (Reynolds, 2004).
Ion exchange chromatography is the most broadly used chromatography method, and
practically all industrial purification processes comprise one or more ion exchange step
(Staby, 2000). In general, the matrices are not as costly as other types of matrix, such as
those used in affinity chromatography. The process also has a high capacity and a
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consistent concentrating effect and so the process is suited to large-scale operations,
such as plasma fractionation.
6.1.2 Q SEPHAROSE FAST FLOW
Q Sepharose Fast Flow is a commonly used strong anion exchanger from GE
Healthcare. The ion exchange group is a quaternary amine group:
–O–CH2CHOHCH2OCH2CHOH CH2N+(CH3)3
Strong ion exchangers are fully charged over the total pH range normally applicable to
proteins and peptides. It has a highly cross-linked agarose base matrix, which gives the
media its chemical and physical stabilities.
6.1.3 SELDI-TOF-MS
6.1.3.1 INTRODUCTION
Surface Enhanced Laser Desorption/Ionisation Time-of-Fight Mass Spectrometry
(SELDI-TOF-MS) is a commercialised ionisation method in mass spectrometry that is
used for the analysis of protein mixtures (Tang, 2004), that employs chromatographic
surfaces. This combination of specificity and reproducibility of mass spectrometry,
allows for a high-throughput analysis of a wide variety of biological samples, rapidly
producing protein profiles (Woolley and Al Rubeai, 2009). The SELDI-TOF-MS
ProteinChip Reader PCS series 4000 apparatus was employed for this particular study.
The SELDI-TOF-MS is made up of three key components: the ProteinChip array, a
mass spectrometer and the data collection and analysis software (Lin et al..
2004;Schipper et al.. 2007). Each chip has an array of 8 -16 spots. The spots are
composed of different chromatographic surface type such as hydrophobic, hydrophilic,
ion exchange or immobilised metallic ion chromatographic matrices(Lin et al.. 2004).
This platform is attractive for studying a wide range of conditions quickly, as it requires
small sample sizes (from as little as 1μL) and minimal or no sample preparation of even
crude protein extracts, because of the equipment’s retentate chromatography feature(Lin
et al.. 2004;Panicker et al.. 2009;Woolley and Al Rubeai, 2009). Effectively, an
experiment is performed on the chip surface immediately before analysis. This reduces
sample loss and allows smaller amounts of proteins to be analysed. The ionisation of
some proteins are suppressed by the presence of others; proteins present in higher
concentrations suppress the ionisation of proteins of lower abundance, allowing for
straightforward quantification of protein concentration. However, Dijkstraet al. (2007)
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also point that this can be a source of variation in sample analysis, reducing mass peak
areas.
6.1.3.2 ADVANTAGES AND LIMITATIONS OF SELDI-TOF-MSTECHNOLOGY
As its name suggests, SELDI-TOF-MS can be considered an enhanced form of the
conventional Matrix-assisted Laser Desorption/Ionisation Time-of-Fight Mass
Spectrometry (MALDI TOF MS). The main difference is in the target surfaces to which
proteins are applied, which are coated with various activated ‘planar chromatographic
chemistries’ (Voderwulbeke et al.. 2005). With the SELDI-TOF-MS technology it is
possible to fractionate a protein mixture, or separate particular classes of proteins on the
chip or array surface. It is also separated from potentially interfering salts and other
sample contaminants by subsequent on-spot washing with appropriate buffers. The
respective chemical properties of each array make it possible to focus the analysis to
either negatively or positively charged proteins, and allows for targeting of specific
metal binding or phosphoproteins.
When used with a robotics system, SELDI-TOF MS is a high throughput technique that
allows hundreds of samples to be tested in a relatively short time. Sample requirements
are very low and can be directly applied without pre-treatment (Seibert et al.. 2004).
Issaqet al.. (2003) estimated the cost of the protein chip arrays to be $75/chip for 8
spots, which although high is economical when the savings in time and labour and the
wealth of information generated is considered.
Numerous summaries of the SELDI-TOF-MS technology’s usefulness and recent
developments have been reviewed (Issaqet al.. 2003; Kiehntopfet al.. 2007; Merchant
and Weinberg, 2000; Seibert et al.. 2004; Vorderwulbeckeet al.. 2005).
As with all analytical methods, SELDI-TOF MS has its limitations. Although it can
rapidly generate proteome profiles from complex mixtures, and is chiefly successful at
discovering proteins in the low-molecular-weight range, it is not routinely reproducible.
In general it has low resolution and mass accuracy, coupled with the inability to
successfully profile high-molecular-weight proteins (Issaq et al.. 2003).
Many of limitations that apply to mass spectrometry in general, apply to SELDI-TOF-
MS. This is true of biases based on analysing multiple analytes and the relatively low
sensitivity when compared to immunoassays such as ELISA (Grizzle et al.. 2005).
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There are also several problems, which may be unique to the SELDI-TOF-MS system
marketed by Ciphergen®. Dijkstraet al.. (2007) writes about many of sources of
variation states in the SELDI-TOF-MS, and how this can affect the resulting spectra.
For example, the competition for sites in the matrix, the washing stage(see 6.3.3) which
can remove weakly bound proteins, all can reduce peak area size. One drawback that is
often stated, is the bias towards peptides and smaller proteins (proteins <30 kDa), and
that the sensitivity and resolution of the Time of Flight (TOF) analyser falls off
markedly above 30kDa. However, with the optimisation of the Energy Absorbing
Molecule (EAM) mixture (see 6.3.3) larger molecules do give a good resolution. In
general, proteins present in high concentrations may also suppress the ionisation of less
concentrated proteins and post-translationally modified proteins such as glycoproteins
or phosphoproteins, by competing for binding places or ionization energy, which can be
misleading (Engwegen et al.. 2007;van Breemen et al.. 2006). This is very true with
blood serum or plasma, which is which contains highly abundant proteins such as
albumin and immunoglobulin (Whelan et al.. 2008). These proteins, which account for
97% of all proteins, suppress middle and low-abundance proteins in the sample. Grizzle
et al. (2005) states that one weakness is the relatively low resolution (± 0.2%) of the
bundled mass spectrometer which may cause problems with analysis of data. This can
make unconditional “peak” determination difficult if a peak matching approach is used
in analysis, and may also potentially represent multiple proteins. For very sensitive
analysis, it has been reported that peaks may vary slightly in location due to
instrumental drift (Grizzle et al.. 2005).
SELDI-TOF-MS as a method has also been criticized because of the lack of data
reproducibility that is seen. This is mainly due to lack of standardization of pre-
analytical and analytical phases and has been reported extensively (Diamandis and Van
Der Merwe, 2005;Dijkstraet al.. 2007b;Kiehntopfet al.. 2007;Liggett et al..
2004;Panickeret al.. 2009).
6.2 EXPERIMENTAL OUTLINE
A Q SepharoseFast Flow HiTrap column has been used to isolate AAT from FIV
filtrate, using the binding conditions of: pH 6.2, 0mM salt. An improvement in the
binding conditions of AAT is attempted using the on the ‘Q-chip’ (Q Sepharose mimic).
Due to the nature of the SELDI-TOF-MS technology, these experiments explore the
most favourable binding conditions only. Good eluting conditions can be based on
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conditions that show poor binding. However, elution has not been explored in this
study, for if it is possible to isolate the protein of interest in a single step, then
subsequently it should be suitable to elute everything off the column. Also, the SELDI-
TOF-MS method is limited, as it does not allow for differing binding, and eluting
buffers to be used. A matrix of 16 conditions based on pH and salt concentration were
initially tested. These are summarised inTable 6.1.
Table 6.1A summary of the initial scouting conditions set to improve isolation of AAT
from FIV filtrate using the SELDI-TOF-MS ‘Q-10’ chip
pH NaCl concentration (mM)
6.2 0 50 100 150
6.8 0 50 100 150
7.4 0 50 100 150
8 0 50 100 150
Additional conditions were then set-upbased on the initial scouting results, to
investigate whether the improved data could be further enhanced and to discover the
limits of AAT binding to the ‘Q-10’ chip. These conditions were of a lower pH and
increased salt concentration, and are summarised in Table 6.2. These experiments were
run on separate days, and so different preparations of Energy Absorbing Molecule
(EAM) were used, as it expires after 24 hours. This has an impact on resulting MS
intensities, andit is not possible to compare the raw data directly if using different
preparations of EAM. Nine of the binding conditions tested at ‘micro-scale’ were then
run at a larger scale, using1mL GE HiTrap QFF columns to validate the use of the
SELDI-TOF-MS results. The conditions tested at the larger scale are summarised
inTable 6.3. Breakthrough curves were run for all the conditions to further explore the
impact of the binding condition. For each condition tested, the column was loaded to
5% breakthrough. Protein isolation was analysed using the following assays: Normal
phase (NP20): a non-selective surface chip, SDS page, AAT specific ELISA, BCA total
protein, and the turbitimer assay for Albumin, Transferrin concentrations. These
methods are explained in section 6.3.
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Table 6.2A summary of all the conditions tested to establish better isolation of AAT
from FIV filtrate using the SELDI-TOF-MS ‘Q-10’ chip.
pH NaCl concentration (mM)
5.1 0 50 100 150 200
5.6 0 50 100 150 200
6.2 0 50 100 150 200
6.2 0 50 100 150 200
6.8 0 50 100 150 200
7.4 0 50 100 150 200
8 0 50 100 150 200
Note. The greyed boxes were run on a separate day, and with a different EAM mixture.
A citrate buffer was used for pH 5.1 to 5.6. A Phosphate buffer was used for pHs 6.8 to
7. Both a citrate buffer and Phosphate buffer were used at pH 6.2 to ensure there was no
variation caused by the buffer type.
Table 6.3A summary of the conditions tested at the larger scale of 1mL using a GE
HiTrap QFF column, to validate the SELDI-TOF-MS runs
pH NaCl concentration (mM)
5.6 0 100 150
6.2 0 100 150
8 0 100 150
6.3 MATERIALS AND METHODS
6.3.1 CHEMICALS
All chemicals were of analytical grade quality, and were obtained from Fisher-Scientific
UK (Loughborough, Leicestershire, UK) unless stated otherwise. Sodium monobasic
Phosphate (NaH2PO4), and sodium dihydrogenPhosphate (Na2HPO4) were purchased
from BDH Limited, VMR International Ltd., (Poole Dorset, England, UK). Buffers
were prepared using deionised water, and were stored at room temperature for a
maximum of one month. The composition of all the buffers used during SELDI-TOF-
MS and column chromatography experiments is given in 5.2Table 5.1. AAT standard
was a product of Sigma-Aldrich Co. Ltd (Poole, UK).
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6.3.2 SAMPLE COLLECTION
The protein solution used in all chromatography runs was derived from frozen FIV
paste. The paste (10-30g) was allowed to thaw at room temperature, and then dissolved
in 10mM Phosphate buffer. The paste was then suspended at 10% w/v in a Phosphate
buffer (10mM Na2H2PO4: 10mM NaOH), pH 6.2. The suspension was then gently
homogenized using a Silverson mixer (Silverson Machines LTD, Chesham, UK) with a
44mm disintegrating head (designed to break up solid materials into small pieces) for
approximately 20 minutes at a temperature of 2-8C. The solution was adjusted to a pH
7.5. A body feed of 3% w/v CeliteTM 1000 (Advanced Mineral Corporation, Goleta,
CA) was then added to the suspension and stirred at room temperature. The solution
was filtered using an air pressure stainless steel filtration device (SM 16249 housing,
Sartorius, Gottingen, Germany) of 47 mm internal diameter (active area of 10x3 m2).
The suspension was firstly filtered through a Seitz K900 depth filter (Seitz-Filter-
Werke,BadKreuznach, Germany), and then through two stacked cellulose acetate filters:
a pre filter with a 0.2 μm pore size (Sartorius, Gottingen, Germany) and a second filter
of pore size 0.45μm (Whatman International Ltd,Maidstone, UK). In all cases, a
maximum pressure of 2MPa was used. This process step is described in Chapter 5 in
detail.
6.3.3 SELDI-TOF MS METHODS
6.3.3.1 GENERAL SELDI-TOF MS METHOD
The analysis of proteins by the SELDI-TOF-MS was carried out in four distinct stages;
1. The purification or enrichment of the proteins of interest on the array or chip
surface (a pre-coated stainless steel slide). The ‘chip type’ was determined by its
coating, which ‘enhances’ the surface to bind preferentially to a specific group
of proteins established on their physiochemical properties.
2. The second step was the creation of charged ions. The sample was further mixed
with a UV energy absorbing matrix (EAM) such as (α-cyano-4-
hydroxycinnamic acid for proteins less than 20 kDa and sinapinic acid for
proteins greater than 20kDa in mass), which caused the entire mixture to
crystallize as it dried. It was then placed into the mass spectrometer, and a fast
UV laser pulse (~4ns) was fired at the array surface. The matrix allows a single
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proton to be added (or in some cases subtracted) from the peptide or protein and
causes the molecule to become charged or ionised. The charged protein(s) were
then accelerated out of the source (receiving constant kinetic energy) using a
series of oppositely charged metal plates and travel into the mass analyser
section of the mass spectrometer.
3. The firing of a laser at the sample and matrix mixture.
4. Determination of the masses of the proteins in that sample, analysis and
comparison of individual samples.
6.3.3.2 ‘Q10’ CHIP PROTOCOL
Q10 ProteinChip arrays and sinapinic acid were obtained from BioRad Laboratories,
Inc. (Hemel Hempstead, UK). This strong anion exchanger encompasses active spots
that contain cationic, quaternary ammonium groups that interact with the negative
charges on the surface of the target proteins. The surface binds proteins that are
negatively charged at a given pH. It works in the same manner as a strong anion
exchange media such as Q Sepharose.
FIV filtrate samples are prepared as described in section 5.3.3.
All samples were diluted 20 fold in 10mM Phosphate buffers, with varying salt
concentrations and pH values as shown inTable 6.2. The same buffers were used for
equilibration and washing steps. The Q10 chips were equilibrated in the appropriate
buffers, by adding 150μL of each buffer into deep-well plates attached to the chips and
placed on a horizontal plate-shaker (600rpm) at room temperature for 5 minutes. This
step is repeated. The reconstituted sample (150μL) is then loaded onto the chip and
mixed at room temperature for 30 minutes. The sample is removed by aspiration and
chips are then washed in the appropriate buffers (150μL) three times, each time they are
placed on the horizontal plate shaker for 5 minutes. This is followed by a quick wash in
deionised water (150μL), to ensure no interference from the Phosphate buffer. The
surfaces were air-dried (approximately 30 minutes) and loaded with 1μL of EAM
solution, a saturated solution of aSPA , made up of 5mg of sinapinic acid (SPA)
reconstituted in 200μLof 100% acetonitrile, and 200μL of 1% v/v Trifluoroacetic acid
(TFA). This step was repeated once more after air-drying. Proteins bound to the Q10
ProteinChip arrays were analyzed by means of a ProteinChip PCS4000 (BioRad Inc.
(Hercules, CA, USA) mass spectrometer, Enterprise version. Instrument and data
collection were controlled through the CiphergenExpress v3.0.6 software interface.
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Overall instrument settings were in positive mode for the ion source at 25 kV and a
digitizer rate at 800 MHz.The instrument settings were determined separately for the
low mass and high mass range of the protein profile. Data collection was set to 150 kDa
optimized for m/z between 2–30 kDa for the low mass range and 30–100 kDa for the
high mass range. For the low mass range, the laser intensities ranged from 185–200
with a detector sensitivity of 8 and number of shots averaged at 180 per spot for each
sample. For the high mass range, the laser intensities ranged from 230–240 with a
detector sensitivity of nine and the number of shots averaged at 150 per spot.
6.3.3.3 ‘NP20’ CHIP PROTOCOL
Normal phase ProteinChips (NP20) (BioRad Laboratories, Inc. (Hemel Hempstead,
UK) were used as an analytical tool to qualitatively and quantitatively assess AAT
standard samples (Sigma), and samples from column chromatography runs, including
load, wash and eluate samples. The NP20 is a non-selective ProteinChip and so all
proteins in a tested sample should bind to the array. The active spots contain silicon
dioxide, which allows proteins to bind via serine, theronine, or lysine (BioRad Inc.,
2004).
All samples were diluted 10-fold, and 5μL is applied directly to an NP20 spot surface.
The spots were air dried for 20-30minutes, and then the surfaces were washed three
times with 5uL deionised water to remove proteins that were not bound to the surface.
The surfaces were briefly air dried (approximately 10 minutes) and loaded with 1uL of
EAM solution: again a saturated solution of 5mg sinapinic acid (SPA) reconstituted in
200μL 100% acetonitrile, and 200μL of 1% TFA. This step was repeated once more
after air-drying. The arrays were analysed using the PC4000 reader (see section 6.3.3.2).
6.3.3.4 HITRAP QFF
All chromatographic procedures were carried out using pre-packed 1mL (7mm by
25mm) HiTrap QSepharose Fast Flow (QFF) columns (GE Healthcare). The mean
particle size was approximately 95μm and the particle size range is 45–165μm as quoted
by the manufacturer. All experiments were performed on an ÄKTA Prime Plus (GE
Healthcare) equipped with a fraction collector. FIV filtrate was prepared as described in
section5.3.3.
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6.3.3.5 PROTEIN QUANTIFICATION
For a description of the protein quantification methods used, i.e. SDS page (reducing),
western blot, Total protein (BCA) assay, Alpha 1-antitrypsin ELISA quantification and
Turbitimer assay in determining albumin and transferrin concentrations see Chapter 5.
6.3.3.5.1SELDI-TOF-MS NP20 ANALYSIS
The method is described in section 6.3.3.3
6.4 RESULTS AND DISCUSSION
6.4.1 ‘Q10 PROTEINCHIP’ MS INTENSITY PROFILE DATA
The Q10 ProteinChipsresults from the initial scouting AAT binding conditions (Table
6.1) are shown in Figure 6.1. The conditions set were based on data from Glaser
(1982),Kee and Cook (2004), Kumpalumeet al.. (2007) who also looked at purifying
AAT from FIV paste, using of an anion exchange isolation step.
AAT binds at 50.1kDa/e; this is confirmed by running an AAT standard (Sigma-
Aldrich) on an NP20 chip and is shown in Figure 6.2. It shows the same mass as seen in
the ‘Q10’ chips, but they have slightly different ionizations and peak shapes owing to
the differing chips, and decreased competition of proteins in the AAT standard mixture.
There is competition amongst different proteins and salts in any specimen for
ionization, a general phenomenon in mass spectrometry termed ‘ion suppression’ which
lowers the yield of specific ions and reduces the sensitivity of detection (Hortin, 2006).
An increase in pH from 6.2-8.0 at 0mM NaCl does not appear to have an impact on
AATbinding;a slight reduction in low mass impurity levels is seen.However, when salt
concentration is increasedfrom 0mM to 150mM NaCl fewerlow and high mass
impuritiesare bound (Data collection was set to 150 kDa optimized for m/z between 2–
30 kDa for the low mass range and 30–100 kDa for the high mass range); this can
clearly be seen with the impurity Transferrin at approximately 79kDa/e, which
gradually decreases as salt concentration is increased at all the pH values tested.
Albumin is much harder to remove and is present under the majority of conditions
tested, even some of the high salt concentrations, except atpH 6.2 and 6.8 at 150mM
NaCl, where binding is reduced significantly. Therefore, based purely on impurity
binding it seems that AAT is best isolated at pH 6.2 or 6.8, with a salt concentration of
150mM.
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Figure 6.2SELDI-TOF-MS (NP20 ProteinChip) spectrum portraying the peak location
of Alpha 1-antitrypsin (approximately showing at 50kDa/e) from an AAT standard
purchased from Sigma-Aldrich. There were impurities present in the standard, but these
have not been shown.
However, the spectra plots do not portray any information on protein concentration; one
of the flaws in the SELDI-TOF-MS design is that product samples cannot be taken for
analysis post SELDI-TOF-MS processing. Protein intensity or the area under the curve
(AUC) of each protein peak can be used as measure of the amount of protein bound
onto the ProteinChip or in other words protein abundance or concentration (Grizzle et
al.. 2005; Meleth et al.. 2005). For this study each protein peak was identified at
50.1kDa/e, 66kDa/e and 79kDa/e for AAT, Albumin, and Transferrin respectively, by
summing the signal intensities based on mass resolution (± 0.3% of the mass) and the
area under the curve or ‘amplitude’ was measured.
In this study, two methods have been used to portray this data effectively: contour plots
and data bars. The contour plots were plotted using SigmaPlot 10.0 (Systat, San Jose,
CA). The contour plots are more descriptive and have been used to depict the binding
intensity of each protein over the range of conditions, effectively showing regions of
very high or low binding, see Figure 6.3. The data bars were plotted in Microsoft
Chapter 6-Improving ‘Q Sepharose’ Step Isolation of Alpha 1-antitrypsin using the SELDI-TOF-MS
Technology: A High Throughput Method
156
Excel, 2007. They are calculated
based on the highest and lowest
values across the whole data set (of
all three proteins, and all buffer
conditions), and so each data bar is
comparable to each other. The data
bar summary allows for easy
comparison across the whole range
of data, gives the exact AUC value,
and also allows for any outliers to be
quickly observed, see Figure 6.4.
Protein NaCl
Concentration
pH 6.2 pH 6.8 pH 7.4 pH 8.0
0mM NaCl 100 90 82 76
50mM NaCl 115 135 83 89
100mM NaCl 97 90 86 71
150mM NaCl 96 59 64 45
0mM NaCl 1515 1409 1174 1065
50mM NaCl 1657 2311 1073 1142
100mM NaCl 1611 2051 2252 1543
150mM NaCl 57 211 1065 1232
0mM NaCl 202 217 124 101
50mM NaCl 21 38 22 41
100mM NaCl 26 27 28 15
150mM NaCl 29 8 25 12
Protein Bound based on Peak Area (AUC)
(mAs) (+/-0.3%)
Transferrin
Albumin
AAT
Figure 6.4 Data bars portray a
summary of the abundance of AAT,
Albumin, and Transferrin based on
peak area under the curve (AUC) at
50.1kDa/e, 66kDa/e and 79kDa/e
respectively from the SELDI-TOF-
MS intensity profiles. Results from
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a range of pH and salt conditions used on the SELDI-TOF-MS Q10 ProteinChips are
shown. The intensity value correlates to the concentration of each protein bound to the
ProteinChip. The peaks are initially recorded by summing the signal intensities between
± 0.3% of the mass. Optimal conditions are highlighted in red.
The contour plot shows AAT to bind with higher intensities at lower pH values of 6.2
and 6.8, and with the highest intensity at a salt concentration of 50mM. However, the
data bar summary reveals that although AAT concentration is at its highest at 50mM
NaCl with peak areas of 115mAs and 135 mAs for pH 6.2 and 6.8 respectively, it is not
significantly higher than the other salt concentrations at pH 6.2 (which range from 96-
100 mAs). The biggest impurity present in the samples is Albumin. Both the contour
and data plots show reduced Albumin binding under buffer conditions of 150mM salt
and at the low pH values of 6.2 and 6.8. Transferrin does not bind well at the majority
of conditions tested. However, increased binding to the Q10’ ProteinChip is seen at
0mM NaCl, and at its highest at pH 6.2-6.8. Therefore, using the results from the
SELDI-TOF-MS spectra data and the protein intensity plots, it can be deduced that the
optimum buffer conditions for isolating AAT using Q-Sepharose is at pH 6.2 for the
increased AAT binding, and using 150mM NaCl for reduced impurity binding.
To investigate whether AAT isolation and binding could be improved further, buffers
were prepared at lower pH conditions, and at increased salt concentrations. These are
summarised in Table 6.2. The spectra resulting from these conditions can be seen in
Appendix 5. In this instance, all for the extended data set covered a lower absorbance
intensity range of approximately 0-5 mA intensity range, compared to 0-40mA
intensity range seen in the initial ‘Q10’ ProteinChip plots. These experiments were run
on two separate days, and different preparations of Energy Absorbing Molecule (EAM)
were used, as it expires after 24 hours. This affects the resulting mass spectra intensities,
making it impossible to compare the results from the two data setsdirectly. Other
possible sources of variation have been described in detail by Dijkstraet al.. ( 2007a). It
has been suggested (Baggerly et al.. 2004) that the use of data processing should be
employed to compare different SELDI-TOF-MS data sets. Therefore, before
comparison all the spectra data have been normalized to be in the same [0, 1] intensity
range using the following equation:
The normalized intensity (NVi) is given,
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6.4.1
Where, for a single spectrum, Vi denotes the raw intensity at the i-th m/z value, and
Vmin and Vmax denote the smallest and largest observed intensities in the spectrum,
respectively. This method of normalisation was applied to the SELDI-TOF-MS
processed data initially used to plot the MS spectra, and so the whole data set using
different EAM samples could be compared. This is shown in Figure 6.5.The additional
buffer conditions show a similar trend to the initial results: at pH 5.1 and 5.6 AAT is
shown to be better isolated from the impurities at higher salt concentrations of 150mM,
and 200mM NaCl. However, buffer conditions at pH 5.1 shows an apparent decrease in
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AAT intensity at the increased salt conditions. Work by Glaser et al.. (1982) suggests
that alpha-l-antitrypsin may begin to denature and aggregate at pH values much lower
than pH 6, which will have an impact on protein intensity. A smaller data set is
investigated in this instance and so it is not possible to create a suitable contour plot
based on the raw intensity data, to show the impact on protein binding. Consequently,
only the data bar summary method has been utilised to look at the binding intensity
ofAAT, Albumin, and Transferrin (Figure 6.6). There is not an obvious trend at pH 5.1
and 5.6 over the salt concentration range. There may be some AAT denaturation as
explained previously, and total impurity removal is again improved under higher salt
concentrations. The highest binding of AAT is seen at pH 5.6, 50mM NaCl, but
acceptable levels are achieved across the salt concentration range, and so it may be
more efficient to implement conditions with better impurity removal. At 200mM NaCl,
there is a general increase in AAT binding as pH is increased, aside from an outlying
low value at pH 6.2.
Protein NaCl
Concentration
pH 5.1 pH 5.6 pH 6.2 pH 6.8 pH 7.4 pH 8.0
AAT 0mM NaCl 29 24 - - - -
50mM NaCl 20 41 - - - -
100mM NaCl 2 22 - - - -
150mM NaCl 20 33 22 - - -
200mM NaCl 8 27 18 32 39 57
Albumin 0mM NaCl 143 154 - - - -
50mM NaCl 63 285 - - - -
100mM NaCl 5 52 - - - -
150mM NaCl 4 1 87 - - -
200mM NaCl 4 11 2 3 5 22
Transferrin 0mM NaCl 2 4 - - - -
50mM NaCl 4 4 - - - -
100mM NaCl 1 4 - - - -
150mM NaCl 3 5 3 - - -
200mM NaCl 2 8 2 5 3 7
Protein Bound based on Peak Area (AUC) (mAs) (+/-0.3%)
Figure 6.6 Data bars portray a summary of the concentration of AAT, Albumin, and
Transferrin based on peak area under the curve (AUC) at 50.1kDa/e, 66kDa/e and
79kDa/e for the additional buffer condition: pH 5.1 and pH 5.6, 0-200mM NaCl, and
pH 6.2, 6.8, 7.4, 8.0 at [200mM NaCl]. The intensity value correlates to the
concentration of each protein bound to the ProteinChip. The peaks are initially recorded
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by summing the signal intensities between ± 0.3% of the mass. Optimal conditions are
highlighted in red.
An additional FIV filtrate sample at pH 6.2, 150mM NaCl was also analysed along with
this new data set. The ratio of AAT to the impurities in both samples (see pH 6.2,
150mM NaCl in Figure 6.4 and Figure 6.6) are very different, with more Albumin
being present in the second sample. The second sample also has a much lower
AATpeak area, which is likely to have been suppressed by the increased Albumin
content in the sample competing for binding places or ionization energy.
6.4.2 PURITY OF AAT FROM ‘Q10 PROTEINCHIP’ MS INTENSITY PROFILE DATA
As seen in the previous section, given that the range of buffer conditions was
investigated in two separate sets of experiments, the intensity or abundance of the
protein in the ‘Q10’ fractionates cannot be compared directly. This is chiefly
attributable to the difference in intensity range, but also to variations in the FIV
precipitate samples. Determining the purity of the protein in the samples is another
method that can be used to normalise the data. The method used to calculate the purity
is described below:
The area under the profile peaks from the intensity plots were quantified for AAT and
the two significant impurities: Albumin (ALB) and Transferrin (Tf). For clarity, the sum
of these relevant proteins is labelled as Total Protein.
Purity of AAT is given by:
6.4.2
Where Total Protein Peak Area is:
6.4.3
The dataset is effectively normalised by taking the ratio of AAT to Total Protein in each
set. The optimum binding conditions are the regions with the highest AAT: Total
Protein ratio, where the most AAT and the lowest totalimpurity intensities are observed.
Figure 6.7 displays a contour plot portraying the purity of AAT across the data range.
As expected, AAT purity is at its highest levels when buffers of high salt [200mM
NaCl] concentrations are used; this is true for the full range of pH levels tested. The plot
also shows that decreasing the pH allows for good purity levels to be achieved for wider
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range of salt concentrations ranges; at [150mMNaCl], AATshows good purity levels at
the low pHs of 5.1-6.2.
Figure 6.7 The percentage purity of AAT (AAT/ Total Protein) when fractionated
using the SELDI-TOF-MS ‘Q10’ ProteinChip under a range of pHs and NaCl
concentrations.
However, some information is lost here, as the plot does not show the impact on
Albumin and Transferrin individually. Figure 6.8 displays a data bar summary of the
percentage purity of all the proteins. This shows that the increase in purity of AAT is
mostly due to the decrease in Albumin concentration. There is no significant trend in
Transferrin purity across all conditions, although the highest levels of Transferrin
”purity” appear at low buffer pHs of 5.1-6.2, with the highest salt concentrations
(150mM-200mM). However, this does not appear to have a major impact on AAT
purity; as it is present in minor concentrations compared to Albumin. The original AAT
MS intensity contour and data plots had shown the best AAT binding at asalt
concentration of 50mM NaCl, but a combined improvement of purity and yield only
achieved at higher salt concentrations.
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6.4.3 HITRAP ‘SCALE-UP’ DATA
The data generated using the SELDI-TOF-MS is known to be variable (Dijkstra et al..
2007). Therefore, a range of conditions using larger strong anion exchange columns
(1mL, GE HiTrap Q Sepharose Fast Flow) is used to test the ‘Q10’ chip
Protein NaCl
Concentration
pH 5.1 pH 5.6 pH 6.2 pH 6.8 pH 7.4 pH 8.0
AAT 0mM NaCl 17% 13% 5% 5% 6% 6%
50mM NaCl 23% 13% 6% 5% 7% 7%
100mM NaCl 27% 29% 6% 4% 4% 4%
150mM NaCl 73% 84% 53% 21% 6% 4%
200mM NaCl 60% 58% 81% 81% 83% 66%
Albumin 0mM NaCl 82% 85% 83% 82% 85% 86%
50mM NaCl 72% 86% 92% 93% 91% 90%
100mM NaCl 65% 66% 93% 95% 95% 95%
150mM NaCl 17% 4% 32% 76% 92% 96%
200mM NaCl 28% 25% 10% 7% 10% 26%
Transferrin 0mM NaCl 1% 2% 11% 13% 9% 8%
50mM NaCl 5% 1% 1% 2% 2% 3%
100mM NaCl 9% 5% 1% 1% 1% 1%
150mM NaCl 10% 12% 16% 3% 2% 1%
200mM NaCl 12% 17% 9% 12% 7% 8%
Protein Purity based on Peak Area data (%)
Figure 6.8A data bar summary of the percentage purity of AAT, Albumin and
Transferrin when fractionated using the SELDI-TOF-MS ‘Q10’ ProteinChip under
differing pH values and NaCl concentrations. Optimal conditions are highlighted in red.
generated data trends. 1mL pre-packed scale columns have been successfully used to
reliably scoutappropriate buffer conditions and matrix types to use at larger scale. Other
studies have shown the usefulness of using 1mL pre-packed columns, for example to
explore a range of hydrophobic interaction media preceding a more comprehensive
study of expanded bed separation on the most suitable choice (Smith et al.. 2002).
For each condition tested, the column was equilibrated, FIV filtrate was loaded, and
unbound protein was washed off using the same buffer, just as the SELDI-TOF-MS
samples were processed. The initial ‘wash peak’ fractions were collected and pooled.
20mM Phosphate, 2M NaCl was used to remove all bound protein from the column in
the ‘elution peak’ , which was also collected in fractions and then pooled (Figure
6.9).Protein intensity and mass were determined using the non-selective SELDI-TOF-
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MS NP20 ProteinChips, in conjunction with an ELISAkit to measure AAT
concentration or the Siemens Turbitimerapparatus to measure Albumin and Transferrin
concentrations.
Figure 6.9An example of the elution profiles from the Hitrap Q Sepharose FF columns.
Fraction IV filtrate is loaded at pH 8, 150mM NaCl on to 1mL pre-packed columns:
The first peak represents the wash of unbound protein with 20mM Phosphate, 150mM
NaCl at pH 8, The second peak shows a salt step elution to 2M NaCl, and the third
peak is a 0.5M NaOH wash. Symbols are: (—) Absorbance, (−••−) NaCl concentration,
(…....) pH
Figure 6.10 and Figure 6.11 show the SELDI-TOF-MS intensity profiles for the eluate
and wash peaks respectively. The eluate profile shows that pH 6.2 is most favourable in
removing the impurities, primarily Albumin. However, salt concentration at pH 6.2 does
not seem to have an obvious impact on impurity binding as seen in the ‘Q10’ chip
experiments. At pH 8, there are fewer impurities bound at the highest salt concentration
of 200mM. The wash profile is clearer in showing impurity removal; there are more
impurities present in the flow-through wash when using conditions of higher salt
concentrations, illustrating that they are not binding to the column.
Chapter 6-Improving ‘Q Sepharose’ Step Isolation of Alpha 1-antitrypsin using the SELDI-TOF-MS
Technology: A High Throughput Method
165
Fi
gu
re
6.
10
SE
LD
I-
TO
F-
M
S
sp
ec
tra
re
pr
es
en
tin
g
pr
ot
ei
n
pr
of
ile
s
of
Fr
ac
tio
n
IV
el
ua
te
sa
m
pl
es
.
FI
V
fil
tra
te
w
er
e
lo
ad
ed
on
to
a
H
iT
ra
p
Q
Se
ph
ar
os
e
FF
co
lu
m
n,
un
de
r
th
e
co
nd
iti
on
s
sh
ow
n
in
th
e
fig
ur
e
.L
oa
di
ng
,e
qu
ili
br
at
io
n
an
d
bi
nd
in
g
w
er
e
ke
pt
un
de
r
th
e
sa
m
e
co
nd
iti
on
s
to
m
im
ic
th
e
SE
LD
I-
TO
F-
M
S
Q
10
te
ch
ni
qu
e
us
ed
ea
rli
er
.A
st
ep
el
ut
io
n
(2
M
N
aC
l)
w
as
us
ed
to
re
m
ov
e
al
lt
he
pr
ot
ei
n
bo
un
d
on
to
th
e
co
lu
m
n,
an
d
so
th
e
pr
of
ile
s
re
pr
es
en
t
th
e
bi
nd
in
g
ca
pa
ci
ty
of
th
e
m
at
rix
.
Th
e
pr
of
ile
s
w
er
e
pr
od
uc
ed
us
in
g
th
e
no
n-
se
le
ct
iv
e
SE
LD
I-
TO
F-
M
S
‘N
P2
0’
Pr
ot
ei
nC
hi
p.
A
m
at
rix
of
9
co
nd
iti
on
s
(p
H
5.
6,
6.
2
an
d
8,
N
aC
lc
on
ce
nt
ra
tio
ns
of
0m
M
,1
50
m
M
,a
nd
20
0m
M
)
w
er
e
an
al
ys
ed
at
1m
L
co
lu
m
n
sc
al
e.
Th
e
A
A
T
pe
ak
is
sh
ow
n
at
a
52
kD
a/
e;
A
lb
um
in
at
66
kD
a/
e
an
d
Tr
an
sf
er
rin
at
79
kD
a/
e.
Chapter 6-Improving ‘Q Sepharose’ Step Isolation of Alpha 1-antitrypsin using the SELDI-TOF-MS
Technology: A High Throughput Method
166
Fi
gu
re
6.
11
SE
LD
I-
TO
F-
M
S
sp
ec
tra
re
pr
es
en
tin
g
w
as
h
pe
ak
s
fr
om
Fr
ac
tio
n
IV
fil
tra
te
sa
m
pl
es
af
te
rt
he
y
w
er
e
lo
ad
ed
on
to
a
H
iT
ra
p
Q
Se
ph
ar
os
e
FF
co
lu
m
n,
un
de
r
th
e
co
nd
iti
on
s
sh
ow
n
in
th
e
fig
ur
e
lo
ad
an
d
w
as
h
co
nd
iti
on
s
w
er
e
th
e
sa
m
e
.
T
he
pr
of
ile
sh
ow
s
pr
ot
ei
n
th
at
di
d
no
tb
in
d
to
th
e
co
lu
m
n.
Th
e
pr
of
ile
s
w
er
e
pr
od
uc
ed
us
in
g
th
e
no
n-
se
le
ct
iv
e
SE
LD
I-
TO
F-
M
S
‘N
P2
0’
Pr
ot
ei
nC
hi
p.
A
m
at
rix
of
9
co
nd
iti
on
s
(p
H
5.
6,
6.
2
an
d
8,
N
aC
lc
on
ce
nt
ra
tio
ns
of
0m
M
,1
50
m
M
,a
nd
20
0m
M
)
w
er
e
167
At pH 8, 0mM NaCl very little or what appears to be no protein is present in the wash,
indicating that all protein, AAT and impurities are binding to column. At lower pH
levels and high salt concentrations more impurity peaks can be seen in the wash
profiles; these proteins are not binding to the column. If the load and wash procedures
are suitably optimised then it is possible there will be no requirement for product elution
optimisation; after washing off unbound proteins, all product could then be removed
from the column using a highly concentrated salt step-elution.
Figure 6.12 A) shows a data bar summary of the concentration of proteins present in the
product eluate, and in the wash peak. The concentrations are determined using ELISA
methods for AAT, and the Siemens Turbitimer method for Albumin and Transferrin.
This eluatedata shows that there is no major change in AAT concentration across all
conditions, and Albumin removal is best at the low pH and high salt concentrations;
these trends are inline with of the initial ‘Q10’ chipresults. Transferrin is present in
higher amounts than was seen in‘Q10’ chips fractions, and so may require an additional
removal step at a later stage. The wash data again confirms a similar trend in AAT
concentration, and almost no AAT is present all across the sample range. More Albumin
is present at high salt concentrations indication non-binding, and is best removed at pH
6.2. There is not much variation in Transferrin concentration. The data bar summaries
also portray the improved removal of impurities at lower pH levels and higher salt
concentration more clearly than in the MS plots.
Figure 6.12 B) shows a data bar summary of the concentration data quantified using
SELDI-TOF-MS NP20 chips. Peak area (mAs) is quantified from the intensity profiles
and is relative to protein abundance. The chips are non-selective and thus should
confirm everything present in the sample. The product eluate samples showAAT to
have the greatest peak area at pH 5.6 and the best Albumin removal at pH 6.2 for all salt
concentrations. Transferrin concentration varies, but no obvious trend is seen; the
lowest concentrations are at outliers of pH8, 0mM NaCl, and pH 5.6, 200mM NaCl. In
the wash peak, the lowest AATlosses are seen at 0mM NaCl. More Albumin is lost at
high concentrations of salt as seen in Figure 6.12 A); the protein concentration wash
data. No obvious trends are seen in Transferrin removal over the buffer condition range
tested, but there is more Transferrin present in the wash peaks than the eluate peaks.
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A)
Protein NaClConcentration
pH 5.6 pH 6.2 pH 8 pH 5.6 pH 6.2 pH 8
AAT 0mM NaCl 0.04 0.04 0.05 0.00 0.004 0.007
100mM NaCl 0.03 0.03 0.01 0.00 0.006 0.014
200mM NaCl 0.01 - 0.00 0.00 0.012 0.008
Albumin 0mM NaCl 1.25 1.47 1.33 0.03 0.11 0.03
100mM NaCl 0.59 0.04 1.12 0.41 0.59 0.30
200mM NaCl 0.09 0.04 0.28 0.29 0.79 0.40
Transferrin 0mM NaCl 0.49 1.10 0.68 0.24 0.30 0.40
100mM NaCl 0.08 0.52 0.42 0.44 0.33 0.57
200mM NaCl 0.06 0.02 0.21 0.29 0.56 0.44
B)
Protein NaCl
Concentration
pH 5.6 pH 6.2 pH 8 pH 5.6 pH 6.2 pH 8
AAT 0mM NaCl 98.53 51.44 58.07 52.06 31.55 6.46
100mM NaCl 168.91 32.74 25.58 70.46 126.31 105.09
200mM NaCl 100.40 26.83 14.99 141.50 82.89 151.96
Albumin 0mM NaCl 837.64 253.66 438.59 113.38 90.83 20.31
100mM NaCl 1256.91 277.16 2306.77 1027.79 1313.32 440.19
200mM NaCl 1127.90 240.10 459.31 1880.12 804.10 1518.61
Transferrin 0mM NaCl 80.74 24.59 6.32 219.48 84.26 16.74
100mM NaCl 26.58 47.14 61.06 185.18 231.18 212.48
200mM NaCl 9.67 56.42 16.21 685.65 67.72 269.60
Protein Bound (mAs) Eluate Peak Unbound Protein (mAs) WashPeak
Protein Bound (g/L) Eluate Peak Unbound Protein (g/L) Wash Peak
Figure 6.12A data bar summary showing the concentration of AAT, Albumin and
Transferrin present in the ‘eluate’ (bound protein) and ‘wash’ peaks (unbound protein)
(see Figure 6.9) from a HiTrap Q Sepharose Fast flow separation step over a range of
conditions (pH 5.6-8, [NaCl] 0-200mM). In A) the data is determined using ELISA
(AAT) and Siemens Turbitimer (Albumin and Transferrin) methods; in B) the data
shows the Peak Area (± 0.003) from the intensity profiles produced using the non-
selective SELDI-TOF-MS ‘NP20’ ProteinChip. The AAT peak is measured at a
50.85kDa/e; Albumin at 66kDa/e and Transferrin at 79kDa/e. Optimal conditions are
highlighted in red.
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Overall, the NP20 chips do provide similar trends to that seen using standard
concentration determination methods. This is far more obvious in the wash data results,
in the MS profiles and in the data bar summaries; this may be due to the slightly lower
overall protein content in the wash samples. There are also more dissimilarities in trends
between wash and eluate data when determining the concentration using the NP20
chips, than seen with the ELISA and Turbitimer methods.
Variability in the plasma-derived FIV samples was seen and this may have affected the
subsequent purification results.Therefore, to eliminate this variability a yield of eluate
or wash sample from protein load was used to re-evaluate the ELISA and Turbitimer
concentration data (Figure 6.13). The eluate yield data showed similar trends to that
seen in the concentration data (Figure 6.12) except in the case of Transferrin
concentration: where this result suggests that more of it is removed at the highest salt
concentration of 200mM NaCl, across all pH values (Figure 6.13). This is also in line
with AAT binding and Albumin removal; providing an optimal buffer condition. It is
also reflects the results predicted in the ‘Q10’ chip data.
Protein NaCl
Concentration
pH 5.6 pH 6.2 pH 8 pH 5.6 pH 6.2 pH 8
0mM NaCl 59% 99% 63% 0% 9% 8%
100mM NaCl 71% 94% 19% 0% 16% 30%
200mM NaCl 90% - 0% 0% 29% 30%
0mM NaCl 56% 42% 49% 1% 3% 1%
100mM NaCl 37% 2% 38% 25% 27% 10%
200mM NaCl 9% 1% 14% 28% 25% 20%
0mM NaCl 37% 100% 50% 18% 30% 29%
100mM NaCl 11% 51% 32% 60% 33% 44%
200mM NaCl 3% 2% 18% 15% 46% 37%
Transferrin
AAT
Albumin
Unbound Protein (% Yield) Wash
Peak
Protein Bound (%Yield) Eluate
Peak
Figure 6.13A data bar summary of percentage protein yield in the ‘eluate’(bound
protein) and percentage yield loss in the ‘wash’(unbound protein) peaks (see Figure
6.9) from a HiTrap Q Sepharose Fast flow separation step over a range of conditions
(pH 5.6-8, [NaCl] 0-200mM). This is based on the concentration data(Figure 6.12)
determined using ELISA methods for AAT, and the Siemens Turbitimer method for
Albumin and Transferrin. Optimal conditions are highlighted in red.
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6.4.4 PURITY OF AAT IN HITRAP QFF SAMPLES
To compare the purity results from the ‘Q10’ chip SELDI-TOF-MS analysis, the purity
of the HiTrap samples is calculated usingboththe concentration and yield data, again
this is normalised using the method described in section 6.4.2. The eluate peak data
analysed using ELISA and Turbitimer methods exhibit similar AAT trends: better purity
of AAT at low pH values and high salt concentrations in the product (Figure 6.7.14
A).No obvious trend is seen in the case of Albumin and Transferrin. The improved
purities of AAT and Transferrin are mainly due to the low concentrations of Albumin
originally observed at pH 5.6, 200mM NaCl and at pH 6.2, 100-200mM NaCl(Figure
6.12 A). The purity data calculated using the peak areas from the NP20 chip samples
do not show obvious trends. AAT has improved purity levels across the range of
conditions tested expect at pH 8,100-200mM NaCl. The NP20 MS profiles as seen in
Figure 6.10 and Figure 6.11 portray a profile of almost no impurities present in the
product peak at pH 5.6,200mM NaCl. However, upon analysisthe purity of AAT is
calculated to be only 8% when using this normalisation method, and this is compared to
Albumin and Transferrin solely. Therefore, the NP20 MS profile does not accurately
reflect column performance, and should be used in conjunction with a quantitative
method, such as that described in section 6.4.2.
The wash peakpurity data shows a better correlation between the ELISA/Turbitimer and
NP20 data. Minimal AAT is present in wash fraction at pH 5.6-6.2, and Albumin is
present in greater quantities at increased salt conditions. More Transferrin appears to be
removed in the wash fraction at 0mM NaCl at all pH levels. In this case, NP20 Chip
can be used to successfully analyse data if there is low sample variation and if the data
set is normalised.
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A)
Protein NaCl
Concentration
pH 5.6 pH 6.2 pH 8 pH 5.6 pH 6.2 pH 8
0mM NaCl 2% 2% 2% 0% 1% 2%
100mM NaCl 4% 6% 1% 0% 1% 2%
200mM NaCl 8% - 0% 0% 1% 1%
0mM NaCl 70% 56% 64% 11% 26% 7%
100mM NaCl 84% 7% 72% 48% 63% 34%
200mM NaCl 54% - 57% 49% 58% 47%
0mM NaCl 28% 42% 33% 89% 73% 91%
100mM NaCl 12% 87% 27% 52% 36% 64%
200mM NaCl 38% - 43% 51% 41% 52%
B)
Protein NaCl
Concentration
pH 5.6 pH 6.2 pH 8 pH 5.6 pH 6.2 pH 8
0mM NaCl 10% 16% 12% 14% 15% 15%
100mM NaCl 12% 9% 1% 5% 8% 14%
200mM NaCl 8% 8% 3% 5% 9% 8%
0mM NaCl 82% 77% 87% 29% 44% 47%
100mM NaCl 87% 78% 96% 80% 79% 58%
200mM NaCl 91% 74% 94% 69% 84% 78%
0mM NaCl 8% 7% 1% 57% 41% 38%
100mM NaCl 2% 13% 3% 14% 14% 28%
200mM NaCl 1% 17% 3% 25% 7% 14%
AAT
Transferrin
Protein Bound (%Purity) Eluate
Peak
AAT
Albumin
Transferrin
Protein Bound (%Purity) Eluate
Peak
Unbound Protein (%Purity) Wash
Peak
Unbound Protein (%Purity) Wash
Peak
Albumin
Figure 6.14The purity of AAT, Albumin and Transferrin in the ‘eluate’ (bound protein)
and ‘wash’ (unbound protein) peak fractions from a HiTrap Q Sepharose Fast flow
separation based on A) Elisa methods for AAT and Turbitimer concentration estimates
for Albumin and Transferrin; B) AUC (Area under the curve of target peaks) from
NP20 chip SELDI-TOF-MS profiles. Total protein is considered to be the summation of
AAT, Albumin and Transferrin concentrations. The Peak Area (± 0.003) is calculated
from the intensity profiles produced using the non-selective SELDI-TOF-MS ‘NP20’
ProteinChip. The AAT peak is measured at a 50.85kDa/e; Albumin at 66kDa/e and
Transferrin at 79kDa/e.
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6.5 CONCLUSIONS
Process step optimization can be time-consuming and costly. High-throughput
technology allows scientists to screen a large number of conditions at reduced time-
scales. The SELDI-TOF-MS has been used to improve the isolation of alpha 1-
antitrypsin (AAT) in FIV filtrate with ‘Q Sepharose’ anion media, by speedily trialling
a variety of buffer conditions. A total of 21 buffer conditions were tested, varying pH,
and salt concentrations. A number of these conditions were mimicked at 1mL scale to
validate the method.
This chapter has highlighted that SELDI-TOF-MS ‘Q10’ technology can be used to
predict the general trends in binding condition of a HiTrap Q-Sepharose FF column.
The ‘Q10’ chips and HiTrap QFF data both successfully showed improved isolation of
AAT at lower pH values of 5.6-6.2, and with the highest salt concentrations tested (150-
200mM NaCl), when measured using the NP20 chips and more traditional protein
determination methods, such as ELISA analysis.
The HiTrap QFF data shows that yields of 94-99% AAT can be achieved but with a
compromise in impurity removal. The optimal condition for the isolation of AATwas
found to be at pH 5.6, 200mM NaCl, where a 90% yield can be achieved, but more
work would need to be done, to determine whether AAT is stable or has been denatured
at this low pH value. This result is reiterated in the SELDI-TOF-MS NP20 profiles,
where very little impurities are seen. A larger data set would be required to determine
the exact conditions to use. However, a large discrepancy in the purity levels was seen
between the Q10 chips and the HiTrap QFF columns. The SELDI-TOF-MS ‘Q10’
fractionation predicted purities > 50% under optimal conditions; in contrast the purities
seen with the HiTrap QFF columns was <10% under the optimal conditions. However,
the very low concentrations of AAT, in this relatively impure FIV filtrate sample does
make the analysis more troublesome.
A fully automated approach would allow for the screening a large number of conditions
at short time-scales. Analysis has shown that variability in samples and differences in
MS intensity can be eliminated by normalising the data.
Analysis of the larger-scale material was carried out using the SELDI-TOF-MS NP20
chips, Elisa, Total protein. NP20 chip MS analysis was found to comparable to ELISA
and Turbitimer immunoassay methods when the dataset was normalised.
Chapter6 -Purifying a New Product From a Side-Fraction: The Feasibility of Purifying Alpha 1-
Antitrypsin From Fraction IV Precipitate
173
Other work by (Gupta and Gowda, 2008) have shown a proportional reduction in AAT
activity as pH is lowered much below pH 7, and so further work on the stability
ofAATunder the conditions suggested in this chapter will need to be analysed in
conjunction with this work.
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6.6 INTRODUCTION
Process changes are inevitable in the manufacture of biologics. Changes that improve
yields are vital in order for companies to remain competitive, and for the processes to
remain robust and economical. The impact of making a change to a manufacturing
process is not trivial; in the biologics sector it is often quoted that “the product is
defined by its manufacturing process”. Product purity, quality and efficacy cannot be
compromised and any changes directly affecting the manufacturing stream or the
analyticalactivities associated will need to be made to remain in line with the rigid
regulatory protocol, where proof of these factors can be timely and costly.However, the
positive impact of making changes to process steps, especially with new emerging
technologies, can be hugely significant, and so a series of trade-offs must be evaluated.
This chapter summarises the research in this thesis to enable process changes to be
evaluated from both a manufacturing and development lifecycle perspective. It also
describes future work activities that can build on this research.
6.7 OVERALL CONCLUSIONS
This thesis explores the impact of both positive and detrimental results of process
changes in the biopharmaceutical industry, with a particular focus on biologics. A
systemic evaluation framework has been created to capture the technical and regulatory
activities involved in process changes so as to rapidly gauge the potential cost and risk
implications.
Chapter 2 describes a survey that was carried out to benchmark typical costs and
durations, as well as to gauge industry attitudes to implementing changes to their
processes. The findings suggested that the majority of changes are made to reduce
batch-to-batch variability and improve product yield or purity. Major changes, that
require thorough efficacy studies, are not frequently made once processes have been
approved for production; the main deterrents being the vast costs and delays in
production where they cannot be stockpiled. Feedback from the survey respondents
suggested that regular communication with regulatory authorities before and during
change implementation is key to avoiding significant future costs and delays in
production. The survey results showed that ifa proposed manufacturing change during
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the development stage or post productapproval is likely to instigate a repeat of lengthy
clinical trials, then companies are likely to reject the proposal for change.
Chapter 3 describes the modelling approach adopted in this thesis to evaluate the
potential of process changes. Key technical activities were captured, namely
development, manufacturing, retrofitting and validation at all stages of development.
The impacts of changes were linked to regulatory activities needed to assess
comparability.Development and product equivalence activities were based on
benchmark costs and time spans taken from the survey, which also helped create the
framework of the model.Mass balance calculations were used to compute process
stream compositions to calculate the manufacturing process yield.
Strategicuncertaintieswere accounted for in the model such as the likelihood of
repeating clinical trials, the market share losses, delays to market from retrofit,
revalidation, or regulatory approval disruptions, and the costs involved in proving
product equivalence. The activities were measured in cost and time delay, and
eventually converted into a single measure of profit: Net Present Value. Incorporating
the risks involved at each step enabled scenarios to be evaluated based on the Expected
Net Present Value and the probability, where p(NPV>0). The entire framework was
translated into Microsoft Excel with macros for Monte Carlo simulations to account for
the uncertainties.
A case study illustrating the implementation of various changes to a plasma
fractionation process was then explored in Chapter 4. Process changes of varying
magnitude and type, were explored at different stages of product development including
post-product approval. The example illustrates how the framework described can be
used to investigate the effects of making process changes, whether these are forced upon
them or are made to enhance productivity. The scenario results showed that the stage of
implementation is far more significant than the process change type; it is not
economically possible in the three cases investigated to make a change at late phase
clinical development. The best approach would be to implement that change once a
product is approved and commercial or once the company is able to stockpile sellable
product, to minimise the impact of process change delays. Major yield enhancing
changes made to traditional fractionation processes were not found to be
economicallyfeasible. Costs and delays involved in undertaking clinical trials as well as
re-registration of the ‘new’ product in all of the countries in which the products are
licensed were too high a cost to pay for relatively small yield enhancements.
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Another process change case study presented in Chapter 5,looked at the purification of a
new product from a waste fraction, however, this time with an experimental outlook.
The protein Alpha 1-antitrypsin (AAT), which is effective in the treatment of hereditary
AAT-deficiency, amongst other indications, was purified from FIV precipitate of a
plasma fractionation scheme using a process suggested by Keeet al. (2004)in a patent.
The initial purification stages were mimicked at laboratory scale, but proved
unsuccessful using FIV precipitate. However, by making changes to the template
process,AAT was successfully purified from FIV precipitate. The addition of a reducing
agent such as DTT to FIV to disrupt the protein structure and precipitate out
surrounding impurities caused filtration problems, and did not provide better yields.
Additional precipitating agents and body feed additions to the FIV dissolution prior to
filtering as suggested in the Keeet al. (2004) patent were also removed, as the filtration
step efficiency was not improved and thebiggest impurityalbumin, was still present at
very high concentrations. Depth filtration and anion exchange chromatography steps
were effectively modified and resulted in a fully functional process. The recovery of
AAT filtrate from depth filtration was greatly improved in this way. The filtration
performance was also improved by removing all filter aids and reducing agents. The
final process recoveries of AATwere very low at 18% or 23% when using Fractogel or
Q-Sepharose media respectively, suggesting that FIV precipitate may not be the ideal
starting material for the purificationof AAT.
Chapter 6 presented an example of process step optimization using the SELDI-TOF-MS
technology to improve the isolation of alpha 1-antitrypsin (AAT) in FIV filtrate with ‘Q
Sepharose’ anion mediaby speedily trialling a variety of buffer conditions. SELDI-TOF-
MS fractionation technology (in this case the ‘Q10’ chip) was found to be useful at
predicting trends in binding efficiencies over a range of pH and salt concentrations
forHiTrap Q-Sepharose FF columns. Improved isolation of AAT was achieved using
‘Q10’ chips at lower pH values of 5.6-6.2, and with the highest salt concentrations
tested (150-200mM NaCl),this was qualified using more robust 1mLHiTrap columns.
The HiTrap QFF data showed that yields of 94-99% AAT can be achieved but with a
compromise in impurity removal. The optimal condition for the isolation of AAT was
found to be at pH 5.6, 200mM NaCl, where a 90% yield was achieved. However, more
work would need to be done, to determine whether AAT is in a stable form or has been
denatured at this low pH value. The HiTrap result seems to coordinate with the SELDI-
TOF-MS NP20 profiles, where almost no impurities were present in the product peak at
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at pH 5.6, 200mM NaCl, although, a larger data set would be required to determine the
exact conditions to use. However, upon further inspection, when the purity of AATwas
quantified, based on the ratio of AAT to total protein an undesirable percentage purity
of only 8% is observed – this is based solely on the two main impurities present:
Albumin and Transferrin. This would determine that SELDI-TOF-MS ‘Q10’
fractionation overestimates the purity that can be achieved at large-scale. However, the
very low concentrations of AAT, in this relatively impure FIV filtrate sample does
make the analysis more troublesome. Analysis has shown that variability in samples and
differences in MS intensity can be eliminated by normalising the data. Analysis of the
larger-scale material was carried out using the SELDI-TOF-MS NP20 chips, ELISA,
Total protein. NP20 chip MS analysis was found to comparable to ELISA and
Turbitimer immunoassay methods when the dataset was normalised.
6.8 FUTURE WORK
The work in this thesis presents a holistic framework for assessing the potential of
process changes using both process economic models embracing development,
manufacturing, and regulatory costs as well as scale-down models for rapid
identification of optimal process conditions. It also provides a strong base for further
work; several examples have been highlighted below.
Whilst the survey work provided valuable insight into the industry attitudes and
practices concerning the implementation of process changes, this could be updated to
discover how the use of the now more mainstream use of Process Analytical
Technology (PAT), and the implementation Quality by Design (QbD) would affect the
responses. In practise, PAT and QbD should afford companies much more process
flexibility and a larger design space, even between development stageswithout affecting
the product quality, and more importantly less involvement from the regulatory
authorities during these critical stages. Technically, this may result in fewer “major”
process changes, and less need for filing for ‘Prior Approval Supplementation’, often
seen as a burden and can prevent manufacturers from implementing continuous
improvement or introducing technological advances.It may also mean that companies
will possibly have to make larger investments earlier in the product lifecycle during
process development in advance of approved commercial operations, moving away
from the more “aggressive” manufacturing approach. On top, whether this really does
provides any “regulatory relief” and faster approval of new product applications and
process changes, and or just “regulatory flexibility” would be useful to find out.A
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secondary survey used to benchmark the costs and time spans of more specific process
change activities, such as validation and retrofittingwould be useful to refine the
correlations used in this thesis.
The systematic framework used in this thesis to capture the activities involved in
process changes is modelled in Microsoft Excel with macros for Monte Carlo
simulations to account for the uncertainties, and is modelled on an individual case
basis. It may also be useful to model the framework dynamically to incorporate the
analysis of process variations with time. The use of commercially available packages
such as Aspen Engineering Suite (Aspen Technology; Cambridge, Massachusetts), and
gPROMS (PSE; London, UK), could be useful in modelling the manufacturing activity,
but would not include the key regulatory and clinical development activities. The use of
a more generic software package such as Extend (Imagine That; San Jose, California)
can be used to model discrete events that can be customized for manufacturing and
development activities. The scenarios used to demonstrate the usefulness of the
framework were based on the purification of polyclonal IVIG by means of a blood-
plasma fractionation process.Further process change scenarios of interest could
involvethe replacement of an earlier fractionation step, and to observe the impact on the
multiple products that are derived from human-derived plasma.
As has previously beensuggested, the experiment to purify AAT from FIV paste yielded
low final recoveries of AATand so FIV precipitate may not be the ideal starting
material. However, the product is in demand, so a study to assess the trade-off of selling
FIV precipitate as a cheap by-product or of purifying AAT from the paste as a new
product needs to be analysed further. Other proteins, such as GC globulin, Protein C,
Mannan binding lectin and C-reactive Protein are present in FIV and may be present at
higher concentrations and so may be more suitable to purify from this fraction point. To
assess this thoroughly, the differing commercial, development, and technical attributes
must be compared. Commercial attributes will include, the potential market demand
(dose per patient and per annum), the presence of direct competitors and indirect
competitors, the possible selling prices, the potential to patent the purification process,
and estimated regulatory approval rates. Development issues should cover the ease of
process development (based on scalability, and the presence of similar processes in
industry), processing time, initial concentration in FIV precipitate, the complexity of
the protein structure, potential overall yield, the final purity, and of course the process
change activities, which will include validation, the risk and cost of clinical trials, and
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assay development. Manufacturing issues to consider will be a comparison of the initial
capital investments as well as the annual cost of goods per gram, as well as perhaps the
utilisation of disposables.
AAT can also be purified from an earlier process fraction (Fraction A+1), which has an
impact on approved products such as Albumin. This has been investigated
experimentally by Kumpalumeet al. (2007, 2008).An economic comparison of the
purification of AAT from FIV paste and from Fraction A+1 including all process
change activities, such as the risk of repeating clinical trials would provide a valuable
insight on the potential new products may have in the traditionally unchanged blood-
plasma fractionation process.
The use of Ciphergen®’s SELDI-TOF-MS ProteinChip technology to investigate the
value of using a high throughput optimisation method and to improve the isolation of
AAT would be more valuable if a fully automated approach was used. This would allow
for the screening of a large number of conditions in short time-scales, and would further
showcase the usefulness of the SELDI-TOF-MS by improving its ability to predict the
results of scaled-up conditions.
It would be valuable to look at further complementary experiments analysing AAT
stability upon reaching the Fraction IV precipitate stage and also during the AAT
purification process suggested in this thesis. The stability of AAT at the initial FIV
precipitate stage could be compared to Kumpalume’s suggested starting point, Fraction
A+1, to assess which was the most economically valid pool. Following on from this, it
would be beneficial to also look at protein re-folding methods that might be useful in
“recapturing” any AAT denatured by some of the harsh fractionation process methods
utilised.
In conclusion, the future work outlined draws upon the background survey, the
framework, and methods utilised in this thesis. The development of more sophisticated
models, increased benchmarked data, and the incorporation of PAT and QbD will
increase the accuracy of prediction of this type of work. With an industry push towards
better global harmonization in product development, regulatory submission and quality,
it will mean it is even more relevant in the future to model process change activities
using a generic systematic approach such as that described in this thesis.
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Appendix 2- Figure 1The Percentage breakdown of respondents who estimated the
durations of post change activities to be less than 3 months; 3-12 months; 12-18
months; or more than 18 months, n=81. Legend: Bioequivalence/comparability studies
( ), Revalidation of process and equipment ( ), Phase I clinical trials ( ), full-scale
clinical trials ( ), re-registration of product ( )
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Appendix: Chapter 3
Appendix 3- Table 1
Unit operation Basis – simple models Key outputs
Centrifugation
Solids carry-over
Solids volume-fraction in
sediment
Sediment composition
Supernatant composition
Microfiltration
Flux
Rejection coefficients
Permeate composition
Retentate composition
Membrane area
or Concentration factor
or Processing time
Diafiltration
Flux
Rejection coefficients
Number of diafiltration
volumes
or Contaminant removal-
fraction
Permeate composition
Retentate composition
Membrane area
or Concentration factor
or Processing time
Number of diafiltration
volumes
or Contaminant removal-
fraction
Dead-end filtration
Flux
Rejected particle-fraction,
Particle volume-fraction in
retentate
Permeate composition
Retentate composition
Membrane area
or Processing time
Chromatography Flowrates, yields
Product stream
composition
Waste stream composition
Processing time
Buffer volumes
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Appendix 3- Table 2 Examples of the Farid, 2001 mass balance models used to model
the manufacturing process task in the process change activity
framework.
Inputs Outputs Mass Balance Calculations
Centrifugation
Solids-carry-over-
fraction, S
Solid-volume-fraction in
sediment,
seds
v
Total feed stream
component masses,
totin
m
Total volume of feed
stream,
totin
V
Solid density, s
* Assumption: Only 1
solid component
Solids removal fraction,
R
Supernatant and sediment
solid component masses,
sups
m ,
seds
m
Supernatant and sediment
liquid component masses,
supil
m ,
sedil
m
1. R
SR  1
2.
seds
m ,
sups
m
insed ss
mRm 
sedin sss
mmm 
sup
3.
inl

intotin sinl
mmm 
intotin sinl
VVV 
in
in
in
l
l
l V
m

4.
sedl
m
s
s
s
sed
sed
m
V


sed
sed
sed
s
s
tot v
V
V 
sedsedsed stotl
VVV 
insedsed lll
Vm 
5.
sedl i
m ,
supl i
m
sed
in
in
sed l
l
il
l i mm
m
m 
sedin ilill i
mmm 
sup
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Inputs Outputs Mass Balance Calculations
Membrane filtration
Calculation mode:
Membrane area per unit,
A / Processing time per
cycle, t
Average flux, J
Volume of feed stream,
inV
No of cycles, n
Concentration factor,
CF
Rejection coefficient,
RC
Output mode:
Membrane area per unit,
A / Processing time per
cycle, t
Total processing time, T
Permeate and retentate
stream component
masses, permim , retim
1. A , t
tnJ
CFVA in



 )1( 1
or
AnJ
CFVt in



 )1( 1
2. T
tnT 
3. retV
CF
VV inret 
4. )10(
0

 ireti
RCm
RC
)1(
0



i
RC
RC
inireti CFmm
i
reti
reti
RC
RC
m
V

0
0



5. )0(
0

 ireti
RCm
RC



00 RCRC retiretret
VVV
0
0
0 



RC
RC
RC ret
in
ini
reti VV
VV
iretireti RCRC
Vm 
 00
6. permim
retiinipermi mmm 
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Inputs Outputs Mass Balance Calculations
Diafiltration
Calculation mode:
Membrane area per unit,
A / Processing time per
cycle, t
Average flux, J
No of cycles, n
Rejection coefficient,
RC
No of diafiltration
volumes, D
Volume of components in
tank, oV
Component masses in
tank, om
Output mode:
Membrane area per unit,
A / Processing time per
cycle, t
Total processing time, T
Permeate and retentate
stream component
masses, permim , retim
1. A , t
tnJ
VDA o


 or
AnJ
VDt o



2. T
tnT 
3. retV
oret VV 
4.
oVfromreti
m
)1( i
oVfrom
RCD
oireti emm


i
reti
reti
oVfrom
oVfrom
m
V


5.
buffVfromreti
m
 oVfrombuffVfrom retiretret VVV
buffVfrombuffVfrom ret
buff
buffi
reti VV
V
V 
iretireti buffVfrombuffVfrom
Vm 
6. retim
buffVfromoVfrom retiretireti
mmm 
7. permim
retiinipermi mmm 
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Inputs Outputs Mass Balance Calculations
Chromatography
Column height, H
No of column volumes,
CV
Linear flow rates, u
Column volume, colV
No of cycles, n
Yield fraction, y
Product-stream-column-
volumes, prodCV
Processing time per cycle,
t
Buffer volumes required,
V
Product and waste stream
masses, i prodm , wasteim
1. rt , EWLr ,,
r
r
r u
CVHt 
2. rV , EWLr ,,
nVCVV colrr 
3. colprodprod VCVV 
iLiprodi ymm Lfrom 
i
prodi
prodi
Lfrom
Lfrom
m
V


 LfromEfrom prodiprodprod VVV
EfromEfrom prod
E
Ei
prodi VV
VV 
iprodiprodi EfromEfrom
Vm 
EfromLfrom prodiprodiprodi
mmm 
prodiEiWiLiwastei mmmmm 
From gel filtration, the equations were
similar except there were no terms related
to the wash step.
b
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Inputs Outputs Mass Balance Calculations
Dead-end filtration
Calculation mode:
Membrane area per unit,
A / Processing time per
cycle, t
Average flux, J
Rejection factor, RF
Particle-volume fraction,
retpv
Output mode:
Membrane area per unit,
A / Processing time per
cycle, t
Permeate and retentate
stream component
masses, permim , retim
1. )10(  ireti RFm
inireti mRFm RF 0 
i
reti
reti
RF
RF
m
V

0
0



2. )0(
0

 ireti
RFm
RF
retp
reti
ret v
V
V RF 0 



00 RFRF retiretret
VVV
0
0
0 



RF
RF
RF ret
in
ini
reti VV
VV
iretireti RFRF
Vm 
 00
3. permim
retiinipermi mmm 
4. A , t
retinperm VVV 
tJ
V
A perm

 or
AJ
V
t perm
*

Viral clearance
No of virus units in inlet
stream, invr
Log clearance factor,
LCF
No of virus units in outlet
stream, outvr
1. outvr
LCF
inout vrvr 10
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Appendix: Chapter 4
Appendix 4- Figure 1 A depiction of the Cohn (Method 6) adapted from Curling et al.
2005. ‘A comparative study of Cohn and chromatographic fractionation using
a novel affinity “Cascade Process”’
Appendix 4- Table 1 Total Protein and AAT content of samples recovered from the
anion exchange step from the process trial run based on the Keeet al., 2004 process for
Fractogel, and Q Sepharose FF under various buffer conditions (Table 5.2). Samples
were measured using the Pierce microplate reducing agent compatible BCATM total
protein assay and an AAT Elisa kit (Immundiagnostik) . All samples were desalted
using AmiconCentricon YM-3 regenerated cellulose filter devices, MWCO 3,000 to
remove DTT from samples prior to analysis.
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Total Protein
Mass (mg)
Total Protein
Yield (%)
Mass AAT
(mg)
AAT Yield
(%)
AAT purity
(%)
Fractogel Run A
Peak 1 429 5% negligible - -
Peak 2 323 4% negligible - -
Peak 3 93 1% negligible - -
Fractogel Run B
Peak 1 295 3% 0.7 25% 0.2%
Peak 2 228 3% 2.6 86% 1.1%
Peak 3 73 1% 0.1 5% 0.2%
Fractogel Run C
Peak 1 303 3% 0.8 27% 0.3%
Peak 2 140 2% 1.9 64% 1.3%
Peak 3 136 2% 0.1 2% 0.1%
Q Sepharose FF Run D
Peak 1 247 3% 0.1 2% 0.0%
Peak 2 271 3% 2.1 70% 0.8%
Peak 3 43 0% 0.0 1% 0.1%
Fractogel Run E
Peak 1 349 4% 0.2 6% 0.1%
Peak 2 124 1% 1.4 46% 1.1%
Peak 3 108 1% 0.1 3% 0.1%
Q Sepharose FF Run F
Peak 1 353 4% 0.2 8% 0.1%
Peak 2 135 1% 7.9 - 5.9%
Peak 3 55 1% 0.0 1% 0.0%
Q Sepharose FF Run G
Peak 1 282 3% 0.6 19% 0.2%
Peak 2 250 3% 13.0 100% 5.2%
Peak 3 97 1% 0.1 2% 0.1%
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Appendix: Chapter 5
Appendix 5 - Figure 1SELDI-TOF-MS spectra representing protein profiles portraying
the impact of further buffer conditions on the binding intensity and isolation of AAT
using the ‘Q10’ ProteinChip. The buffer conditions shown are a combination of pH 5.1-
5.6 and 0-200mM NaCl.
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